Rare GLP1R variants (about 1:500) attenuate weight loss with semaglutide but not tirzepatide, whereas rare LOF GIPR variants have little effect on drug responses
www.linkedin.com/posts/daniel-drucker-922982101_new-genetā¦
Daniel J. Drucker
Daniel Joshua Drucker (born 23 June 1956) is a Canadian endocrinologist renowned for his breakthrough discoveries of the biological actions of glucagon-like peptides GLP-1 and GLP-2, including GLP-1's key role in stimulating glucose-dependent insulin secretion, reducing food intake, protecting the heart, and reducing systemic inflammation. His scientific research has been a driving force in GLP-1's journey from a newly discovered peptide sequence to the mechanism behind globally used and life-changing therapeutics for type 2 diabetes and obesity. It has also driven transformative new therapeutics for intestinal failure and other metabolic disorders. A Fellow of the Royal Society, and laureate of the 2023 Wolf Prize in Medicine, he is a University Professor of Medicine at the University of Toronto and Senior Investigator at the Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto. More on Wikipedia
-
Daniel J Drucker
@DanielJDrucker
-
Daniel J Drucker reposted
The Lancet
@TheLancet
Stopping GLP-1 treatment linked to twice the risk of heart attack, stroke or death compared with continuing, in people with type 2 diabetes and no cardiovascular disease, according to a new study.
Find out more in @LancetRH_Europe: www.thelancet.com/journals/lanepe/article/PIIS2666-7762(2⦠-
Daniel J Drucker
@DanielJDrucker
The FDA is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. FDA www.fda.gov/safety/medical-product-safety-information/medā¦
-
Daniel J Drucker
@DanielJDrucker
SYNCHRONIZE CVOT Cardiovascular safety for the GCGR-GLP-1R co-agonist survodutide yet lingering tolerability issues highlight need for more flexibe dosing going forward www.thelancet.com/journals/lancet/article/PIIS0140-6736(2ā¦
-
Daniel J Drucker
@DanielJDrucker
A real world look at neurological outcomes post minor stroke in people with T2D using TriNetX highlighting lower risk of dementia with GLP-1 medicines link.springer.com/article/10.1007/s00415-026-14251-9
-
Daniel J Drucker
@DanielJDrucker
We live in a real world data environment that is fast and relentless. How should we incorporate real world data into the totality of evidence? Some perspectives from the REDDIE program @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06896-y
-
Daniel J Drucker
@DanielJDrucker
Studies of NOD and human T1D islets identify pancreatic α cells as nonprofessional antigen-presenting cells and expand the current understanding of antigen presentation in autoimmune diabetes @ScienceAdvances www.science.org/doi/10.1126/sciadv.aei0410
-
Daniel J Drucker
@DanielJDrucker
Retatrutide and the improvement of obstructive sleep apnea www.nejm.org/doi/full/10.1056/NEJMoa2611477?query=featureā¦
-
Daniel J Drucker reposted
Eric Topol
@EricTopol
GLP-1 peptides protect the gut from immune injury.
Essential role of endogenous GLP-1 family peptides to reduce inflammation and restore mucosal integrity in the experimental model @DanielJDrucker @CellRepMed
www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26⦠-
Daniel J Drucker
@DanielJDrucker
Will GLP-1 medicines be useful in the clinic for substance use disorders? We will soon find out @marilenharo www.nature.com/articles/d41586-026-03252-3
-
Daniel J Drucker
@DanielJDrucker
This Friday 8 am @SinaiHealth @uoftmedicine in Toronto, the 2026 Burrow Lecture, 8 am, Professor @cevansmo #diabetes #islets
-
Daniel J Drucker
@DanielJDrucker
Over 6 weeks in people with MASLD inhibition of fructose metabolism has beneficial metabolic effects that extend beyond the organs that metabolize fructose @NatMetabolism
www.nature.com/articles/s42255-026-01626-5 -
Daniel J Drucker
@DanielJDrucker
Here the authors propose that a gut microbial aldehyde-alcohol dehydrogenase, AdhE, converts metformin to pharmacologically inactive products, lowering intestinal and systemic drug exposure www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00378-5 @Cell_Metabolism
-
Daniel J Drucker
@DanielJDrucker
New P3 data for the oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes in China @NatureMedicine
www.nature.com/articles/s41591-026-04651-9 -
Daniel J Drucker
@DanielJDrucker
Genetic variation and type 2 #diabetes New perspectives @MolMetab www.sciencedirect.com/science/article/pii/S221287782600133X @DiabetologiaJnl
-
Daniel J Drucker reposted
Max Kozlov
@maxdkozlov
SCOOP: Top researchers at Columbia, Stanford, and others thought they were elected to elite scientific societies alongside Nobel laureates. The catch? The organizations are a sham.
I spent the last month investigating a massive academic scam, for @Nature
www.nature.com/articles/d41586-026-02980-w -
Daniel J Drucker
@DanielJDrucker
A childhood window into genetic variation linked to childhood adiposity @NatureGenet www.nature.com/articles/s41588-026-02772-y
-
Daniel J Drucker
@DanielJDrucker
@TheEndoSociety has posted a new document published in Endocrine Reviews and free to read: Obesity science, research gaps, and opportunities in the new era of obesity medicines: an Endocrine Society scientific statement @EndoSocJournals academic.oup.com/edrv/advance-article/doi/10.1210/endrev/ā¦
-
Daniel J Drucker
@DanielJDrucker
Cohort studies across the lifespan for type 2 #diabetes Progress, clinical implementation and future directions @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06812-4
-
Daniel J Drucker
@DanielJDrucker
Here the authors identify the glucagon-PKA-PDE2A-NCLX signaling axis as a key metabolic rheostat integrating mitochondrial calcium dynamics with lipid homeostasis, providing a promising therapeutic target for MASLD @MolMetab www.sciencedirect.com/science/article/pii/S2212877826001171
-
Daniel J Drucker
@DanielJDrucker
The weight loss proteome in mice www.nature.com/articles/s42255-026-01599-5 @NatMetabolism
-
Daniel J Drucker
@DanielJDrucker
In an open label study for up to 26 weeks, dulaglutide was associated with greater improvements in glycaemic control and variability compared with insulin among adolescents with transfusion-dependent β-thalassaemia (TDT)-induced diabetes @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06835-x
-
Daniel J Drucker
@DanielJDrucker
From TMAO to DNICs the expanding concepts linking microbiota metabolism to cardiovascular and metabolic pathways. Modulating DNIC formation by the gut microbiota could be a strategy to support cardiometabolic health @CellCellPress www.cell.com/cell/fulltext/S0092-8674(26)00924-4
-
Daniel J Drucker
@DanielJDrucker
New studies in Drosophila and mice redefine the intestinal muscle as a responder to specific signals that adjust adult organ (intestine) features and sustain reproductive demands.
www.cell.com/cell/fulltext/S0092-8674(26)00822-6 -
Daniel J Drucker
@DanielJDrucker
A framework identifying ten priorities in #t2d prevention, toward context-specific, actionable interventions capable of altering the natural history of disease early in the life course and restoring metabolic health. www.nature.com/articles/s41591-026-04550-z
-
Daniel J Drucker
@DanielJDrucker
The decades long quest for reprogramming islet cell phenotypes #diabetes continues here using a metabolic pathway approach www.nature.com/articles/s41589-026-02293-z
-
Daniel J Drucker reposted
Eric Topol
@EricTopol
The GLP-1 drugs have evidence for beneficial impactā heart, kidney, liver, joints, immune system, and braināthat are independent of weight loss
@Cell_Metabolism @DanielJDrucker
www.cell.com/cell-metabolism/abstract/S1550-4131(26)00279-2 -
Daniel J Drucker
@DanielJDrucker
How does GLP-1 work? Gustav HƄllƩn the producer of Zero Order has figured it out. Have a listen
www.youtube.com/watch?v=VCIWc2TXwVo -
Daniel J Drucker
@DanielJDrucker
The scientific journey enabling the development of #microbiome -targeted therapies for #obesity prevention and treatment. An update @cellhostmicrobe www.cell.com/cell-host-microbe/fulltext/S1931-3128(17)304ā¦
-
Daniel J Drucker
@DanielJDrucker
A physiological homeostatic circuit through which obesity causes type 2 diabetes and #insulin resistance @Cell_Metabolism www.cell.com/cell-metabolism/abstract/S1550-4131(26)00274-3
-
Daniel J Drucker
@DanielJDrucker
P2 data over 16 weeks reveal an investigational small molecule GLP-1R agonist HRS-7535 dose-dependently reduced albuminuria, HbA1c and body weight in patients with diabetic kidney disease receiving intensive contemporary therapy www.thelancet.com/journals/eclinm/article/PIIS2589-5370(2ā¦
-
Daniel J Drucker
@DanielJDrucker
Automated CT-derived Perivascular Adipose Tissue biomarkers are associated with existing and future #t2d and may enable identification of undiagnosed or high-risk individuals undergoing routine abdominal CT diabetesjournals.org/diabetes/article/doi/10.2337/db25-11ā¦
-
Daniel J Drucker
@DanielJDrucker
Rates of anxiety and depression in real world data from Shanghai in people with #t2d using GLP-1 medicines are low but increase slightly after discontinuation of the medicines @NatMetabolism www.nature.com/articles/s42255-026-01567-z
-
Daniel J Drucker
@DanielJDrucker
Evaluating the progress in biological clocks #aging @EricTopol @NatureMedicine www.nature.com/articles/s41591-026-04495-3
-
Daniel J Drucker
@DanielJDrucker
P3 data assessing the efficacy and safety of setmelanotide once daily in acquired hypothalamic obesity over 52 weeks www.nejm.org/doi/full/10.1056/NEJMoa2512275
-
Daniel J Drucker
@DanielJDrucker
More evidence from studies of mice deficient in α cells that α cells are required for nutrient homeostasis by regulating the dynamics of β cell networks, notably under conditions of amino acid exposure www.science.org/doi/10.1126/sciadv.aea9045
-
Daniel J Drucker
@DanielJDrucker
Assessment of body composition remodeling during the trajectory of #t2d link.springer.com/article/10.1007/s00125-026-06797-0
-
Daniel J Drucker
@DanielJDrucker
It seems increasingly likely that information derived from proteomic clocks will be useful for enrolling clinical trials and for risk stratification in the clinic www.nature.com/articles/s43587-026-01163-6
-
Daniel J Drucker
@DanielJDrucker
New studies in mice and human islets interrogate direct islet vs. Tanycyte dependent actions of liraglutide to control insulin secretion and glucose homeostasis, emphasizing the importance of the glycemic state for liraglutide action link.springer.com/article/10.1007/s00125-026-06779-2 @DiabetologiaJnl
-
Daniel J Drucker
@DanielJDrucker
The rapid rise of TriNetX-so many papers, hundreds of new associations-cause for celebration, concern, or simply careful scrutiny? @ScienceMagazine www.science.org/content/article/medical-students-are-usinā¦
-
Daniel J Drucker
@DanielJDrucker
α-cell-derived glucagon positioned as a gatekeeper of immune and neuronal control of insulin secretion at fasting glucose in mice @CellReports www.cell.com/cell-reports/fulltext/S2211-1247(26)00664-9
-
Daniel J Drucker
@DanielJDrucker
A reminder of the benefits of exercise for cardiovascular health. In adults with #obesity, regular physical activity over 52 wks, with or without GLP-1R agonists, but not liraglutide alone, promotes vascular health & ā¬ļøCMT over in adults with obesity. www.nature.com/articles/s42255-026-01554-4
-
Daniel J Drucker
@DanielJDrucker
In a mouse model of obesity-induced metabolic inflammation that accelerates leukemogenesis, dual therapy with an anti-IL-17A antibody and a GLP-1R agonist reduced leukemic burden, findings supported by clinical phenotyping @uk_biobank www.jci.org/articles/view/202856
-
Daniel J Drucker
@DanielJDrucker
A metabolic update and perspective on #masld #mash @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06774-7
-
Daniel J Drucker
@DanielJDrucker
Adiposity and #cancer Will use of GLP-1 medicines bend the curve? Is weight loss the potential mechanistic driver? www.nature.com/articles/s42255-026-01529-5
-
Daniel J Drucker
@DanielJDrucker
Here the authors present evidence in mice that liraglutide promotes anti-depressant actions independent of the GLP-1R by modulating a microbiota-endocannabinoid metabolic pathway, revealing a potential therapeutic target for depression @cellhostmicrobe www.cell.com/cell-host-microbe/fulltext/S1931-3128(26)001ā¦
-
Daniel J Drucker
@DanielJDrucker
The next chapter from Prof Steven Kahn clearly conceived before #ada2026 now more timely, published in @DiabetesCareADA diabetesjournals.org/care/article/doi/10.2337/dci26-0089/⦠#diabetes
-
Daniel J Drucker
@DanielJDrucker
Understanding the determinants of and ways to mitigate #exercise associated nocturnal #hypoglycemia in adults with type 1 #diabetes diabetesjournals.org/care/article/doi/10.2337/dc26-0381/1⦠#ada2026
-
Daniel J Drucker
@DanielJDrucker
Registry data from Hong Kong demonstrates that hyperglycaemic exposure was associated with an elevated long-term cancer risk in type 2 diabetes and earlier high HbA1c exposures contributed more strongly to cancer risk than later exposures @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06758-7
-
Daniel J Drucker reposted
Eric Topol
@EricTopol
More than 40 studies @ASCO consistent on this topic for link between GLP-1 drugs and reduced cancer incidence or improved prognosis
www.washingtonpost.com/health/2026/06/03/science-around-g⦠@arianaeunjung @PostRowland -
Daniel J Drucker
@DanielJDrucker
New from Professor Blau, inhibition of the gerozyme 15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss www.pnas.org/doi/10.1073/pnas.2606533123
-
Daniel J Drucker reposted
Eric Topol
@EricTopol
Very good review on this topic, by @DanielJDrucker @NatureCancer
www.nature.com/articles/s43018-025-01110-1 -
Daniel J Drucker
@DanielJDrucker
Identification of the acute pancreas-independent actions of GIP vs. GLP-1 in humans-note the profound actions of GIP on HR and DBP dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/doā¦
-
Daniel J Drucker
@DanielJDrucker
Preclinical studies support combined MC3R/MC4R agonism as a promising approach for next-generation obesity therapeutics #weightloss www.nature.com/articles/s41467-026-73372-x
-
Daniel J Drucker
@DanielJDrucker
One of the fascinating frontiers of GLP-1 biology that cannot easily be studied in RCTs, unless one chooses families at genetic risk, or studies people with #cancer where weight gain is known to be deleterious. We summarized the field here @NatureCancer www.nature.com/articles/s43018-025-01110-1
Eric Topol
@EricTopol
Whether there is a real impact of GLP-1 drugs on cancer is unresolved. If confirmed, it could simply reflect weight loss or, as seen for other conditions (e.g. heart, kidney), weight loss independent effects. We need dedicated trials to resolve this important question.
git link -
Daniel J Drucker
@DanielJDrucker
In people with a suboptimal clinical response after MBS, semaglutide results in substantial and clinically significant body weight reduction along with improvement in metabolic parameters and quality of life, compared to placebo @NatureMedicine www.nature.com/articles/s41591-026-04416-4
-
Daniel J Drucker
@DanielJDrucker
Irisin induction in response to exercise confers direct neuroprotective effects in an inflammation-driven neurodegenerative condition in mice, making it an attractive therapeutic candidate for multiple sclerosis @NatMetabolism www.nature.com/articles/s42255-026-01527-7
-
Daniel J Drucker
@DanielJDrucker
Impressive TRIUMPH-1 #weightloss data for retatrutide investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
Amyloid-dependent StAR upregulation in beta cells under conditions of islet amyloid deposition could contribute to mitochondrial dysfunction @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06749-8
-
Daniel J Drucker
@DanielJDrucker
Rare but real? Two cases of ophthalmic lymphoid hyperplasia on dulaglutide therapy, presenting with vision loss, resolving after discontinuation of dulaglutide www.nejm.org/doi/full/10.1056/NEJMc2600397
-
Daniel J Drucker
@DanielJDrucker
Post hoc analyses using epigenetic clocks over 32 weeks shows semaglutide slows #aging approximated through analysis of epigenetic clocks and reduces inflammation in 45 adults with human immunodeficiency virus (HIV)-associated lipohypertrophy www.nature.com/articles/s41467-026-72861-3
-
Daniel J Drucker reposted
EASO
@EASOobesity
2026 Obesity Prize for Excellence Winner - Professor Sadaf Farooqi š
Watch this excellent short video and learn more about her research ā”ļø Beyond willpower: the biological basis of weight regulation.
eco-newsletter.co.uk/article/professor-sadaf-farooqi-2026⦠-
Daniel J Drucker
@DanielJDrucker
The fascinating biology of targeting nuclear receptor ligands to GLP-1 receptor + cells continues, with the latest chapter studying GLP-1 E2 in NOD mice, with or without low dose aCD3 @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06750-1
-
Daniel J Drucker
@DanielJDrucker
Genetic deletion studies in adult mice reveals that glucagon deficiency in adult alpha cells is specifically injurious to β-cells and not corrected by exendin-4 across multiple domains of β-cell function www.jbc.org/article/S0021-9258(26)02017-X/fulltext
-
Daniel J Drucker
@DanielJDrucker
Four decades of GLP-1 science. Humble origins. Not flashy, rarely in high profile Journals, yet highly reproducible from Boston to Toronto to Copenhagen, from mice to rats to humans. Now changing options in clinical medicine for people with challenging cardiometabolic disorders
EASD
@EASDnews
š®1st, the impact was not clear. Now, it is one of the biggest breakthroughs in #diabetestherapy after #insulin.šExclusively on the EASD e-Learning platform, @DanielJDrucker, Jens Holst, @lotte_bjerre & Michael Nauck recount āThe #glp1 Storyā. Watch here: easd-elearning.eu/episode/367/The-story-of-GLP-1.html
-
Daniel J Drucker
@DanielJDrucker
In SURPASS CVOT tirzepatide was associated with a reduced risk of major kidney events driven by a reduction in new-onset macroalbuminuria in PPL with low-to-moderate-risk CKD #t2d and slowed decline in kidney function in high-risk chronic kidney disease. www.thelancet.com/journals/landia/article/PIIS2213-8587(2ā¦
-
Daniel J Drucker
@DanielJDrucker
New advances in understanding the wide range in human islet cell heterogeneity and secretory phenotypes from the Integrated Islet Distribution Program (IIDP). The abundance of Ī“ cells showed the strongest association with insulin secretion and #t2d
www.nature.com/articles/s41467-026-70689-5 -
Daniel J Drucker
@DanielJDrucker
Chasing GPR75 for #weightloss supported by phenotypes in mice with conditional postnatal CNS deletion of GPR75 @MolMetab www.sciencedirect.com/science/article/pii/S2212877826000657
-
Daniel J Drucker
@DanielJDrucker
The never ending mysteries of metformin action, the latest chapter unfolds www.nature.com/articles/s42255-026-01530-y
-
Daniel J Drucker
@DanielJDrucker
By studying gut #microbiota profiles after metabolic surgery the authors infer that surgery-specific microbial adaptations influence metabolic improvements and may help to explain heterogeneity in T2D remission after bariatric surgery www.nature.com/articles/s42255-026-01525-9
-
Daniel J Drucker
@DanielJDrucker
Real world data suggest a benefit for pre-existing exposure to GLP-1 medicines and a range of post-intracerebral hemorrhage (ICH) outcomes in patients with type 2 diabetes mellitus journals.lww.com/10.1227/neu.0000000000004079
-
Daniel J Drucker
@DanielJDrucker
The expanding use of GLP-1 medicines in children and adolescents raises multiple compelling research questions to ensure we fully understand the long term safety and benefit:risk profile of these agents across a range of different populations with varying co-morbidities.
Julia Belluz
@juliaoftoronto
A few years back, the @AmerAcadPeds
recommended more intensive medical intervention for kids with obesity, including GLP-1s. T
he question now is not whether we should give these drugs to kids.
It's: why are we even here?
My latest @nytopinion
www.nytimes.com/2026/05/06/opinion/glp1-kids-ozempic.html⦠-
Daniel J Drucker
@DanielJDrucker
Among the interesting molrcules studied in P3 trials Novo Nordisk is Zenagamtide, the unimolecular Amycretin that showed compelling weight loss potential in P2 www.novonordisk.com/content/dam/nncorp/global/en/investorā¦
-
Daniel J Drucker
@DanielJDrucker
Studies in insulin infused people with #t1d reveal that elevated GIP levels alone cannot effectively restore the glucagon response to insulin-induced hypoglycemia in T1D diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
Neuroligin-3 (NLGN3), an exercise-induced mediator that enhances insulin sensitivity and alleviates inflammation is proposed as a promising therapeutic target for #obesity associated insulin resistance diabetesjournals.org/diabetes/article/doi/10.2337/db25-02ā¦
-
Daniel J Drucker reposted
Ziyad Al-Aly, MD
@zalaly
At 3 years, NAION was more frequent among people who started GLP-1 drugs:
āø GLP-1 drugs: 39.1 cases per 10,000 persons
āø SGLT2 inhibitors: 29.3 cases per 10,000 persons
That works out to 6 to 10 extra cases per 10,000. A 35% higher risk on GLP-1. -
Daniel J Drucker
@DanielJDrucker
New experimental insights into vagal mechanisms triggered by allulose to improve insulin sensitivity diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
Will we see successful registration studies for alcohol use disorder? Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial - The Lancet www.thelancet.com/journals/lancet/article/PIIS0140-6736(2ā¦
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose prioritization of individuals with #obesity and a high risk for obesity associated complications for weight loss interventions www.nature.com/articles/s41591-026-04353-2
-
Daniel J Drucker
@DanielJDrucker
Predicting type 1 diabetes using genetics @NatureGenet www.nature.com/articles/s41588-026-02578-y
-
Daniel J Drucker
@DanielJDrucker
The authors have some strong thoughts and concerns surrounding the impact of science policy and funding for HCPs, scientists and people living with #diabetes
-
Daniel J Drucker
@DanielJDrucker
Recruiting pan PPAR agonism via targeted delivery to incretin receptor+ cells to enhance the efficacy of GLP-1R-GIPR co-agonism in mice www.nature.com/articles/s41586-026-10427-5
-
Daniel J Drucker
@DanielJDrucker
Beyond real world data, information from randomised placebo-controlled trials with semaglutide and liraglutide do not show an increased incidence of NAION in participants receiving GLP-1RA medicines bjo.bmj.com/content/early/2026/04/28/bjo-2025-328729
-
Daniel J Drucker
@DanielJDrucker
Congratulations to Professor Jens Holst @Metabolcenter @UCPH_Research @EASDnews Newly elected international member of the @theNASciences
-
Daniel J Drucker
@DanielJDrucker
Hundreds of interventions augment thermogenesis in mice. Here an adipokine, Adissp (adipose-secreted signaling protein), increases glucose uptake and a thermogenic program producing weight loss and glucose control, suggesting a promising therapeutic agent www.science.org/doi/full/10.1126/sciadv.aed2780
-
Daniel J Drucker
@DanielJDrucker
P3 top line data for Survodutide #weightloss #obesity www.globenewswire.com/news-release/2026/04/28/3282220/0/eā¦
-
Daniel J Drucker
@DanielJDrucker
Real world data in more than 8,000 matched patients in TriNetx suggests that Glucagon-like peptide-1 receptor agonist use is associated with reduced heart damage during cancer treatment with cardiotoxic medicines www.nature.com/articles/s43856-026-01618-2
-
Daniel J Drucker
@DanielJDrucker
As the disease-modifying properties of GLP-1 medicines take center stage, a focus on targeting inflammation emerges as a unifying mechanism underlying the benefit of GLP-1 medicines across a wide range of obesity-associated disorders @sciam www.scientificamerican.com/article/zepbounds-and-ozempicsā¦
-
Daniel J Drucker
@DanielJDrucker
The vascular smooth muscle cell GLP-1 receptor and the control of blood ... youtu.be/mQfhjnYWaYc via @YouTube
-
Daniel J Drucker
@DanielJDrucker
The leading GLP-1 medicine, tirzepatide, activates both the GIP and GLP-1 receptors, producing unsurpassed glucose control and weight loss. Yet human genetics and data from Maritide have spurred enthusiasm for molecules blocking the GIPR www.biorxiv.org/content/10.64898/2026.04.21.719783v2
-
Daniel J Drucker
@DanielJDrucker
In search of the lost tribe of clinical,y meaningfully sarcopenia after #weightloss with GLP-1 medicines A new review www.nature.com/articles/s41366-026-02088-1 #obesity @IntJObesity
-
Daniel J Drucker
@DanielJDrucker
Here engineered commensals as a modular, responsive platform for multi-metabolite modulation of host-microbiota metabolism, for the treatment of hepatic encephalopathy @CellCellPress www.cell.com/cell/fulltext/S0092-8674(26)00384-3?dgcid=raā¦
-
Daniel J Drucker
@DanielJDrucker
A new comprehensive review on human adipose tissue from @ryden_mikael @karolinskainst @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06735-0
-
Daniel J Drucker
@DanielJDrucker
New concepts frm islet epigenetics revealing DNAm remodelling in healthy beta cells reflects a long-term adaptation to metabolic demand, which, in T2D, is accelerated as part of a compensatory response that fails under sustained insulin resistance www.nature.com/articles/s42255-026-01495-y
-
Daniel J Drucker
@DanielJDrucker
Weight loss produces many cardiometabolic benefits and is a key goal and feature of Rx with GLP-1 medicines. Here @MedakKyle highlights how semaglutide reduces blood pressure in mice through the vascular smooth muscle cell GLP-1 receptor @JCI_insight
insight.jci.org/posts/238
JCI insight
@JCI_insight
Supporting the concept that #glp1 agonist drugs lower #bloodpressure independent from their weight loss effects: doi.org/10.1172/jci.insight.201148
Kyle D. Medak @MedakKyle Daniel J. Drucker @DanielJDrucker & team @SinaiHealth identify the vascular smooth muscle GLP-1 receptor as a key cellular target for the actions of GLP-1 medicines to lower blood pressure.
The figure: Renal GLP1R/Glp1r is expressed in human and murine vascular smooth
muscle cells (VSMCs) and Glp1rVSM-/- mice have reduced Glp1r transcripts in renal
tissues. -
Daniel J Drucker
@DanielJDrucker
Weight loss produces many cardiometabolic benefits and is a key goal and feature of Rx with GLP-1 medicines. Here @MedakKyle highlights how semaglutide reduces blood pressure in mice through the vascular smooth muscle cell GLP-1 receptor @JCI_insight insight.jci.org/posts/238
-
Daniel J Drucker reposted
EASD
@EASDnews
š We're proud to announce Prof. Anette Ziegler as the recipient of the 58th EASD Claude Bernard Prize: the highest honour our association bestows. Her career has been driven by 1 vision: a world w/out #t1d. Join us in celebrating her at #easd2026.
ššwww.easd.org/prizes/claude-bernard/ -
Daniel J Drucker
@DanielJDrucker
Hundreds of elegant rodent studies infer the possibility of augmenting adipose tissue thermogenesis for the treatment of human #obesity Here is the latest www.nature.com/articles/s41467-026-72233-x
-
Daniel J Drucker
@DanielJDrucker
Novo Nordisk highlights top line HbA1c reduction with oral semaglutide in PIONEER Teens www.novonordisk.com/content/nncorp/global/en/news-and-medā¦
-
Daniel J Drucker
@DanielJDrucker
Myeloid TREM2-Endothelial cell interactions identified as a driver of diabetic vasculopathy and a potential therapeutic target in Diabetes Mellitus-associated Peripheral Artery Disease @ScienceTM www.science.org/doi/10.1126/scitranslmed.adu3761
-
Daniel J Drucker
@DanielJDrucker
Here the authors nominate hypothalamic Cav3.1 as a neuronal leucine sensor and npropose it as a tractable target for anti- #obesity therapy www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00111-7
-
Daniel J Drucker
@DanielJDrucker
A skin-hypothalamus axis linking heat memory and metabolic dysfunction and highlight that global warming is exacerbating metabolic diseases. www.cell.com/cell/fulltext/S0092-8674(26)00346-6
-
Daniel J Drucker
@DanielJDrucker
A potentially targetable pathogenic signature of EV-associated miRNAs capable of stratifying type 1 diabetes risk #islets @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06720-7
-
Daniel J Drucker
@DanielJDrucker
As Maritide is being evaluated in a large P3 (MARITIME) program for type 2 diabetes, obesity, and related disorders, KN069, a long-acting GIPR antagonist/GLP-1R agonist has been asessed in single and multiple ascending dose studies in China pubmed.ncbi.nlm.nih.gov/42010360/
-
Daniel J Drucker
@DanielJDrucker
Should the vagus nerve be a target for #obesity therapeutics?
www.nature.com/articles/s41575-026-01203-x -
Daniel J Drucker
@DanielJDrucker
Here the authors highlight potential therapeutic benefits of 4 weeks of β2-AR stimulation for improving muscle-specific glucose uptake in individuals with or at risk for developing diabetes #t2d www.nature.com/articles/s41467-026-71897-9
-
Daniel J Drucker
@DanielJDrucker
The authors submit that comprehensive tissue-specific characterization of exercise-responsive lncRNAs may inform the development of lncRNA-targeted therapeutics that harness the beneficial effects of exercise www.sciencedirect.com/science/article/pii/S2212877826000426 @MolMetab
-
Daniel J Drucker
@DanielJDrucker
While some may experience anhedonia on GLP-1 medicines, real world data continues to support the neuropsychiatric safety and no imbalance of #suicide of these agents in people with #t2d www.nature.com/articles/s41380-026-03619-y
-
Daniel J Drucker
@DanielJDrucker
The first few decades of GLP-1 research were driven by basic science observations in the lab, later verified in the clinic. Now, unexpected patient observations with GLP-1 medicines provide novel insights, and scientists then head back to the lab to figure out the mechanisms.
Julia Belluz
@juliaoftoronto
#glp1 drugs (#ozempic, #wegovy, etc.) were supposed to be about weight loss and diabetes.
Theyāre turning into something much bigger.
Here's a thread about what I've learned reporting this story for @nytopinion for over a year:
www.nytimes.com/interactive/2026/04/15/opinion/glp1-healt⦠-
Daniel J Drucker
@DanielJDrucker
Revisiting changes in cognitive function and biomarkers of Alzheimerās disease in REWIND alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.71391
-
Daniel J Drucker
@DanielJDrucker
The role of fructose not only as a caloric source, but also as a regulator of metabolic health and disease www.nature.com/articles/s42255-026-01506-y @NatMetabolism
-
Daniel J Drucker
@DanielJDrucker
Within the adult human cortex more than 3000 genes showed sex-biased expression www.science.org/doi/10.1126/science.aea9063
-
Daniel J Drucker
@DanielJDrucker
A critical role for Oxytocin-mediated adipose lipolysis in mammalian lactation @Cell_Metabolism www.cell.com/cell-metabolism/abstract/S1550-4131(26)00107-5
-
Daniel J Drucker
@DanielJDrucker
ACHIEVE-4 with Orforglipron H2H vs. Insulin glargine #t2d 2,700 people, 2 years, Cardiovascular safety, reduced risk of all cause mortality and no evidence of liver injury investor.lilly.com/news-releases/news-release-details/achā¦
-
Daniel J Drucker
@DanielJDrucker
Congratulations to Professor Klaus Kaestner @PennMedicine The @EASDnews 2026 Albert Renold Prize Awardee for outstanding achievements in the field of pathophysiology and treatment of diabetes www.easd.org/prizes/albert-renold/
-
Daniel J Drucker reposted
Harlan Krumholz
@hmkyale
Great work by @DanielJDrucker and team; biologically plausible mechanism of GLP1-RA benefit independent of weight loss. Excellent article by @megtirrell @CNN describing the publication. Could it justify new approaches for these drugs? I think so. www.cnn.com/2026/04/14/health/glp1-liver-health-benefits-ā¦
-
Daniel J Drucker
@DanielJDrucker
Extending concepts surrounding the weight loss-independent benefits of semaglutide in people with metabolic liver disease use mouse models #mash @megtirrell www.cnn.com/2026/04/14/health/glp1-liver-health-benefits-⦠@CNN
-
Daniel J Drucker
@DanielJDrucker
How do GLP-1 meds improve liver health through #weightloss independent mechanisms? Here @ChusaGzlzRellan & colleagues identify Liver Sinusoidal Endothelial Cells as direct targets of semaglutide, linking LSECs to reduction of #inflammation #fibrosis #mash www.cell.com/cell-metabolism/abstract/S1550-4131(26)00105-1
-
Daniel J Drucker
@DanielJDrucker
Although #weightloss is highly beneficial to reduce fat and inflammation in the liver, posthoc analysis of the ESSENCE trial reveals substantial weight loss-independent benefits of semaglutide #mash How does this happen?
-
Daniel J Drucker
@DanielJDrucker
Pediatric #masld @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06724-3
-
Daniel J Drucker
@DanielJDrucker
Neuronal lipid droplet-derived lipids support neuron function by providing fatty acids and phospholipids to sustain mitochondrial and endoplasmic reticulum function and homeostasis. www.nature.com/articles/s42255-026-01508-w
-
Daniel J Drucker
@DanielJDrucker
Genetic screens provide mechanistic insights into the regulation of proinsulin/insulin homeostasis www.nature.com/articles/s41467-026-71726-z
-
Daniel J Drucker
@DanielJDrucker
Expanding the #genetics of #pregnancy associated nausea and vomiting www.nature.com/articles/s41588-026-02564-4
-
Daniel J Drucker
@DanielJDrucker
A new review on GIP from the experts. While the narrative clearly highlights GIPR agonism suppresses food intake, the Figure implies GIP increases food intake diabetesjournals.org/care/article/doi/10.2337/dci25-0141/ā¦
-
Daniel J Drucker
@DanielJDrucker
Towards actionable ascertainment of #diabetes risk in cluster subtypes with #weightloss diabetesjournals.org/diabetes/article/doi/10.2337/db25-07ā¦
-
Daniel J Drucker
@DanielJDrucker
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that TOX3 in POMC-lineage cells are essential for maintaining energy homeostasis in mice, driving thermogenesis, thereby revealing therapeutic opportunities for metabolic disorders #obesity www.nature.com/articles/s41467-026-71575-w
-
Daniel J Drucker
@DanielJDrucker
#weightloss is a cornerstone of the medical management of #mash as lifestyle management clearly helps reduce hepatosteatosis. Surprisingly, posthoc analysis of ESSENCE trial data with semaglutide reveals substantial weight loss-independent benefits-how does this happen?
-
Daniel J Drucker
@DanielJDrucker
Once again there is no clinical evidence for any significant adverse outcome associated with the use of GLP-1 medicines and reduced nutrient intake in this descriptive study, only conjecture and speculation. Patients living with obesity are not well served by headlines of ārisksā
EASO
@EASOobesity
New study finds nutritional risks in users of GLP-1 drugs
āMuscle health depends on sufficient protein intake and regular physical activity, especially resistance exercise. W/ GLP-1s reduced appetite can make it harder to meet protein needsā
#eco2026 media -
Daniel J Drucker
@DanielJDrucker
The weight loss independent actions of GLP-1 medicines continue to surprise. The next chapter, focused on #mash drops this Tuesday
Scott Isaacs
@scottisaacsmd
New review by Maria Gonzalez-Rellan & Daniel Drucker focuses on the expanding benefits of GLP-1 meds like semaglutide & tirzepatide. Beyond glucose/weight control: ā CVD events, CKD progression, MASLD, OA, sleep apnea (via anti-inflammatory paths) partly weight-loss independent.
www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25⦠-
Daniel J Drucker
@DanielJDrucker
New from Professor Belsham @uoftmedicine @physiologyuoft
The naturally ocurring phytohormone BAP causes #weightloss in obese mice via sex-specific mechanisms @MolMetab www.sciencedirect.com/science/article/pii/S2212877826000505 -
Daniel J Drucker
@DanielJDrucker
Happy birthday to Professor Emeritus Bernie Zinman, newly elected member of the @CdnMedHallFame @uoftmedicine @SinaiHealth www.cdnmedhall.ca/bernard-zinman-oc-mdcm-frcpc #diabetes @DiabetesCanada
-
Daniel J Drucker
@DanielJDrucker
As the therapeutic benefits of GLP-1 medicines expand, the interest in the weight loss independent contributions continues to unfold linkinghub.elsevier.com/retrieve/pii/S2666379125002873
-
Daniel J Drucker
@DanielJDrucker
Potential cerebrovascular benefits of GLP-1 medicines in real world data for patients with moyamoya disease thejns.org/view/journals/j-neurosurg/aop/article-10.3171-ā¦
-
Daniel J Drucker
@DanielJDrucker
In rats, amylin modulates emotional and social behaviors in a divergent sex-dependent manner www.nature.com/articles/s41398-026-04011-8
-
Daniel J Drucker
@DanielJDrucker
A new chapter from the Scherer lab on adipose tissue communication via extracellular vesicles www.nature.com/articles/s41467-026-71740-1
-
Daniel J Drucker
@DanielJDrucker
A new chapter unfolds for ā¦@lotte_bjerreā© a scientist that moved GLP-1 science from bench to bedside, improving the health of people living with cardiometabolic disorders. A singular record of scientific achievement. Thank you for your contributions to GLP-1 science
-
Daniel J Drucker
@DanielJDrucker
A missense variant in GLP1R that is associated significantly with increased efficacy of GLP1 medications with an additional ā0.76ākg of #weightloss expected per copy of the effect allele. How will this change clinical practice? www.nature.com/articles/s41586-026-10330-z
-
Daniel J Drucker
@DanielJDrucker
Here the authors highlight new concepts of GLP-2 action, with a focus on the gut brain axis controlling metabolic and cognitive health pubmed.ncbi.nlm.nih.gov/41943399/
-
Daniel J Drucker
@DanielJDrucker
P1 trial data for targeting ANGPTL3 #cholesterol #triglycerides www.nature.com/articles/s41591-026-04307-8
-
Daniel J Drucker
@DanielJDrucker
Here the authors discover that increased activity measured as daily steps partially offsets the health risks of sedentary behavior www.nature.com/articles/s41467-026-71652-0
-
Daniel J Drucker
@DanielJDrucker
Here the authors highlight the great potential of gut microbial enzyme-oriented therapies for #precisionmedicine #microbiota www.nature.com/articles/s41575-026-01195-8
-
Daniel J Drucker
@DanielJDrucker
A gentleman and scholar, leader in #islet biology, Editor of @Diabetes_ADA Professor Gordon Weir @Harvard @AmDiabetesAssn @JoslinDiabetes www.legacy.com/us/obituaries/name/gordon-weir-obituary?id⦠March 27 2026
-
Daniel J Drucker
@DanielJDrucker
In Memoriam: Bert W. O'Malley, MD, 1937-2025 academic.oup.com/jcem/advance-article/doi/10.1210/clinem/⦠@Baylor @TheEndoSociety
-
Daniel J Drucker
@DanielJDrucker
Down at the gym, new recommendations for harmonizing preclinical #exercise physiology www.cell.com/cell-metabolism/abstract/S1550-4131(26)00099-9
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines and #pancreatitis After 21 years, lots of smoke, no fire. Here a look at Tirzepatide www.sciencedirect.com/science/article/abs/pii/S1424390326ā¦
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose repurposing readily accessible DPP-4 inhibitors to enhance anti-tumor CD8+ T cell responses #cancer www.biorxiv.org/content/10.64898/2026.03.31.715681v1
-
Daniel J Drucker
@DanielJDrucker
Associations in humans suggest that Hyperglucagonemia in the face of higher hepatic lipid content in early #t2d is not due to differences in insulin sensitivity or glucagonotropic metabolites but could suggest hepatic glucagon resistance diabetesjournals.org/care/article/doi/10.2337/dc25-3077/1ā¦
-
Daniel J Drucker
@DanielJDrucker
Novel irisin-driven cellācell and inter-tissue immune interactions improve #obesity and glucose intolerance, and increase energy expenditure, with no reduced food intake and muscle loss in obese mice. www.nature.com/articles/s42255-026-01491-2
-
Daniel J Drucker
@DanielJDrucker
Studies of mouse adipose tissue biology continue to underpin the enthusiastic pursuit of new targets to enhance thermogenesis in humans www.nature.com/articles/s41467-026-71266-6
-
Daniel J Drucker
@DanielJDrucker
The epidemiology of GLP-1 medicines-suggestive protective associations with reduced rates of respiratory diseases and serious infections require further confirmation jamanetwork.com/journals/jamanetworkopen/fullarticle/2847134
-
Daniel J Drucker
@DanielJDrucker
Preclinical studies define potential strategies against hepatic insulin resistance by targeting sulfenylated or āoxidatively activatedā p-GSK-3β. www.nature.com/articles/s42255-026-01507-x
-
Daniel J Drucker
@DanielJDrucker
Prespecified analyses reveal semaglutide reduced MACE in patients at risk for substantial liver fibrosis, in the overall SELECT population www.nature.com/articles/s41591-026-04281-1
-
Daniel J Drucker
@DanielJDrucker
Important new #weightloss option for people with overweight and #obesity Orforglipron, the first
@US_FDA approved small molecule GLP-1 medicine. Innovation from Chugai and Eli Lilly investor.lilly.com/news-releases/news-release-details/fdaā¦
Daniel J Drucker
@DanielJDrucker
Using the new voucher system, orforglipron represents the fastest approval of a New Molecular Entity (NME) @US_FDA since 2002.www.fda.gov/news-events/press-announcements/fda-approves-ā¦
-
Daniel J Drucker
@DanielJDrucker
Systemic DPP-4 inhibition is not cardioprotective in humans however microbial-derived DPP4 exacerbates cardiac I/R injury highlighting the hypoxia-lactate-BaDPP4 axis as a promising target for #microbiota-based cardioprotection www.cell.com/cell-host-microbe/abstract/S1931-3128(26)001ā¦
-
Daniel J Drucker
@DanielJDrucker
Here surface-anchored Adpn EVs restore tissue-specific insulin signaling and improve obesity-related metabolic dysfunctions, highlighting their potential as a novel biotherapeutic strategy for #t2d and #mash www.sciencedirect.com/science/article/pii/S2212877826000451 @MolMetab
-
Daniel J Drucker
@DanielJDrucker
The 2026 Canada @GairdnerAwards Laureates from Cryo-EM to amyloid aggregation,systems proteomics, cholera control, bacterial immunity, BP control after spinalinjury #science www.newswire.ca/news-releases/2026-canada-gairdner-awardsā¦
-
Daniel J Drucker
@DanielJDrucker
A continuous intravenous LEAP2 infusion for 5 hrs reduces glycemia and food intake in men with #obesity diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
While waiting for FOCUS, analysis of a matched real world TriNetX cohort of 350,536 patients with #t2d and #cvd followed for up to 5 years revealed reduced rates of legal blindness pubmed.ncbi.nlm.nih.gov/41907810/
-
Daniel J Drucker reposted
Ethan J. Weiss
@ethanjweiss
Another win for the lower is better crowdā¦
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease | New England Journal of Medicine www.nejm.org/doi/full/10.1056/NEJMoa2600283?query=RP -
Daniel J Drucker
@DanielJDrucker
As the weight loss-independent actions of GLP-1 medicines unfold a greater reduction in PsA disease activity (ACR50) was seen as early as Week 4 in the Ixekizumab and Tirzepatide treatment arm before clinically meaningful weight loss was observed investor.lilly.com/news-releases/news-release-details/phaā¦
-
Daniel J Drucker
@DanielJDrucker
The journey towards therapeutic manipulation of energy expenditure for #weightloss www.cell.com/trends/endocrinology-metabolism/fulltext/S10ā¦
-
Daniel J Drucker reposted
-
Daniel J Drucker
@DanielJDrucker
Studies in mice identify a septal inhibitory circuit through which GLP-1R signaling modulates alcohol-related behaviors in mice and highlight the dLS as a therapeutic target for Alcoholism Use Disorders www.cell.com/neuron/abstract/S0896-6273(26)00125-X
-
Daniel J Drucker
@DanielJDrucker
In the ATLAS data semaglutide-induced downregulation of PTPRU & genetically reduced PTPRU function promote greater #weightloss This gene has no previous known functional relationship to weight loss or related metabolic functions. www.cell.com/cell/fulltext/S0092-8674(26)00274-6 #genetics @CellCellPress
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that maltolāa widely used food additiveāis a previously unrecognized risk factor for hyperglycemia-associated bone fragility and #fractures #diabetes @Cell_Metabolism www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00095-1
-
Daniel J Drucker
@DanielJDrucker
Resolving the molecular and cellular processes that govern the organismal biology of the laboratory mouse across space, time, and inflammation @CellCellPress www.cell.com/cell/abstract/S0092-8674(26)00273-4
-
Daniel J Drucker
@DanielJDrucker
The paucity of well powered RCTs with GLP-1 medicines in neuropsychiatric disorders is offset by the recurring tsunami of real world data, here benefits in anxiety, depression and substance use disorders #t2d #obesity www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(2ā¦
-
Daniel J Drucker
@DanielJDrucker
An open-source web atlas of all orphan oGPCR expression in the human brain to serve as a neuro-resource for the broader scientific community. www.biorxiv.org/content/10.64898/2026.03.23.713764v1
-
Daniel J Drucker
@DanielJDrucker
How do GLP-1 medicines lower blood pressure #hypertension #weightloss helps yet the vascular smooth muscle GLP-1 receptor is also critical @NatRevNeph www.nature.com/articles/s41581-026-01074-0
-
Daniel J Drucker
@DanielJDrucker
Looking for the magical benefits of Time Restricted Eating beyond calorie restriction in humans? Here is a 6 month trial in #pcos The search continues www.nature.com/articles/s41591-026-04316-7 There are many paths to #weightloss and better health #diet
-
Daniel J Drucker
@DanielJDrucker
Once weekly basal #insulin icodec approved for adults with type 2 #diabetes @US_FDA www.novonordisk.com/content/nncorp/global/en/news-and-medā¦
-
Daniel J Drucker
@DanielJDrucker
Real world data reveal early GLP1RA initiation in liver transplant recipients was associated with reduced mortality, hospitalizations, respiratory, and cardiorenal complications without compromising graft safety. journals.lww.com/transplantationdirect/fulltext/2026/0400ā¦
-
Daniel J Drucker
@DanielJDrucker
Longitudinal studies in humans (86% male), baseline VMI 30.4 reveal that sustained visceral fat loss, rather than #weightloss is linked to better cognition and attenuation of brain atrophy years later, mainly associated with improved glycemic control. www.nature.com/articles/s41467-026-71141-4
-
Daniel J Drucker
@DanielJDrucker
The primary cilium functions as a non-redundant signaling compartment essential for GLP-1R action in islet beta cells @MolMetab www.sciencedirect.com/science/article/pii/S2212877826000414
-
Daniel J Drucker
@DanielJDrucker
Preclinical and clinical studies indicate that NKX6.1 mRNA expression could serve as a biomarker to predict islet graft function independently of islet mass, purity, and viability #transplantation #t1d @ScienceTM www.science.org/doi/10.1126/scitranslmed.aed3562
-
Daniel J Drucker
@DanielJDrucker
In this real world analysis, the authors found that the cardiometabolic benefits of GLP-1 medicines in people with #t2d are only evident when patients take the medicines, ideally for at least 3 years #cvd bmjmedicine.bmj.com/content/5/1/e002150
-
Daniel J Drucker
@DanielJDrucker
Preclinical and clinical exploration of dual GLP-1R-GLP-2R agonism for metabolic disease via PG-102 www.nature.com/articles/s41467-026-71080-0
-
Daniel J Drucker
@DanielJDrucker
The complexity of #inflammation in #mash and the opportunity for therapeutic intervention with a depiction of GLP-1 receptors as āextrahepaticā @Cell_Metabolism www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00087-2
-
Daniel J Drucker
@DanielJDrucker
#exercise as medicine www.cell.com/cell-metabolism/abstract/S1550-4131(26)00086-0
-
Daniel J Drucker
@DanielJDrucker
More data on the extent to which #genetics explains the extent of #weightloss heterogeneity in people after #bariatricsurgery insight.jci.org/articles/view/198133
-
Daniel J Drucker
@DanielJDrucker
A new review, the #genetics of #obesity www.nature.com/articles/s42255-026-01497-w
-
Daniel J Drucker
@DanielJDrucker
PLIN5 phosphorylation identified as a lever to tune hepatocyte lipid flux, suggesting therapeutic potential for targeting mitochondriaāLD coupling #masld #mash www.nature.com/articles/s42255-026-01476-1
-
Daniel J Drucker
@DanielJDrucker
Long term #diet impact on the gut #microbiome personalized #precisionnutrition and the road to improved cardiometabolic health. The Autobahn or the I-10? www.nature.com/articles/s41591-026-04312-x
-
Daniel J Drucker
@DanielJDrucker
Tirzepatide for familial partial lipodystrophy, observational studies academic.oup.com/jcem/advance-article/doi/10.1210/clinem/ā¦
-
Daniel J Drucker
@DanielJDrucker
Insights from derivation of human IPS #stemcell derived islet-like or off-target enterochromaffin (EC)-like cells in the pancreas #diabetes @UHN_Research www.nature.com/articles/s41467-026-70666-y
-
Daniel J Drucker
@DanielJDrucker
Scrutiny of #weightloss independent outcomes after metabolic surgery in PPL with #t2d www.nature.com/articles/s41366-025-02011-0
-
Daniel J Drucker
@DanielJDrucker
Localization of the inflammation associated anti-aversive actions of GIPR agonism via sites distinct from those that suppress appetite in the DVC www.cell.com/cell-reports/fulltext/S2211-1247(26)00194-4
-
Daniel J Drucker
@DanielJDrucker
#exercise timing, intensity and benefits #t2d #diabetes #circadian www.cell.com/trends/endocrinology-metabolism/fulltext/S10ā¦
-
Daniel J Drucker
@DanielJDrucker
A. muciniphila VHAKM enhances GLP-1 secretion in a strain- and form-dependent manner, with live cells showing superior efficacy www.biorxiv.org/content/10.64898/2026.03.18.708496v1
-
Daniel J Drucker
@DanielJDrucker
People with #t1d deserve P3 clinical trials to study the cardioprotective and kidney-sparing actions of GLP-1 medicines www.nature.com/articles/s41591-026-04274-0
-
Daniel J Drucker reposted
Jeffrey Flier
@jflier
With great sadness I report the passing of my scientific mentor Jesse Roth at age 91. Jesse was a brilliant & innovative scientist who led the field of membrane receptor biology from NIH diabetes branch. A small part of that family tree is shown. May his memory be a blessing.
-
Daniel J Drucker
@DanielJDrucker
Here comes 7.2mg semaglutide once weekly (Wegovy HD), 20.7% mean #weightloss in USA pharmacies next month #obesity www.novonordisk.com/content/nncorp/global/en/news-and-medā¦
-
Daniel J Drucker
@DanielJDrucker
P3 40 week data for Retatrutide in people with #t2d investor.lilly.com/news-releases/news-release-details/lil⦠@EliLillyandCo #weightloss
-
Daniel J Drucker
@DanielJDrucker
Patience you must have. The oral small molecule GLP-1 RA pills are coming, providing more options and hopefully, real value for patients #t2d #weightloss www.nature.com/articles/d41586-026-00856-7
-
Daniel J Drucker
@DanielJDrucker
Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans: ā¦@CellRepMedā© www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26ā¦
-
Daniel J Drucker
@DanielJDrucker
An update on new clinical trial data for setmelanotide in rare genetic forms of #obesity ir.rhythmtx.com/news-releases/news-release-details/rhythmā¦
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that treatment of adipocytes with BMPs results in an energy expending phenotype without transdifferentiation into beige adipocytes, providing a new approach to treat #obesity related metabolic disease. @JCI_insight insight.jci.org/articles/view/194140
-
Daniel J Drucker
@DanielJDrucker
It turns out that weight regain reverts many of the benefits achieved with #weightloss Insights from the CALERIE-2 trial
diabetesjournals.org/care/article-abstract/doi/10.2337/dc⦠-
Daniel J Drucker
@DanielJDrucker
Postmenopausal #osteoporosis Should some individuals with rapid #weightloss on GLP-1 medicines #obesity consider anti-resorptive therapy on top of lifestyle management? How to prospectively identify candidates? academic.oup.com/edrv/advance-article/doi/10.1210/endrev/ā¦
-
Daniel J Drucker
@DanielJDrucker
Does Aleniglipron move to the top of the list of the small molecule oral GLP-1RAs moving forward towards P3 and competition with Orforglipron #weightloss #obesity ir.structuretx.com/static-files/c7999175-be7e-40d4-8812-2⦠@StructureTx
-
Daniel J Drucker
@DanielJDrucker
Compellng efficacy and safety/discontinuation rates for the oral small molecule GLP-1RA Aleniglioron #weightloss #obesity @StructureTx ir.structuretx.com/news-releases/news-release-details/strā¦
-
Daniel J Drucker
@DanielJDrucker
The greater consistency of the glycaemic response to resistance #exercise performed in the morning while fasted vs in the afternoon after eating # T1D @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06713-6
-
Daniel J Drucker
@DanielJDrucker
Blautia wexlerae affects host metabolic control in part through #mcrobiota metabolites stimulating GLP-1 secretion www.biorxiv.org/content/10.64898/2026.03.13.709143v1
-
Daniel J Drucker
@DanielJDrucker
Under severe inflammatory conditions such as LPS administration, pancreatic production of GLP-1 functions in an immunological rather than a metabolic role to directly regulate local macrophage accumulation www.mdpi.com/2073-4409/15/5/482
-
Daniel J Drucker
@DanielJDrucker
The human alpha cell's competence to secrete glucagon depends on paracrine inhibitory input from beta (serotonin [5-HT], γ-aminobutyric acid [GABA]) and delta (somatostatin [SST]) cells #islets www.cell.com/cell-reports/fulltext/S2211-1247(26)00146-4
-
Daniel J Drucker
@DanielJDrucker
Cross platform OMICs and #genetics analyses highlight pleiotropic genetic and neuroimmune mechanisms that link type 1 #diabetes with cognition and neuropsychiatric disease risk www.nature.com/articles/s41467-026-70694-8
-
Daniel J Drucker
@DanielJDrucker
The enteric nervous system-a #microbiota perspective www.nature.com/articles/s44324-026-00106-4
-
Daniel J Drucker
@DanielJDrucker
The cellular complexity and plasticity of the human adipose vasculature www.nature.com/articles/s42255-026-01475-2
-
Daniel J Drucker
@DanielJDrucker
GLP-1 RA exposure in systemic lupus erythematosus patients with type 2 diabetes mellitus is associated with reduced risks of lupus nephritis, and systemic lupus erythematosus flares
www.amjmed.com/article/S0002-9343(26)00146-4/abstract -
Daniel J Drucker
@DanielJDrucker
Safety first-new analyses of B12-compounded Tirzepatide @EliLillyandCo investor.lilly.com/node/53991/pdf
-
Daniel J Drucker
@DanielJDrucker
Acarbose, used for decades in people with #t2d is proposed as a nephroprotective agent via reduced TDP-43 aggregation in podocytes, preventing podocyte loss, and mitigating albuminuria www.science.org/doi/10.1126/scitranslmed.ads4585
-
Daniel J Drucker
@DanielJDrucker
Congratulations to Prof Naveed Sattar, MBChB, PhD, FRCP (Glasg), FRCPath, FRSE, FMedSci: 2026 Outstanding Achievement in Clinical Diabetes Research Awardee @AmDiabetesAssn
-
Daniel J Drucker
@DanielJDrucker
Congratulations to Dr. Chantal Mathieu, MD, PhD: 2026 Distinguished International Service in the Cause of Diabetes Awardee @AmDiabetesAssn @EASDnews www.prnewswire.com/news-releases/the-american-diabetes-asā¦
-
Daniel J Drucker
@DanielJDrucker
There are increasing options for accessing legitimate @US_FDA approved GLP-1 medicines. Yet over the counter supplements with attractive claims abound with advertising designed to separate consumers from hard earned coin. How expensive is your urine?
-
Daniel J Drucker
@DanielJDrucker
No doubt #weightloss also provides a range of additional benefits to many of the comorbidities successfully targeted by GLP-1 medicines. Yet for some conditions (not all) weight loss-independent mechanisms also contribute #hypertension insight.jci.org/articles/view/201148
stephen o'rahilly (its pronounced O-RA-hill-EEE)
@StephenORahilly
Semaglutide Reduces Murine Blood Pressure Through the Vascular Smooth Muscle GLP-1 Receptor insight.jci.org/articles/view/201148 From @DanielJDrucker Convincing demonstration of a therapeutically relevant effect of GLP1Ra agonism that is independent of its effects on appetite
-
Daniel J Drucker
@DanielJDrucker
Hyperinsulinemia, adiposity, causality and #obesity The latest perspectives www.nature.com/articles/s41574-026-01240-1
-
Daniel J Drucker
@DanielJDrucker
The pursuit of supplements to slow the #aging process and extend healthspan continues-from epigenetic clocks to expensive urine, the benefits or lack thereof reflect the utility of the endpoints www.nature.com/articles/s41591-026-04239-3
-
Daniel J Drucker
@DanielJDrucker
Studies in Drosophila reveal that Akh (glucagon-mimetic) signaling pathway provides new understanding of the regulatory mechanisms between metabolic disease and cardiac arrhythmia. elifesciences.org/articles/94512
-
Daniel J Drucker
@DanielJDrucker
High intensity interval training HIIT identified as a potent stimulus for improving muscle oxidative and metabolic health in type 2 #diabetes in part via expanding muscle mitochondrial cristae density link.springer.com/article/10.1007/s00125-026-06694-6
-
Daniel J Drucker
@DanielJDrucker
ERāmitochondria calcium coupling is essential for glucose-induced GLP-1 secretion in L cells @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06693-7
-
Daniel J Drucker
@DanielJDrucker
GRK2 ia a previously unrecognized regulator of α-cell glucagon secretion that influences systemic energy balance and cardiac performance through endocrine crosstalk. www.sciencedirect.com/science/article/pii/S0026895X26000155
-
Daniel J Drucker
@DanielJDrucker
Dietary restriction strategies for #aging #healthspan www.nature.com/articles/s43587-026-01091-5
-
Daniel J Drucker
@DanielJDrucker
A peak at the tolerability data for petrelintide, a potential key point for differentiation in the emerging class of Amylin-based medicines for #weightloss #obesity www.zealandpharma.com/media/ouvbokrh/20260305_zupreme-1-cā¦
Daniel J Drucker
@DanielJDrucker
Favorable tolerability, up to 9% placebo-subtracted #weightloss for Petrelintide, an Amylin Analog, in People Living With Overweight and Obesity after 42 weeks www.businesswire.com/news/home/20260305198579/en/Genentecā¦
-
Daniel J Drucker
@DanielJDrucker
The vascular smooth muscle GLP-1R controls the baseline kidney proteome and the renal proteomic response to semaglutide in mice @JCI_insight insight.jci.org/articles/view/201148 #kidney
-
Daniel J Drucker
@DanielJDrucker
Favorable tolerability, up to 9% placebo-subtracted #weightloss for Petrelintide, an Amylin Analog, in People Living With Overweight and Obesity after 42 weeks www.businesswire.com/news/home/20260305198579/en/Genentecā¦
-
Daniel J Drucker
@DanielJDrucker
Preclinical studies show that an inhibitor of the gerozyme 15-hydroxyprostaglandin dehydrogenase (PGDHi), which boosts PGE2 levels, increases skeletal muscle mass, strength, and regeneration in the presence of semaglutide www.biorxiv.org/content/biorxiv/early/2026/02/28/2026.02.ā¦
-
Daniel J Drucker
@DanielJDrucker
More data linking gut microbial metabolism of aromatic amino acids, phenylalanine and tyrosine, associate with circulating pro-atrial natriuretic peptide and estimated glomerular filtration rate #microbiome www.nature.com/articles/s41467-026-69405-0
-
Daniel J Drucker
@DanielJDrucker
Here tanycyte-derived EVs identified as regulators of feeding diurnality through insulin precursor-directed targeting and delivery of mTORC components to hypothalamic neurons.#diabetes #obesity www.nature.com/articles/s42255-026-01474-3
-
Daniel J Drucker
@DanielJDrucker
Are substance use disorders the next frontier for GLP-1 medicines.? Moving the needle from real world data to large RCTs will be critical www.nature.com/articles/d41586-026-00734-2
-
Daniel J Drucker
@DanielJDrucker
Semaglutide significantly improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and promoted substantial #weightloss in patients with antipsychotic-induced metabolic disturbances. diabetesjournals.org/care/article/doi/10.2337/dc25-2041/1ā¦
-
Daniel J Drucker
@DanielJDrucker
More chemogenetic evidence for the importance of murine PPGNTS+IRT neurons in the control of satiety, food intake and body weight @MolMetab www.sciencedirect.com/science/article/pii/S2212877826000311
-
Daniel J Drucker
@DanielJDrucker
By linking tryptophan and indole to GLP-1 secretion and glucose homeostasis, the authors propose new avenues for developing novel strategies to combat type 2 #diabetes @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06688-4
-
Daniel J Drucker
@DanielJDrucker
New from Megan Capozzi @UW Postprandial glycogen repletion and the surprising role of glucagon insight.jci.org/articles/view/201076 @JCI_insight
-
Daniel J Drucker
@DanielJDrucker
Law and order? Safety and quality? What will 2026 bring to GLP-1 medicine sales and distribution? www.fda.gov/news-events/press-announcements/fda-warns-30-ā¦
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines have multiple direct and indirect effects that modify cardiovascular risk. Here Kyle Medak @SinaiHealth and colleagues identify an important role for the VSM GLP-1R in the reduction of blood pressure #hypertension @JCI_insight @uoftmedicine insight.jci.org/articles/view/201148
-
Daniel J Drucker
@DanielJDrucker
A roadmap towards developing metabotherapies for intestinal disease. #microbiota www.nature.com/articles/s41575-026-01178-9
-
Daniel J Drucker
@DanielJDrucker
Subcutaneous bimagrumab perhaps once weekly is a very feasible approach for drug delivery going forward link.springer.com/article/10.1007/s40262-022-01189-0
Michael Albert, MD
@MichaelAlbertMD
I don't care how good it is; intravenous means it will require an infusion, which inherently means it won't be widely available or accessible.
Daniel J Drucker
@DanielJDrucker
The BELIEVE study, the efficacy and safety of intravenous bimagrumab and open-label subcutaneous semaglutide, alone or in combination, in adults with #obesity www.nature.com/articles/s41591-026-04204-0
-
Daniel J Drucker
@DanielJDrucker
Taken too soon Prof Ross Laybutt @DiabetologiaJnl @EASDnews link.springer.com/article/10.1007/s00125-026-06704-7
-
Daniel J Drucker
@DanielJDrucker
The BELIEVE study, the efficacy and safety of intravenous bimagrumab and open-label subcutaneous semaglutide, alone or in combination, in adults with #obesity www.nature.com/articles/s41591-026-04204-0
-
Daniel J Drucker
@DanielJDrucker
New preclinical studies identify lipidated IL-22, a pleiotropic gut hormone secretagogue, as a novel anti- #obesity treatment with multiple modes of action www.cell.com/molecular-therapy-family/molecular-therapy/aā¦
-
Daniel J Drucker
@DanielJDrucker
šÆ
Michael Mindrum, MD
@MichaelMindrum
1. Weight regain is exceptionally common in obesity via lifestyle changes ā Dr Kevin Hall while at NIH before it was gutted had modeled how for every kg of weight loss there is an avg 25 kcal decrease in metabolic rate and 100 kcal increase in appetite. This is driven by hormonal and neurological changes in the hypothalamus.
2. Obesity is a chronic complex and relapsing disease. Every intervention whether lifestyle, drug , or surgery meets the brains defense against weight loss. Drugs and surgery operate by reducing the power of that defense described in #1. When you stop the drug that treated the chronic disease, the manifestations of the disease return
3. Obesity as a disease is not intuitive to understand. Without education and training, a physician falls back on beliefs they learned in society such as āobesity is a behaviourā. This is at the root of toxic bias and stigma which has caused harm in countless physician patient interactions.
Just as an internist calls upon an EP specialist to offer expert advice, education, and management on atrial fibrillation, a cardiologist could spend some time learning from an obesity specialist and appreciate that perhaps they have insufficient understanding to offer an informed opinion on a topic -
Daniel J Drucker
@DanielJDrucker
Is persistence improving with new #weightloss medicines www.jmcp.org/doi/10.18553/jmcp.2026.32.3.281
-
Daniel J Drucker
@DanielJDrucker
The important role of IL2RA in immune tolerance and β-cell protection highlighted by early onset type 1 #diabetes diabetesjournals.org/diabetes/article/doi/10.2337/db25-08ā¦
-
Daniel J Drucker
@DanielJDrucker
The #microbiota driven road towards development of personalized therapies for patients receiving allo-HCT, integrating #microbiome profiles with individual risk data #gvhd www.nature.com/articles/s41568-026-00910-6
-
Daniel J Drucker
@DanielJDrucker
Studies in mice define endocrine-exocrine beta cell-derived CCK signaling as a bona fide driver of #obesity associated PDAC development and uncover avenues to target the endocrine pancreas to subvert exocrine tumorigenesis. #pancreaticcancer www.nature.com/articles/s41467-026-69821-2
-
Daniel J Drucker
@DanielJDrucker
Obesity and neurodegeneration www.nature.com/articles/s42255-026-01477-0
-
Daniel J Drucker
@DanielJDrucker
SEL1L-HRD1 endoplasmic reticulum (ER)-associated degradation (ERAD) is a regulator of PC2 biology and an essential mechanism for maintaining α cell function and glucagon biosynthesis www.nature.com/articles/s41467-026-69928-6
-
Daniel J Drucker
@DanielJDrucker
ACHIEVE-3 Oral semaglutide vs. Orforglipron #t2d www.thelancet.com/journals/lancet/article/PIIS0140-6736(2ā¦
Daniel J Drucker
@DanielJDrucker
ACHIEVE-3 Orforglipron (12 & 36mg) vs. Oral semaglutide at doses (7 & 14mg) approved for #t2d #diabetes investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
ACHIEVE-3 Orforglipron (12 & 36mg) vs. Oral semaglutide at doses (7 & 14mg) approved for #t2d #diabetes investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
A simplified model GlucoseGo for predicting hypoglycaemia during #exercise #t1d @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06692-8
-
Daniel J Drucker
@DanielJDrucker
A new role for the ion channel VRAC in balancing nutrient absorption and antimicrobial defense in enterocytes to safeguard gut homeostasis www.nature.com/articles/s41467-026-69963-3
-
Daniel J Drucker
@DanielJDrucker
How to navigate the evidence-based road to reducing rates of #obesity associated #cancer www.nature.com/articles/s41416-026-03355-8
-
Daniel J Drucker
@DanielJDrucker
The early evolution of predictive autoimmune responses in children on the path to #t1d development n the TRIGR study www.nature.com/articles/s41467-026-69923-x
-
Daniel J Drucker
@DanielJDrucker
Based on studies in mice identifying P. copri as a key microbial mediator via macrophages & T cells of cold-induced adipose remodeling and thermogenesis, the authors propose microbial metabolites as potential metabolic therapies #obesity @Cell_Metabolism www.cell.com/cell-metabolism/abstract/S1550-4131(26)00019-7
-
Daniel J Drucker
@DanielJDrucker
Semaglutide as an add-on treatment to insulin exerted relevant clinical beneficial effects on the glycometabolic control in patients with LADA #diabetes academic.oup.com/jcem/advance-article/doi/10.1210/clinem/ā¦
-
Daniel J Drucker
@DanielJDrucker
Studies of sperm mitochondrial activity in mice #obesity reveal that microRNA let-7 in sperm reprograms offspring metabolism by modulating mitochondrial function during early development
www.nature.com/articles/s41467-026-69686-5 -
Daniel J Drucker
@DanielJDrucker
New from Klaus Kaestner @PennMedicine Foxl1 orchestrates key events during the epithelial transition of the fetal mammalian gut via signaling in telocyte progenitors www.nature.com/articles/s41467-026-69791-5
-
Daniel J Drucker
@DanielJDrucker
Beyond the next incremental gain in #weightloss and A1c reduction, the important opportunity for improving cardiometabolic health requires improving adherence and persistence @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06617-x @kamleshkhunti #diabetes
-
Daniel J Drucker
@DanielJDrucker
P2 #weightloss data #obesity for an emerging triple G agonist in China, mean baseline weight 92.2 kg link.springer.com/article/10.1007/s00125-025-06617-x
-
Daniel J Drucker reposted
Shivani Misra
@ShivaniM_KC
Whoeverās making fun are clearly idiots!
Come and sit in clinic with me and feel good that we have more solutions for those who donāt to lose any weight on 15mg of tirzepatide or who have side effects and cannot tolerate it.
A suite of options are needed - Iām super happy Novo did this trial.
Dr. Spencer Nadolsky
@DrNadolsky
Everyone is making fun of Novo for doing this trial. I think it should be applauded that big pharma took a swing even though they missed.
Science won. Investors did not. -
Daniel J Drucker reposted
Beverly G. Tchang, MD
@BevTchangMD
I wouldn't call 23% a miss.
SURMOUNT-1 data reminds us that tirzepatide did not work for weight loss in ~10% of people.
All of my patients who didn't see significant #weightloss with tirzepatide will be trialed on CagriSema. Amylin introduces a different mechanism.
The differentiation here will unmask the heterogeneity of #obesity
Dr. Spencer Nadolsky
@DrNadolsky
Everyone is making fun of Novo for doing this trial. I think it should be applauded that big pharma took a swing even though they missed.
Science won. Investors did not. -
Daniel J Drucker
@DanielJDrucker
Here the authors propose that S-nitrosoglutathione reductase (GSNOR), a pivotal denitrosation enzyme that controls Adipose tissue thermogenesis is a therapeutic target for age-related #obesity www.nature.com/articles/s41467-026-69793-3
-
Daniel J Drucker
@DanielJDrucker
Studies in mice suggest that uncoupled respiration in white adipocytes contributes to whole-body energy expenditure and could be a promising target for #obesity treatment www.nature.com/articles/s42255-026-01467-2
-
Daniel J Drucker
@DanielJDrucker
Preclinical studies suggest that targeting immunometabolic pathways with a glucokinase activator may offer a therapeutic strategy to alleviate cardiac dysfunction and reduce infarct vulnerability in #t2d www.nature.com/articles/s44161-025-00769-0 #cvd
-
Daniel J Drucker
@DanielJDrucker
Here cell type- and disease-specific metabolic consequences of loss of the Y chromosome #diabetes www.nature.com/articles/s41591-026-04213-z
-
Daniel J Drucker
@DanielJDrucker
Cagri-Sema vs, Tirzepatide H2H in REDEFINE-4 #weightloss #obesity www.novonordisk.com/content/nncorp/global/en/news-and-medā¦
-
Daniel J Drucker
@DanielJDrucker
Studies in mice demonstrate the importance of glutamatergic neurons in GPR75ās regulation of food intake and protection from #obesity www.cell.com/cell-reports/fulltext/S2211-1247(26)00089-6
-
Daniel J Drucker
@DanielJDrucker
IL-22 identified as an important regulator of intestinal GLP-1 production and glucose homeostasis during diet-induced #obesity in mice www.nature.com/articles/s41467-026-69734-0
-
Daniel J Drucker
@DanielJDrucker
A new review looks at the metabolic effects of Non-Nutritive Sweeteners #diabetes #obesity academic.oup.com/nutritionreviews/advance-article/doi/10.ā¦
-
Daniel J Drucker
@DanielJDrucker
A detailed look at the hepatic spatial proteome @NatMetabolism www.nature.com/articles/s42255-026-01459-2
-
Daniel J Drucker
@DanielJDrucker
Considerations on frailty and type 1 diabetes #t1d @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06681-x
-
Daniel J Drucker
@DanielJDrucker
A 3D perspective on adipose tissue #cancer interactions in the TME www.nature.com/articles/s41388-026-03697-w
-
Daniel J Drucker
@DanielJDrucker
Can and should one target visceral adipose tissue to improve cardiometabolic health? www.nature.com/articles/s43587-026-01076-4
-
Daniel J Drucker
@DanielJDrucker
Congratulations to Dr Ron Wald, staff nephrologist @UnityHealthTO @uoftmedicine @nkf
www.kidney.org/press-room/toronto-nephrologist-to-be-hono⦠@DrRonWald -
Daniel J Drucker
@DanielJDrucker
Here adipocyte #circadian disruption impairs metabolic health through mitochondrial complex I dysfunction, establishing clock control of complex I as a key regulator of metabolic homeostasis.
www.nature.com/articles/s42255-026-01464-5 -
Daniel J Drucker
@DanielJDrucker
The potential and challenges of developing amylin-based treatments for cardiometabolic disease www.nature.com/articles/s42255-026-01465-4
-
Daniel J Drucker
@DanielJDrucker
First Psoriatic arthritis now #psoriasis together with ixekizumab investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
7.2mg semaglutide once weekly coming to @EMA_News www.novonordisk.com/content/nncorp/global/en/news-and-med⦠#weightloss #obesity
-
Daniel J Drucker
@DanielJDrucker
More than 10 years ago, GLP-1R expression was (mis)-localized to the normal and neoplastic thyroid epithelium using non-validated reagents raising concerns about the risk of differentiated thyroid #cancer with GLP-1 medicines academic.oup.com/jcem/article-abstract/97/1/121/2833224?
Daniel J Drucker
@DanielJDrucker
Here, new analyses show use of GLP-1RA are not associated with recurrent/progressive DTC. Eligible patients with DTC should not be denied the cardiometabolic benefits of GLP-1RA when clinically indicated academic.oup.com/jcem/advance-article/doi/10.1210/clinem/ā¦
-
Daniel J Drucker
@DanielJDrucker
Beta cell development and function. The case for iron www.nature.com/articles/s41467-026-69574-y
-
Daniel J Drucker
@DanielJDrucker
The as yet unfulfilled promise of GLP-1 medicines and neurodegenerative disorders @jclinicalinvest www.jci.org/articles/view/194745
-
Daniel J Drucker
@DanielJDrucker
AI-IR is a robust metric for predicting both #diabetes and the composite #cancer incidence and could be utilized for identification of high-risk individuals and focused screening.
www.nature.com/articles/s41467-026-68355-x #ai #insulin resistance -
Daniel J Drucker
@DanielJDrucker
GLP-1 (glucagon-like peptide 1) protects the mouse heart after ischaemia by activating ATP-sensitive K+ channels on pericytes that constrict coronary capillaries www.nature.com/articles/s41467-026-69555-1
-
Daniel J Drucker
@DanielJDrucker
Based on studies in humans & mice with FMT, the authors infer that gut #microbiota driven dysregulation of BA signaling, particularly impaired TGR5 activation due to diminished GDCA, underlies glycolipid metabolic dysfunction in #obesity prone individuals. www.sciencedirect.com/science/article/pii/S22113835250079ā¦
-
Daniel J Drucker
@DanielJDrucker
Another real world parse of NAION risk from a VA new user cohort. The incidence rate of NAION was 123 per 100 000 person-years among semaglutide initiators and 67 per 100 000 person-years among SGLT2i #t2d jamanetwork.com/journals/jamaophthalmology/fullarticle/28ā¦
-
Daniel J Drucker
@DanielJDrucker
A new plausible molecular mechanism by which environmental exposures induce location-specific, three-dimensional changes in chromatin structure that transmit susceptibility to metabolic disorders to subsequent unexposed generations in mammal www.nature.com/articles/s41467-026-69214-5
-
Daniel J Drucker
@DanielJDrucker
What do tennis star Serena Williams, television personality Oprah Winfrey and actors Kathy Bates and Whoopi Goldberg have in common? The rise of GLP-1 medicines led by semaglutide #weightloss #obesity www.nature.com/articles/d41586-026-00228-1
-
Daniel J Drucker
@DanielJDrucker
Studies in mice reveal an unexpected role for carnitine in the optimal efficacy of GLP-1RAābased anti- #obesity therapy and loss of adipose tissue #weightloss www.science.org/doi/10.1126/science.ady5532
-
Daniel J Drucker
@DanielJDrucker
Broadening the intersection of GIPR signaling with anorectic and aversive actions of PYY in mice @MolMetab www.sciencedirect.com/science/article/pii/S2212877826000189
-
Daniel J Drucker
@DanielJDrucker
Rare LoF variants in TUB predispose to young-onset #obesity in humans, likely through impairing leptin sensitivity in AgRP+ neurons www.science.org/doi/10.1126/scitranslmed.adw0458
-
Daniel J Drucker
@DanielJDrucker
The fascinating metabolic biology of protein fragments Here
the Asp rosin-Ptprf axis offers a potential therapeutic target for #diabetes and #obesity www.cell.com/cell-reports/fulltext/S2211-1247(26)00052-5 -
Daniel J Drucker
@DanielJDrucker
In a cohort study of women with benign uterine pathology or endometrial hyperplasia, combined GLP-1RA and progestin was associated with reduced Endometrial #cancer risk jamanetwork.com/journals/jamanetworkopen/fullarticle/2844879
-
Daniel J Drucker
@DanielJDrucker
Topline data on Ribupatide an oral GLP-1R-GIPR medicine with a focus on double digit #weightloss at 26 weeks www.kailera.com/press-release/kailera-therapeutics-and-heā¦
-
Daniel J Drucker reposted
Helmholtz Diabetes Center (HDC)
@helmholtz_diabc
š We are live!
The website for the 13th Helmholtz Diabetes Conference is now online!
Explore the speaker list and key information on the meeting on 21ā23 September!
Program & registration coming soon.
š www.helmholtz-munich.de/en/diabetes-conference
#savethedate #staytuned #helmholtzdiabetes2026 -
Daniel J Drucker
@DanielJDrucker
A 24-week semaglutide 1mg qw intervention in people with #overweight #obesity induces neurobiological remodelling in the left temporal lobe dissociated from changes in cognitive function or metabolic improvement dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/doā¦
-
Daniel J Drucker
@DanielJDrucker
New studies developing the model of Human Jejunal Enteroids HJEs in preclinical for L cell biology, GLP-1 secretion and enteroendocrine dysfunction. #diabetes www.nature.com/articles/s41366-026-02024-3
-
Daniel J Drucker
@DanielJDrucker
A spotlight on pancreatic exocrine fibrosis and #t2d @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06678-6 #islets
-
Daniel J Drucker
@DanielJDrucker
Partitioned polygenic risk scores offer a promising approach for early risk stratification, personalised prevention and improved management for #t2d #hypertension www.nature.com/articles/s41467-025-67449-2 #genetics
-
Daniel J Drucker
@DanielJDrucker
AI based analysis of human pancreatic histology provides a foundation for future research into relevant diagnostic and therapeutic targets, refining several hypotheses regarding tissue alterations associated with #t2d www.nature.com/articles/s41467-026-69295-2
-
Daniel J Drucker
@DanielJDrucker
Mouse and cliniucal data support a #weightloss independent action of semaglutide to protect cartilage and improve osteoarthritis @Cell_Metabolism www.cell.com/cell-metabolism/abstract/S1550-4131(26)00008-2
Daniel J Drucker
@DanielJDrucker
Here is the pilot clinical trial using semaglutide in people with osteoarthritis, demonstrating remarkable cartilage thickening after 24 weeks www.cell.com/cell-metabolism/abstract/S1550-4131(26)00008-2 #osteoarthritis
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines and Olympic athletes š„š„š„-Performance altering medicines? Negatively, positively? Helping to achieve weight thresholds? Desirable #weightloss ? Multiple dimensions to the possibilities @Olympics www.medpagetoday.com/popmedicine/cultureclinic/119770
-
Daniel J Drucker
@DanielJDrucker
Observational cohort data from All of Us suggest that prior Rx for GLP-1RAs may reduce alcohol consumption by decreasing use frequency. www.medrxiv.org/content/10.64898/2026.01.15.26344218v1
-
Daniel J Drucker
@DanielJDrucker
The intersection of #genetics susceptibility, childhood red meat consumption and risk of #t1d #nutritionalepiemiology @DiabetologiaJnl link.springer.com/article/10.1007/s00125-026-06671-z
-
Daniel J Drucker reposted
U.S. FDA
@FDA
Today, the FDA is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies ā including Hims & Hers and other compounding pharmacies ā as similar alternatives to FDA-approved drugs. www.fda.gov/news-events/press-announcements/fda-intends-tā¦
-
Daniel J Drucker
@DanielJDrucker
An overview of The Physiology Of the WEight Reduced State (POWERS) study #weightloss www.nature.com/articles/s41366-025-01944-w
-
Daniel J Drucker
@DanielJDrucker
Here the authors identify the prostratin and aPKC/GLUT1 signalling pathways as putative targets for treating #diabetes through enhancing intestinal glucose excretion www.nature.com/articles/s41467-026-69193-7
-
Daniel J Drucker
@DanielJDrucker
Making gut epithelium, an update from the maestro @HansClevers www.cell.com/cell/fulltext/S0092-8674(25)01438-2 #stemcells @CellCellPress
-
Daniel J Drucker
@DanielJDrucker
Here the authors highlight the therapeutic potential of a ketogenic diet and microbiome modulation for the treatment of sepsis. www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00005-7
-
Daniel J Drucker
@DanielJDrucker
Studies in cells and mice reveal that the human GLP1R A316T variant exhibits characteristics of constitutive activation but dampened GLP-1RA responses www.science.org/doi/10.1126/sciadv.adw0899
-
Daniel J Drucker
@DanielJDrucker
Expanding evidence that the brain controls peripheral immune responses. A bidirectional tumourābrain communication network involving Npy2r vagal sensory input and sympathetic output that cooperatively regulate anti-cancer immunity www.nature.com/articles/s41586-025-10028-8
-
Daniel J Drucker
@DanielJDrucker
On my way to ā¦@DukeUā© to visit the outstanding faculty in metabolism, cardiovascular disease, medicine and GPCR signalling. Need to stay on top of the literature so perused the airport news stand for the latest ā¦@DukeMedSchoolā©
-
Daniel J Drucker
@DanielJDrucker
As the #obesity #weightloss medicine market matures, @novonordisk looks to the pipeline including the unimolecular Amycretin entering P3 trials #td assets.main.pro2.maf.media-server.com/da6ae64538184ebfa39ā¦
-
Daniel J Drucker
@DanielJDrucker
As the orforglipron clinical trials portfolio expands #weightloss #t2d #obesity two notable trials in cardiovascular disease and peripheral artery disease are now highlighted investor.lilly.com/static-files/45a92498-43d0-4e2d-a4e6-aā¦
-
Daniel J Drucker
@DanielJDrucker
Health care registry data from Ontario with 10 yr F/U reveals that maternal #diabetes particularly #t1d and #t2d is associated with a small increased epilepsy risk in offspring publications.aap.org/pediatrics/article-abstract/doi/10.1ā¦
-
Daniel J Drucker
@DanielJDrucker
A new look at the development of ILC lineages with perspectives on links to NK and T cells #inflammation www.nature.com/articles/s41590-025-02414-1
-
Daniel J Drucker
@DanielJDrucker
Alcohol use disorders and use of GLP-1 medicines after bariatric surgery. A real world perspective jamanetwork.com/journals/jamanetworkopen/fullarticle/2843122
-
Daniel J Drucker
@DanielJDrucker
New #weightloss data for PF-08653944 (PFā3944; previously called MET-097i) at 28 weeks including several months at once monthly dosing intervals #obesity www.pfizer.com/news/press-release/press-release-detail/pfā¦
-
Daniel J Drucker
@DanielJDrucker
Dissecting the importance of the murine GCGR vs the GLP-1R for the CNS and #weightloss actions of survodutide @MolMetab www.sciencedirect.com/science/article/pii/S2212877826000104
-
Daniel J Drucker
@DanielJDrucker
A microphysiological system (MPS) featuring multicellular human hepatic spheroids physically integrated with self-organized microvascular networks for studies of #insulin resistance www.nature.com/articles/s41467-025-68031-6
-
Daniel J Drucker
@DanielJDrucker
#diabetes remission occurred earlier and more frequently in young vs. older adults within the first 5 years after RYGB @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06665-3
-
Daniel J Drucker
@DanielJDrucker
Here, chronic alcohol consumption in humans or mice was associated with decreased GLP-1R gene expression in brain regions involved in the reinforcing effects of ethanol www.nature.com/articles/s41398-026-03838-5
-
Daniel J Drucker
@DanielJDrucker
A $1.2 B upfront deal for development of medicines #weightloss www.astrazeneca.com/media-centre/press-releases/2026/astrā¦
-
Daniel J Drucker
@DanielJDrucker
αMG stimulates endogenous glucagon secretion via SGLT1 in mice and may lead to a therapeutic strategy for #obesity associated metabolic diseases. www.sciencedirect.com/science/article/pii/S2212877826000086 @MolMetab
-
Daniel J Drucker reposted
Nature Reviews Drug Discovery
@NatRevDrugDisc
For readers interested in GLP-1-based therapies for obesity and beyond, such as Roche's candidate CT-388, here's a comprehensive review
www.nature.com/articles/s41573-025-01183-8
rdcu.be/e09xH -
Daniel J Drucker
@DanielJDrucker
Novel methods for non-invasive interrogation of the onset of type 1 #diabetes #t1d www.science.org/doi/10.1126/sciadv.adw8946
-
Daniel J Drucker
@DanielJDrucker
Vagal mechanoreceptors monitor the cardiac cycle and initiate a blood-volume-dependent reflex that defends the constancy of circulation. www.nature.com/articles/s41586-025-10010-4
-
Daniel J Drucker
@DanielJDrucker
Towards understanding the clinical dose-response (duration, intensity) for the pleiotropic benefits of #exercise www.nature.com/articles/d41586-026-00237-0
-
Daniel J Drucker
@DanielJDrucker
Introducing the inflammatome, a comprehensive set of 2,000 genes consistently upregulated in various inflammatory diseases vs. healthy controls. www.cell.com/cell-reports/fulltext/S2211-1247(25)01655-9
-
Daniel J Drucker
@DanielJDrucker
Discovery of an allosteric ligand that stabilizes a GPCR-G protein-β-arrestin megacomplex, thereby mediating sustained receptor signaling following internalization www.cell.com/cell/abstract/S0092-8674(25)01436-9
-
Daniel J Drucker
@DanielJDrucker
Never forget
-
Daniel J Drucker
@DanielJDrucker
Among burn patients who received GLP-1 RAs within 30 days of injury in TriNetX there was at 90 days post-burn, significantly lower rates of soft tissue infection, opioid prescriptions, readmission, and mortality www.sciencedirect.com/science/article/abs/pii/S0305417925ā¦
-
Daniel J Drucker
@DanielJDrucker
The evolution of cystic fibrosis-related #diabetes link.springer.com/article/10.1007/s00125-025-06653-7
-
Daniel J Drucker
@DanielJDrucker
Substantial 22.5% #weightloss for 1 year #obesity with the dual GLP-1R-GIPR medicine CT-388 from @Roche www.roche.com/media/releases/med-cor-2026-01-27
-
Daniel J Drucker
@DanielJDrucker
New insights into cross-ancestry and tissue-informed multi-omics causal inference approaches demonstrating their power in uncovering molecular processes driving #t2d #diabetes #genetics www.nature.com/articles/s42255-025-01444-1
-
Daniel J Drucker
@DanielJDrucker
Here the authors advocate that integrating gut #microbiome data into clinical strategies may enable targeted interventions for specific #obesity subtypes, advancing prevention and personalized care. www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25ā¦
-
Daniel J Drucker
@DanielJDrucker
Food for thought and food that is bought. After starting a GLP-1 medicine, participants purchased fewer calories, sugars, saturated fats, and carbohydrates, alongside modestly more protein. The share of ultraprocessed foods also decreased š©š°jamanetwork.com/journals/jamanetworkopen/fullarticle/2844224
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose oral #microbiome -host interactions as novel targets for #obesity prevention and intervention www.cell.com/cell-reports/fulltext/S2211-1247(25)01591-8
-
Daniel J Drucker
@DanielJDrucker
Bempedoic acid produces direct PPARα activation as a key mechanism of BA action, providing a molecular basis for its lipid-lowering effects and suggesting broader therapeutic potential beyond the liver www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00549-2
-
Daniel J Drucker
@DanielJDrucker
Using TriNetX real world data in people with #t2d the authors present evidence of a delayed neuroprotective effect of GLP-1RAs for incident #parkinsonsdisease dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70459
-
Daniel J Drucker
@DanielJDrucker
New high resolution structural insights into species specific structural determinants of diabetogenic amyloid oligomers www.pnas.org/doi/10.1073/pnas.2528103123
-
Daniel J Drucker
@DanielJDrucker
Should one consider trials of GLP-1 medicines in #fibromyalgia Real world data and use of pain medicines academic.oup.com/rheumatology/advance-article/doi/10.1093ā¦
-
Daniel J Drucker
@DanielJDrucker
An appraisal of mouse models for MASLD and MASH-associated HCC www.nature.com/articles/s41575-025-01162-9
-
Daniel J Drucker
@DanielJDrucker
Comprehensive analyses reveal that muscle cells utilize both CAV1 and CLTC-dependent pathways for INSR dynamics and internalization. www.biorxiv.org/content/10.1101/2021.06.29.450241v3 #insulin
-
Daniel J Drucker
@DanielJDrucker
A spatially-resolved single cell atlas of sex-differentially expressed (sex-DE) genes in human VMH and ARC #hypothalamus www.biorxiv.org/content/10.1101/2024.12.07.627362v3
-
Daniel J Drucker
@DanielJDrucker
New therapeutic approaches, such as low-dose colchicine, PCSK9 inhibitors, antithrombotic therapies, GLP1 receptor agonists and SGLT2 inhibitors, offer new therapeutic avenues for reducing residual risk #cvd #heartdisease www.nature.com/articles/s41569-026-01249-z
-
Daniel J Drucker
@DanielJDrucker
A possible sensitizing effect of HRT on tirzepatide-associated weight loss in postmenopausal women with overweight or obesity i www.thelancet.com/journals/lanogw/article/PIIS3050-5038(2ā¦
-
Daniel J Drucker
@DanielJDrucker
#weightloss responses and weight regain-acknowledging inter-individual heterogeneity with responses to GLP-1 medicines www.reuters.com/business/healthcare-pharmaceuticals/many-ā¦
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose targeting olfactory receptors using a synthetic agonist HOR1-C59 reduces obesity through hepatic fatty acid oxidation www.cell.com/cell/abstract/S0092-8674(25)01429-1?dgcid=raā¦
-
Daniel J Drucker
@DanielJDrucker
In children with stage 1 #t1d, 1 year of high-dose oral insulin did not alter progression to dysglycemia or #diabetes or immune response to insulin diabetesjournals.org/care/article/doi/10.2337/dc25-2818/1ā¦
-
Daniel J Drucker
@DanielJDrucker
An ex vivo approaching for interrogating the gut brain axis and blood brain barrier function www.nature.com/articles/s42003-025-09472-z
-
Daniel J Drucker
@DanielJDrucker
A mechanistic link, via CD226+ NK cells and IL-21 bridging adaptive and innate immunity, in the progression and remission of T1D that could potentially be exploited in #t1d immunotherapy www.nature.com/articles/s42255-025-01439-y
-
Daniel J Drucker
@DanielJDrucker
Individuals with remission of type 2 diabetes after RYGB have better beta cell function than those not achieving remission, but the groups did not differ with respect to beta cell mass. link.springer.com/article/10.1007/s00125-025-06659-1
-
Daniel J Drucker
@DanielJDrucker
A mechanistic explanation for the dissociation between the thermogenic and glycaemic effects of BAT activation www.nature.com/articles/s42255-025-01429-0
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that metabolomic changes caused by varying carbohydrate-to-fat ratio
CFR dietary patterns, offer potential insights into mechanisms that could guide targeted dietary intervention strategies www.nature.com/articles/s41467-026-68353-z -
Daniel J Drucker reposted
Eric Topol
@EricTopol
Can GLP-1 drugs reduce the incidence of cancer, independent of weight loss? Results from cohort studies are encouraging for many types (Figure) and clinical trials are ongoing @NatureCancer
www.nature.com/articles/s43018-025-01110-1 -
Daniel J Drucker reposted
Eric Topol
@EricTopol
The gastrointestinal side effects of GLP-1 drugs are mediated by the brain, not the gut. The gut-brain axis at work @jclinicalinvest
www.jci.org/articles/view/194744 -
Daniel J Drucker
@DanielJDrucker
Will advances in #precisionmedicine unlock the mystery of heterogeneity in inter-individual responses to GLP-1 medicines www.jci.org/articles/view/194742 #genetics @jclinicalinvest
-
Daniel J Drucker
@DanielJDrucker
Can one optimize next generation GLP-1 medicines through deconstructing of GPCR signaling? @jclinicalinvest www.jci.org/articles/view/194752
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines might stimulate cell proliferation in some GLP-1R+ cell types, while exerting direct and indirect effects on the Tumour MicroEnvironment. It will take time to see the overall impact on #obesity associated cancer. Free to read @NatureCancer rdcu.be/eZlv0
Daniel J Drucker
@DanielJDrucker
Beyond #weightloss How might GLP-1 medicines modify rates of #obesity associated cancer and response to treatment? www.nature.com/articles/s43018-025-01110-1
-
Daniel J Drucker
@DanielJDrucker
Burn baby burn (Disco Inferno 1976)-analysis and visualization of human energy expenditure data www.nature.com/articles/s42255-025-01445-0
-
Daniel J Drucker
@DanielJDrucker
The roles of gut and liver restricted LXR inverse agonists in lipid metabolism and metabolic diseases in preclinical models and humans www.nature.com/articles/s41591-025-04169-6
-
Daniel J Drucker
@DanielJDrucker
Beyond #weightloss How might GLP-1 medicines modify rates of #obesity associated cancer and response to treatment? www.nature.com/articles/s43018-025-01110-1
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that the hepatic PPA1 FGF21 axis is a therapeutic target for #obesity and related metabolic disorders. diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
The authors propose that targeting mitochondrial dNTP transport may offer a therapeutic strategy to mitigate #obesity induced inflammation and its associated diseases www.science.org/doi/10.1126/science.adq9006
-
Daniel J Drucker
@DanielJDrucker
Are their detectable #weightloss independent actions of tirzepatide in #osa Obstructive Sleep Apnea www.nature.com/articles/s41591-025-04071-1
-
Daniel J Drucker
@DanielJDrucker
GluFormer provides a generalizable framework for encoding CGM glycaemic patterns #ai and may inform precision medicine approaches for metabolic health www.nature.com/articles/s41586-025-09925-9
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines and suicidal ideation. The evidence is thin www.reuters.com/business/healthcare-pharmaceuticals/us-fd⦠#weightloss
-
Daniel J Drucker
@DanielJDrucker
More metabolite signatures for predicting #t2d including 67 associations not previously reported across bile acid, lipid, carnitine, urea cycle and arginine/proline, glycine and histidine pathways #precisionmedicine www.nature.com/articles/s41591-025-04105-8
-
Daniel J Drucker
@DanielJDrucker
Birthday wishes going out to Professor Ron Kahn, a giant in #diabetes research @harvardmed @AmDiabetesAssn @BreakthroughT1D @theNASEM @diabetesmaster
-
Daniel J Drucker
@DanielJDrucker
In humans nighttime metabolic dysfunction is a hallmark of #masld with multiple pathogenic pathways upregulated at night, including hepatic and peripheral insulin resistance, DNL, and systemic NEFA exposure www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00535-2 #circadian
-
Daniel J Drucker
@DanielJDrucker
#thyroid cancer and GLP-1 medicines. Ascertainment bias looms large. Among a national cohort of patients newly initiated on GLP1-RAs, we found increased use of thyroid ultrasound, biopsy, and surgery when compared with matched patients receiving SGLT2Is www.sciencedirect.com/science/article/abs/pii/S0039606025ā¦
-
Daniel J Drucker
@DanielJDrucker
A FMD is superior to a baseline diet for inducing clinical response, clinical remission and biochemical improvement in mild-to-moderate CD #crohnsdisease #ibd www.nature.com/articles/s41591-025-04173-w
-
Daniel J Drucker
@DanielJDrucker
Both glutamate and glucagon released by αācells cooperatively activate neighbouring Ī“ācells through AMPA and glucagon receptors, enabling spatiotemporal feedback control of glucagon secretion. #hypoglycemia www.nature.com/articles/s42255-025-01422-7
-
Daniel J Drucker
@DanielJDrucker
The beta cell GLP-1 network-a journey in progress diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
Here single-cell transcriptomics to delineate inflammatory processes of circulating immune cells during infection, immune-mediated inflammatory diseases and #cancer www.nature.com/articles/s41591-025-04126-3 #inflammation
-
Daniel J Drucker
@DanielJDrucker
Public health and sugar sweetened beverages www.nature.com/articles/s43016-025-01289-7
-
Daniel J Drucker
@DanielJDrucker
Single cell resolution of how abdominal subcutaneous adipose tissue (SAT) in men and women with severe #obesity adapts to modest lifestyle-induced (8ā10%) #weightloss followed by substantial bariatric surgery-induced (20ā45%) weight loss, www.nature.com/articles/s42255-025-01433-4
-
Daniel J Drucker
@DanielJDrucker
Continued investigation into AMPK and itās nutrient-sensing mechanisms holds promise for identifying new strategies to restore metabolic balance in disease. www.nature.com/articles/s42255-025-01442-3
-
Daniel J Drucker
@DanielJDrucker
The L cell as an inflammation sensor. GLP-1 an enteroendocrine hormone with anti-inflammatory roles, was upregulated in the ileum of people with HIV and correlated directly with systemic cytokines but inversely with lymph node pyroptosis www.biorxiv.org/content/10.64898/2026.01.09.698696v1
-
Daniel J Drucker
@DanielJDrucker
Variation in the GLP2R and the risk of chronic metabolic disorders @uk_biobank #genetics www.metabolismjournal.com/article/S0026-0495(25)00359-2/fā¦
-
Daniel J Drucker
@DanielJDrucker
Here, the anti-adipogenic properties of novel small molecule clock activators with demonstrated anti-obesity efficacy in mice www.biorxiv.org/content/10.64898/2026.01.08.698495v1 #circadian
-
Daniel J Drucker
@DanielJDrucker
P2 #weightloss data over 13 weeks for VK2735 the once weekly GIPR-GLP1R medicine in adults with #obesity or overweight and ā„ā1 weight-related comorbidity onlinelibrary.wiley.com/doi/10.1002/oby.70106
-
Daniel J Drucker
@DanielJDrucker
Identification of an intestinotrophic YAP-1 activating fungus-derived peptide expands the therapeutic potential of the mycobiome, positioning it as a source of biologics for inflammatory and iatrogenic gut disorders. www.nature.com/articles/s41564-025-02233-y
-
Daniel J Drucker
@DanielJDrucker
Loss of TRPM7 kinase function impairs mTOR signaling, leading to reduced α-cell proliferation and glucagon secretion @MolMetab www.sciencedirect.com/science/article/pii/S2212877826000013
-
Daniel J Drucker
@DanielJDrucker
α-cells use glucagon-mediated and/or GLP-1āmediated paracrine signaling to fine-tune β-cell #insulin secretion via microtubule remodeling diabetesjournals.org/diabetes/article/doi/10.2337/db24-10ā¦
-
Daniel J Drucker
@DanielJDrucker
Preclinical experimentation supports that ciliopathy-associated #obesity particularly Alstrƶm syndrome, may be mitigated by ACBP neutralization. www.nature.com/articles/s41467-025-66235-4
-
Daniel J Drucker
@DanielJDrucker
Beyond the gym, testosterone and systemic metabolism www.nature.com/articles/s42255-025-01431-6
-
Daniel J Drucker
@DanielJDrucker
The TOGETHER PsA trial, tirzepatide+ixekizumab for adults with active psoriatic arthritis and obesity or overweight. New benefits (ACR50) for patients across clinically important endpoints #psoriasis #arthritis investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
Congratulations to Professor Roman Hovorka, the 2025 Manpei Suzuki Prizze in #diabetes Honoree www.mrl.ims.cam.ac.uk/news/double-accolade-diabetes-techn⦠@Cambridge_Uni @EASDnews
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that the adiposeāgut axis, via ā¬ļøAFABP secretion in obesity binding to plasma transferrin, leading to iron accumulation in and impaired function of ISCs, is a therapeutic target for #obesity-associated intestinal disorders www.nature.com/articles/s42255-025-01425-4
-
Daniel J Drucker
@DanielJDrucker
Stopping effective medications to treat hundreds of serious chronic diseases results in resurgence of the disease. #obesity is no different, yet why are PPL surprised? Stopping obesity drugs means people regain weight and lose heart health benefitsĀ www.statnews.com/2026/01/07/what-happens-after-stopping-gā¦
-
Daniel J Drucker
@DanielJDrucker
A new look at circulating microRNAs in cystic fibrosis-related #diabetes link.springer.com/article/10.1007/s00125-025-06645-7 @DiabetologiaJnl
-
Daniel J Drucker
@DanielJDrucker
After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation.
www.nature.com/articles/s41591-025-04090-y -
Daniel J Drucker
@DanielJDrucker
Here authors reveal proteins causally implicated in the pathogenesis of #t2d which may be leveraged for personalized medicine tailored to individuals of African ancestry. www.nature.com/articles/s41588-025-02421-w
-
Daniel J Drucker
@DanielJDrucker
The latest look at NAION and use of GLP-1 medicines; one additional case per approximately 2,700 treated patients diabetesjournals.org/care/article/doi/10.2337/dc25-1238/1ā¦
-
Daniel J Drucker
@DanielJDrucker
Supply, demand, pricing and outcomes for accessible GL:P-1 medicines in the USA. The impact on patientsā health and on overall health care spending for patients, payers, and society while ensuring equitable access at fair prices for all Americans www.nejm.org/doi/full/10.1056/NEJMp2516280
-
Daniel J Drucker
@DanielJDrucker
Studies of #inflammation related signals from cord blood at birth reveals a protein subset that predicts #t1d with high accuracy (AUCā=ā0.89ā±ā0.02), independently of HLA genetic risk www.nature.com/articles/s41467-025-67712-6
-
Daniel J Drucker
@DanielJDrucker
The #microbiome and metabolism-what have we learned and where are we going? www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00445-0
-
Daniel J Drucker
@DanielJDrucker
Studies in mice lead to the proposal that Sirt6 activation or galectin-3 inhibition in macrophages may represent a therapeutic approach for #obesity associated adipose fibroinflammation and #insulin resistance. www.nature.com/articles/s41467-025-66040-z
-
Daniel J Drucker
@DanielJDrucker
How to best model glucotoxicity preclinically to study #diabetes www.nature.com/articles/s41574-025-01220-x
-
Daniel J Drucker
@DanielJDrucker
Habener was known for giving clinical trainees their first shot at learning science. His imagination, brainstorming, mentorship and pursuit of discovery changed the world of endocrinology and medicine @MassGeneralNews @harvardmed
Endocrine News
@Endocrine_News
Remembering @TheEndoSociety Laureate Joel F. Habener, MA, MD, who passed away last month at the age of 88.
In this Q&A from 2020, he and @DanielJDrucker discuss their Warren Alpert Foundation Prize-winning research of key intestinal hormones and more:
endocrinenews.endocrine.org/gut-instincts-the-endocrinolo⦠-
Daniel J Drucker
@DanielJDrucker
A nuanced discussion on the complex role of A. muciniphila in human health #microbiota #diabetes #obesity #inflammation
www.nature.com/articles/s41564-025-02222-1 -
Daniel J Drucker
@DanielJDrucker
A new role for aged brain neuronal EVs as an important messenger in triggering bone-fat imbalance by transferring WDFY1 to bone www.nature.com/articles/s43587-025-01032-8
-
Daniel J Drucker
@DanielJDrucker
A sex-specific role of GPR110 in #mash by regulating hepatic oestrogen sensitivity www.nature.com/articles/s42255-025-01436-1
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that emerging therapeutic strategies targeting autonomic function could offer promising opportunities to improve metabolic health www.nature.com/articles/s41574-025-01221-w
-
Daniel J Drucker
@DanielJDrucker
Despite the heralded anti-inflammatory actions of statins, simvastatin had no effect on recurrences of acute or acute on chronic flares of #pancreatitis gut.bmj.com/content/early/2026/01/02/gutjnl-2025-337154
-
Daniel J Drucker reposted
Eric Topol
@EricTopol
Even though the 1st GLP-1 drug was approved 20 years ago, there are dozens of new molecules and combinations in the pipeline , including muscle building drugs (Table). A new @NatureMedicine review by @DanielJDrucker, a pioneer of this field.
www.nature.com/articles/s41591-025-04124-5 -
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines. Thanks for coming to my TED talk. Happy New Year
The Lancet Diabetes & Endocrinology
@TheLancetEndo
Beyond a singular focus on GLP-1: why we need a new nomenclature now www.thelancet.com/journals/landia/article/PIIS2213-8587(2ā¦
#glp-1 receptor agonists #incretins
#obesity type 2 #diabetes #t2d -
Daniel J Drucker
@DanielJDrucker
All about chylomicrons in the clinic from Prof Rob Hegele, from #genetics to the environment to therapy academic.oup.com/jcem/advance-article/doi/10.1210/clinem/ā¦
-
Daniel J Drucker
@DanielJDrucker
Patients with #diabetes and #cancer who received GLP-1 RA experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin academic.oup.com/jcem/advance-article/doi/10.1210/clinem/ā¦
-
Daniel J Drucker
@DanielJDrucker
Complementary approach. Pilot and feasibility RCTs for continuing GLP-1 medicines (goal= weight maintenance not weight loss) throughout pregnancy. There is no biological reason why these medicines should not be safe and probably beneficial during #pregnancy
Scott Isaacs
@scottisaacsmd
Data on GLPā1 RA discontinuation in pregnancy are concerning: women who stop GLPā1s before or early in pregnancy have higher gestational weight gain, more excess gain, and higher risks of preterm birth, gestational diabetes, and hypertensive disorders.
Preconception counseling must balance the benefits of GLPā1 medication weight loss with the very significant weight gain rebound and cardiometabolic risks once these drugs are stopped for pregnancy.
jamanetwork.com/journals/jama/fullarticle/2841781 -
Daniel J Drucker reposted
Michael Weintraub, MD
@MWeintraubMD
Does oral semaglutide or injectable semaglutide provide more weight loss? Which has more side effects? š¤šš
The short answer is there is no difference. What matters is the circulating drug levels. š©øš
āCorrected for circulating drug levels, there is little difference in a broad range of pharmacodynamic outcomes when semaglutide is delivered by the oral versus the injectable route.ā
pubmed.ncbi.nlm.nih.gov/34622228/ -
Daniel J Drucker
@DanielJDrucker
DNA methylation contributes to control of how temperature impacts BAT adaptation in mice with diet-induced #obesity @MolMetab www.sciencedirect.com/science/article/pii/S2212877825002224
-
Daniel J Drucker
@DanielJDrucker
A new review @jclinicalinvest illustrates the critical nature of gut-brain communication in human disease and the potential to target gut-brain pathways for therapeutic benefit www.jci.org/articles/view/196346
-
Daniel J Drucker
@DanielJDrucker
Studies in mice and human #islets identify JNK3 as a regulator of β cell function and survival and suggest that targeting this pathway may enhance incretin-based therapies @jclinicalinvest www.jci.org/articles/view/185707
-
Daniel J Drucker
@DanielJDrucker
By studying the atomic structure of pathological pancreatic hIAPP fibrils in 3 patient donors, the authors contribute to the therapeutic and mechanistic exploration of #t2d www.cell.com/cell/abstract/S0092-8674(25)01377-7
-
Daniel J Drucker
@DanielJDrucker
Patience we must have. There are multiple dimensions of innovation unfolding, some very early and as Yogi Berra said, it is tough to make predictions especially about the future
Terry Maratos-Flier
@Maratosflier
After tirzepatide what's really innovative? These are mostly small improvements. Will be hard to get them covered by insurance and tirzepatide (and maybe sema) likely to be first step in standard of care.
-
Daniel J Drucker
@DanielJDrucker
Free to read @NatureMedicine Where will GLP-1 medicines make their next impact to improve human health? www.nature.com/articles/s41591-025-04124-5.epdf?sharing_tā¦
Daniel J Drucker
@DanielJDrucker
2026 will bring waves of innovation to GLP-1 medicines from mechanisms to modalities to molecules delivery systems and new indications. #weightloss #obesity A glimpse of the.future here www.nature.com/articles/s41591-025-04124-5
-
Daniel J Drucker
@DanielJDrucker
An understanding of the molecular mechanisms supporting interactions of EVs with recipient cells and their functions can provide new strategies to use them for therapeutic approaches www.nature.com/articles/s41580-025-00922-4
-
Daniel J Drucker
@DanielJDrucker
New obesogenic OMICs-derived signatures for risk prediction, here an adipose-linked, #microbiome -connected metabolic signature that outperforms BMI in stratifying cardiometabolic risk and guiding precision interventions. www.nature.com/articles/s41591-025-04009-7 #obesity #heartdisease
-
Daniel J Drucker
@DanielJDrucker
By extensive molecular and genetic analyses of #insulin production and T2D pathology in human pancreatic βā (EndoC-βH1) cells and related models, the authors provide potential therapeutic targets for #t2d #genetics www.nature.com/articles/s42255-025-01407-6
-
Daniel J Drucker
@DanielJDrucker
2026 will bring waves of innovation to GLP-1 medicines from mechanisms to modalities to molecules delivery systems and new indications. #weightloss #obesity A glimpse of the.future here www.nature.com/articles/s41591-025-04124-5
-
Daniel J Drucker
@DanielJDrucker
A progress report on Open Science www.science.org/content/article/open-science-delivering-bā¦
-
Daniel J Drucker
@DanielJDrucker
Studies in mice support the contention that GLP1R expression in a subset of lymphatic endothelial cells underlies that GLP-1R agonism could be an effective therapy for improving lymphatic contractile function in secondary lymphedema. www.biorxiv.org/content/10.64898/2025.12.26.696603v1
-
Daniel J Drucker
@DanielJDrucker
New data identify tanycytic cilia as key sensors regulating energy balance in a sex-dependent manner www.biorxiv.org/content/10.64898/2025.12.31.697168v1
-
Daniel J Drucker
@DanielJDrucker
May you and your friends and family enjoy good health, happiness, respect, democracy, competent governance, safety, adventure, access to sufficient food, housing, equality of opportunity and peace in 2026
-
Daniel J Drucker
@DanielJDrucker
Strain and tissue-specie variation in murine transcriptomic signatures #genetics www.cell.com/cell-genomics/fulltext/S2666-979X(25)00364-7 @CellGenomics #genetics
-
Daniel J Drucker
@DanielJDrucker
Here the authors suggest that targeting circulating forms of autophagy-related gene 7 ( ATG7) and linked pathways may represent a promising therapeutic approach for #insulin resistance and #diabetes www.pnas.org/doi/10.1073/pnas.2503783123
-
Daniel J Drucker
@DanielJDrucker
The ongoing interest in #diabetes clusters continues along the road to personalized medicine #t2d diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker reposted
JCI insight
@JCI_insight
Gut inflammation in mice is alleviated by glucose-dependent insulinotropic polypeptide receptor: www.youtube.com/watch?v=0KdTS04Y6hI&t=1s
-
Daniel J Drucker
@DanielJDrucker
Substantial preclinical, real world and anecdotal data link GLP-1R signaling to reward pathways and attenuation of substance use disorders. Yet ++ challenges remain. More clinical trial data is coming in 2026, hopefully moving the field forward www.nature.com/articles/d41586-025-04147-5
-
Daniel J Drucker
@DanielJDrucker
Studying antibiotic-treated mice, the authors infer that Tirzepatide improves renal function and metabolic parameters in DKD mice through gut #microbiome regulation #microbiota #diabetes
www.frontiersin.org/journals/molecular-biosciences/articl⦠-
Daniel J Drucker
@DanielJDrucker
In April 2025 at the Warren Prize Symposium @MassGeneralNews Joel Habener delivered an insightful overview of his decision to first isolate anglerfish proglucagon cDNAs, reflecting local prohibition on mammalian cloning at the time and the accessibility of anglerfish islets.
Daniel J Drucker
@DanielJDrucker
Joel Habener @MassGeneralNews @Harvard at one of the lab social gatherings in the mid 1980s with one of the labs talented research fellows, currently the President of @Penn Larry Jameson
Daniel J Drucker
@DanielJDrucker
Joel Habener pioneer in molecular biology, mentor, led foundational research that discovered a hormone dubbed GLP-1, which would later become the key ingredient in Ozempic and Mounjaro ā¦@MassGeneralNewsā© ā¦@TheEndoSocietyā© ā¦@Harvardā© www.wsj.com/health/pharma/joel-habener-whose-research-helā¦
-
Daniel J Drucker
@DanielJDrucker
Joel Habener @MassGeneralNews @Harvard at one of the lab social gatherings in the mid 1980s with one of the labs talented research fellows, currently the President of @Penn Larry Jameson
Daniel J Drucker
@DanielJDrucker
Joel Habener pioneer in molecular biology, mentor, led foundational research that discovered a hormone dubbed GLP-1, which would later become the key ingredient in Ozempic and Mounjaro ā¦@MassGeneralNewsā© ā¦@TheEndoSocietyā© ā¦@Harvardā© www.wsj.com/health/pharma/joel-habener-whose-research-helā¦
-
Daniel J Drucker
@DanielJDrucker
GIP did not prevent #hypoglycaemia following excess prandial insulin and physical activity after meal ingestion in males with type 1 #diabetes #t1d dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/doā¦
-
Daniel J Drucker reposted
Journal of Clinical Investigation
@jclinicalinvest
Count down: Our top 5 most-accessed manuscripts of 2025!
#3: Anti-inflammatory actions of glucagon-like peptide 1 (#glp-1) medicines beyond metabolic benefits: doi.org/10.1172/JCI194751
@DanielJDrucker @SinaiHealth -
Daniel J Drucker
@DanielJDrucker
Joel Habener pioneer in molecular biology, mentor, led foundational research that discovered a hormone dubbed GLP-1, which would later become the key ingredient in Ozempic and Mounjaro ā¦@MassGeneralNewsā© ā¦@TheEndoSocietyā© ā¦@Harvardā© www.wsj.com/health/pharma/joel-habener-whose-research-helā¦
-
Daniel J Drucker
@DanielJDrucker
Projections for the global economic burden of #diabetes It is hard to make predictions about the future said Yogi www.nature.com/articles/s41591-025-04027-5
-
Daniel J Drucker
@DanielJDrucker
What is the clinical evidence from RCTs or high quality real world data that GLP-1 medicines actually increase the risk of cancer in people with Multiple Endocrine Neoplasia? #cancer
Neil Floch MD
@NeilFlochMD
GLP-1 do not increase the risk of cancer unless patients have Multiple Endocrine Neoplasia
-
Daniel J Drucker
@DanielJDrucker
After an exhausting few days, now back at home, Santa catches up on new data for GLP-1 medicines, and one of his personal interests, Age-related macular degeneration and #weightloss therapies. Santa (almost) never gets tired of TriNetX data www.sciencedirect.com/science/article/abs/pii/S2468653025ā¦
-
Daniel J Drucker
@DanielJDrucker
How important is GLP-2 for glucagon secretion, and is this putative effect direct or indirect? New human data from SĆørum et al suggest that any effect is very modest at best and not direct academic.oup.com/jes/advance-article/doi/10.1210/jendso/bā¦
-
Daniel J Drucker
@DanielJDrucker
Real world data from TriNetX #cancer assessing the safety of GLP-1 medicines and key outcomes in the context of immune checkpoint inhibitor therapy in people with #t2d www.sciencedirect.com/science/article/pii/S0168822725010885
-
Daniel J Drucker
@DanielJDrucker
Glucagon exerts a positive chronotropic effect in the isolated mouse heart via GCGR & via HCN channels in the sinus node. Glucagon-containing GLP-1 medicines are on the way, reminding us of the species-specific differences in cardiac GCGR expression www.mdpi.com/1422-0067/27/1/126
-
Daniel J Drucker
@DanielJDrucker
By studying muscle, liver and cerebral cortex tissue responses to intermittent fasting in male mice, the authors highlight therapeutic targets for metabolic and neurodegenerative disorders and #aging www.biorxiv.org/content/10.1101/2025.04.13.648650v2
-
Daniel J Drucker
@DanielJDrucker
Based on studies manipulating duodenal myoelectric activity in rats, the authors suggest targeting duodenal myoelectrical activity may provide a minimally invasive alternative to RYGB for #diabetes treatment link.springer.com/article/10.1007/s00125-025-06642-w @DiabetologiaJnl
-
Daniel J Drucker
@DanielJDrucker
Does a maladapted macrophage-driven inflammatory #islet resolution potentially contribute to the beta cell failure of type 2 diabetes? #t2d @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06638-6
-
Daniel J Drucker
@DanielJDrucker
Live a healthy life, and your #aging clocks will follow www.nature.com/articles/s41514-025-00318-w
-
Daniel J Drucker
@DanielJDrucker
Parsing the #genetics of the GIP/GIPR signaling system to dissociate reduction of cardiovascular risk from changes in BMI and HbA1c #cvd #heartfailure #mendelianrandomization academic.oup.com/eurheartj/advance-article/doi/10.1093/euā¦
-
Daniel J Drucker
@DanielJDrucker
Here, age- and sex- specific reference levels for the hormones GLP-1, GIP and glucagon from a Danish school cohort www.nature.com/articles/s41390-025-04551-7
-
Daniel J Drucker
@DanielJDrucker
My holiday season wishes for 2025 and for the 2026 New Year. Let us live together respectfully, in good health and build a better future for our families, our fellow citizens and for all those with whom we share this planet. Merry Xmas yāall!
-
Daniel J Drucker
@DanielJDrucker
Clinical P1 SAD/MAD evaluation of the long-acting GLP-1R antagonist Imapexitide in healthy human volunteers academic.oup.com/jcem/advance-article/doi/10.1210/clinem/ā¦
-
Daniel J Drucker
@DanielJDrucker
Many health care systems still enact barriers to hinder or prevent reimbursement and access to GLP-1 medicines for high risk PPl with #obesity #cvd despite compelling RCT evidence for benefit. Penny wise pound foolish discrimination
JAMA Cardiology
@JAMACardio
#semaglutide consistently lowered hospitalization rates and hospital days in high-risk adults with #obesity and cardiovascular disease, with effects observed across clinical subgroups. jamanetwork.com/journals/jamacardiology/fullarticle/10.10ā¦
-
Daniel J Drucker
@DanielJDrucker
The latest view from Indianapolis-explaining a component of tirzepatide action #weightloss through a CNS hypothalamic leptin sensitization MOA enabling increased energy expenditure in mice www.biorxiv.org/content/10.64898/2025.12.18.695152v1
-
Daniel J Drucker
@DanielJDrucker
Studies in mice reveal that the SCoR2 denitrosylase regulates nutrient metabolism, similar to sirtuins, and is a potential drug target for #obesity and #masld www.science.org/doi/10.1126/scisignal.adv0660
-
Daniel J Drucker
@DanielJDrucker
Is the steatotic liver generally resistant to glucagon action? Here, the presence of hepatic steatosis did not alter hepatic glucose metabolism and leucine oxidation in response to insulin and rising concentrations of glucagon www.jci.org/articles/view/200913
-
Daniel J Drucker
@DanielJDrucker
Amylin activated distributed CNS networks revealed by resting-state fMRI following peripheral amylin administration in wild-type (WT) and receptor-activity modifying protein 1/3 knockout (RAMP1/3 KO) mice @MolMetab www.sciencedirect.com/science/article/pii/S2212877825002200
-
Daniel J Drucker
@DanielJDrucker
The GLP-1 medicine field continues to evolve, offering new effective options for people living with #obesity #weightloss coming to US distribution channels in January 2026 Higher dose oral semaglutide now approved @US_FDA @novonordisk www.novonordisk.com/content/nncorp/global/en/news-and-medā¦
-
Daniel J Drucker
@DanielJDrucker
Hitting the gas pedal for better health and longevity #aging #healthspan Scientists uncover the potential of enhanced hydrogen sulfide generation to promote healthy aging @Cell_Metabolism www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00526-1
-
Daniel J Drucker
@DanielJDrucker
Amidated gut hormone peptidergic signaling as a determinant of sex-specific metabolic and behavioral states in Drosophila @MolMetab www.sciencedirect.com/science/article/pii/S2212877825002194
-
Daniel J Drucker
@DanielJDrucker
48 week P2B data for the GCGR-GLP-1R co-agonist in people with metabolic liver disease #mash ir.altimmune.com/news-releases/news-release-details/altimā¦
Daniel J Drucker
@DanielJDrucker
Some key endpoints in the Pemvidutide #mash trial, with comparative analysis to other investigational and approved MASH drugs
-
Daniel J Drucker
@DanielJDrucker
The @EASDnews Journal leadership "call on the #diabetes community to join us in our endeavour: to publish robust research grounded in a foundation of strong EDI principles" highlighting that EDI is essential for rigorous science and good for health link.springer.com/article/10.1007/s00125-025-06629-7
-
Daniel J Drucker
@DanielJDrucker
An allosteric mechanism of GPR120 activation for the treatment of #alzheimers disease www.nature.com/articles/s43587-025-01028-4
-
Daniel J Drucker
@DanielJDrucker
Will GLP-1 medicines eventually support brain health with #aging A look at the evidence to date www.nature.com/articles/s43587-025-01029-3
-
Daniel J Drucker
@DanielJDrucker
Are there clinically meaningful metabolic benefits for people with #t2d looking out or through the window to gain increased exposure to natural light? What would Alice think? www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00490-5
-
Daniel J Drucker
@DanielJDrucker
In 2026 @US_FDA will review NDA submissions for Cagri-Sema, Retatrutide and Orforglipron, potentially broadening options for use of GLP-1 medicines and achievement of #weightloss in people living with #obesity www.novonordisk.com/content/nncorp/global/en/news-and-medā¦
-
Daniel J Drucker
@DanielJDrucker
The #weightloss maintenance data for the small molecule oral GLP-1 medicine orforglipron in the ATTAINāMAINTAIN trial has arrived #obesity investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
Among the more interesting therapeutic applications of GLP-2R agonists is their potential use in Graft vs. Host Disease to protect the gut epithelium and enhance barrier function, as described in exciting preclinical studies by Norona, Zeiser et al ashpublications.org/blood/article/136/12/1442/460963/Glucā¦
Post not available here, view on X
Daniel J Drucker
@DanielJDrucker
Bernardo Yusta in the Drucker lab set out to replicate & explore mechanisms linking GLP-2R signaling to gastrointestinal & immune outcomes in GvHD. Although teduglutide was bioactive, it did not rescue gut damage or reduce inflammation in mice. www.sciencedirect.com/science/article/pii/S2212877825002182 @MolMetab
Daniel J Drucker
@DanielJDrucker
GLP-2 is also known to control barrier function. GLP-2R KO mice with GvHD exhibited increased levels of bacteremia and higher mortality, consistent with greater susceptibility to impairment of barrier function and loss of gut mucosal integrity @MolMetab www.sciencedirect.com/science/article/pii/S2212877825002182
Daniel J Drucker
@DanielJDrucker
The gut #microbiota exert important actions influencing the extent of gut injury in GvHD. Whether shifts in #microbiota species evident with gain or loss of GLP-2R signaling are linked to GvHD severity in mice remains uncertain @MolMetab www.sciencedirect.com/science/article/pii/S2212877825002182
-
Daniel J Drucker
@DanielJDrucker
The long-awaited SURPASS-CVOT is here, just in time for the holidays #t2d #cvd #tirzepatide www.nejm.org/doi/full/10.1056/NEJMoa2505928
-
Daniel J Drucker
@DanielJDrucker
More clinical trial data for mazdutide H2H vs. dulaglutide in in Chinese participants with #t2d www.nature.com/articles/s41586-025-10031-z
-
Daniel J Drucker
@DanielJDrucker
Strategies to counter clinical hyperinsulinemia #hypoglycemia #genetics #bariatricsurgery include targeting #insulin secretion or insulin or GLP-1 receptor activity. Which option will prove successful for what condition www.cmghjournal.org/article/S2352-345X(25)00247-4/fulltext
-
Daniel J Drucker
@DanielJDrucker
A vagal sensory pathway that integrates satiety signals to modulate #sleep www.nature.com/articles/s41467-025-66112-0
-
Daniel J Drucker
@DanielJDrucker
Single-nuclei sequencing, chemogenetics, circuit tracing, and pharmacology resolve how enteric neuron populations can modulate GI motility, secretion, food intake, and #inflammation www.cell.com/cell/abstract/S0092-8674(25)01359-5
-
Daniel J Drucker
@DanielJDrucker
A novel vagal circuit that integrates internal protein status with nutrient-specific cues in mice to guide adaptive #protein appetite and maintain amino acid homeostasis @MolMetab #diet www.sciencedirect.com/science/article/pii/S2212877825002108
-
Daniel J Drucker
@DanielJDrucker
The accessory protein MRAP2 identified as an important regulator of MC3R function providing further evidence for the crucial role of MRAP2 in energy homeostasis www.science.org/doi/10.1126/scisignal.adu4315
-
Daniel J Drucker
@DanielJDrucker
A variety of experimental approaches lead the authors to infer that that decreases in adipocyte NPY1R during #weightloss boost lipolytic capacity and contribute to improved systemic cardiometabolic health @MolMetab www.sciencedirect.com/science/article/pii/S2212877825002121
-
Daniel J Drucker
@DanielJDrucker
Beyond setbacks in neurodegenerative diseases, what opportunities and challenges await GLP-1 medicines in a wide range of neuropsychiatric conditions and substance use disorders? @CellRepMed www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25ā¦
-
Daniel J Drucker
@DanielJDrucker
An update look at the therapeutic potential of brown adipose tissue www.nature.com/articles/s41574-025-01225-6 #weightloss
-
Daniel J Drucker
@DanielJDrucker
Here the authors suggest that adipocyte glycogen turnover can be therapeutically modulated for disorders of energy homeostasis www.nature.com/articles/s41467-025-67515-9
-
Daniel J Drucker
@DanielJDrucker
Branched Chain Amino Acids identified as an immune priming factor, a potential mechanism underlying the well-established association between circulating BCAA and diverse diseases of #aging #inflammation www.sciencedirect.com/science/article/pii/S2212877825002157
-
Daniel J Drucker
@DanielJDrucker
Real world TriNetX data over short exposure times reveals that tirzepatide use in patients with #schizophrenia spectrum disorders is associated with improved clinical outcomes, including reduced risks of mortality, hospitalization, and suicidal behavior www.sciencedirect.com/science/article/abs/pii/S0924977X25ā¦
-
Daniel J Drucker
@DanielJDrucker
Does adjuvant semaglutide improve neurological outcomes in acute large vessels occlusive #stroke www.nature.com/articles/s41467-025-66167-z
-
Daniel J Drucker
@DanielJDrucker
The GDF3āSMAD2/3 axis as a critical driver of age-associated chromatin remodeling adipose tissue macrophage-mediated inflammation and a promising therapeutic target for mitigating macrophage-related inflammation in #aging www.nature.com/articles/s43587-025-01034-6
-
Daniel J Drucker
@DanielJDrucker
As we end 2025 a reminder that the majority of papers purporting to detect the immunoreactive GLP-1R (and hundreds of other proteins) use non-validated antisera and authors, reviewers, and Journal Editors don't care enough to demand reagent validation www.sciencedirect.com/science/article/pii/S156757692501999X
-
Daniel J Drucker
@DanielJDrucker
GLP-2 and GIP are potent stimulators of superior mesenteric artery blood flow in anesthetized rats physoc.onlinelibrary.wiley.com/doi/10.14814/phy2.70699
-
Daniel J Drucker
@DanielJDrucker
The latest chapter in the pursuit of targetable microRNAs as a therapeutic strategy for #obesity and various forms of #diabetes diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
New P1 data for CRB-913, a highly peripherally restricted oral small molecule CB1 inverse agonist targeting chronic #obesity management ir.corbuspharma.com/news-events/press-releases/detail/458ā¦
-
Daniel J Drucker
@DanielJDrucker
A detailed high resolution analysis looking at the cellular effects of biased GLP-1R agonism #islets @MolMetab @imperialcollege www.sciencedirect.com/science/article/pii/S221287782500211X
-
Daniel J Drucker
@DanielJDrucker
New preclinical and clinical insights into highly selective GIPR agonism with LY3537021 in #t2d www.sciencedirect.com/science/article/pii/S2212877825002054 @MolMetab @LillyDiabetesIn
-
Daniel J Drucker
@DanielJDrucker
LDHA inhibition could be a novel therapeutic strategy for #diabetes treatment link.springer.com/article/10.1007/s00125-025-06626-w @DiabetologiaJnl
-
Daniel J Drucker
@DanielJDrucker
A look back and ahead at recent progress in GLP-1 medicines #weightloss #obesity from Timo Müller @HelmholtzMunich @TimoMueller_IDO
www.nature.com/articles/s41574-025-01219-4 -
Daniel J Drucker
@DanielJDrucker
MC3R has a conserved role across mammals in controlling growth and pubertal timing @MolMetab www.sciencedirect.com/science/article/pii/S221287782500208X
-
Daniel J Drucker
@DanielJDrucker
Mouse studies highlight the therapeutic potential of existing and emerging strategies to manipulate the bile acid pool and to regulate dietary fat absorption across a spectrum of conditionsāfrom malabsorptive disorders to cardiometabolic diseases www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00494-2
-
Daniel J Drucker
@DanielJDrucker
The transcription factor DEC1 links #circadian rhythms to human β cell maturation, highlighting the essential role of circadian control in generating fully functional SC- #islet organoids #stemcells www.cell.com/cell-reports/fulltext/S2211-1247(25)01438-X
-
Daniel J Drucker
@DanielJDrucker
A TRIUMPH for the GCGR-GLP1R-GIPR triple agonist Retatrutide in P3. Participants with #obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks. Mild dysesthesias noted #weightloss #arthritis investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
PPARα-dependent mitochondrial programming promotes the differentiation of SC-β cells and may be a promising target to improve β cell replacement efforts for #t1d #stemcells #islets
www.nature.com/articles/s41467-025-66022-1 -
Daniel J Drucker
@DanielJDrucker
So many proposed therapeutic opportunities established in mice act via enhanced adipose tissue thermogenesis and some through #microbiota -how should we assess their translational relevance for #weightloss in humans? www.nature.com/articles/s41467-025-67172-y
-
Daniel J Drucker
@DanielJDrucker
High definition imaging suggests that the size and cellular composition of pancreatic #islets may, therefore, represent influential factors that impact β-cell loss during #t1d disease progression. www.nature.com/articles/s41467-025-66198-6
-
Daniel J Drucker
@DanielJDrucker
The ZEUS randomized clinical trial will formally test the hypothesis that IL-6 inhibition with ziltivekimab will lower incident cardiovascular event rates and potentially slow kidney decline among participants with known ASCVD, CKD, and elevated hsCRP. jamanetwork.com/journals/jamacardiology/article-abstract/ā¦
-
Daniel J Drucker
@DanielJDrucker
Diet soda (Artificially Sweetened Beverages) and #t2d Many opinions, less compelling evidence for harm diabetesjournals.org/care/article-abstract/doi/10.2337/dcā¦
-
Daniel J Drucker
@DanielJDrucker
Type 2 #diabetes genetic burden shapes metabolic heterogeneity and accelerates progression in preclinical type 1 diabetes #t1d #t2d #genetics diabetesjournals.org/diabetes/article-abstract/doi/10.233�
-
Daniel J Drucker
@DanielJDrucker
New from Professor Woo @BBDC_UofT The insulin-PI3K-PTEN axis within murine vagal neurons is essential in optimizing the autonomic output that determines peripheral inflammatory and metabolic homeostasis www.nature.com/articles/s41467-025-67192-8
-
Daniel J Drucker
@DanielJDrucker
The progress in GLP-1 medicines for #obesity was not easily predicted. In 1998, @ScienceMagazine ran a series on Regulation of Body Weight, informed by advances in mouse and human #genetics Understandably, little attention to the GLP-1 pathway at that time www.science.org/doi/10.1126/science.280.5368.1383
-
Daniel J Drucker
@DanielJDrucker
New from @imperialcollege Key pathways linking GLP-1R signaling to regulate β-cell mitochondrial remodelling and function #islets #diabetes www.nature.com/articles/s41467-025-66115-x @TomasLab_ICL
-
Daniel J Drucker
@DanielJDrucker
Discussions for the journey towards new therapeutic approaches for healthy #weightloss therapeutics šŖ#obesity
onlinelibrary.wiley.com/doi/10.1002/jcsm.70147 -
Daniel J Drucker
@DanielJDrucker
New single cell transcriptomics data inform a cell-typeāspecific model for how FGF1 elicits long-term reprogramming of hypothalamic circuits to achieve #diabetes remission in mice @MolMetab www.sciencedirect.com/science/article/pii/S2212877825002078
-
Daniel J Drucker
@DanielJDrucker
Human and mouse genetics identifies that vinculin (VCL) works as a hub gene crucial for cell connection and signaling pathways essential for ENS formation #hirschprung disease www.jci.org/articles/view/198531
-
Daniel J Drucker
@DanielJDrucker
A new review of Food Intelligence @juliaoftoronto @KevinH_PhD #diet #weightloss www.nature.com/articles/d41586-025-03977-7
-
Daniel J Drucker
@DanielJDrucker
Congratulations Professor Gloyn! @Stanford @TheEndoSociety endocrinenews.endocrine.org/anna-gloyn-wins-2026-transatl⦠@annagloyn
-
Daniel J Drucker
@DanielJDrucker
@StructureTx post highly competitive data for the once daily small molecule GLP-1 medicine Aleniglipron with impressive #weightloss at 36 weeks #obesity ir.structuretx.com/news-releases/news-release-details/strā¦
Daniel J Drucker
@DanielJDrucker
As with all small molecule GLP-1 medicines, tolerability, peak to trough, titration schemes, and potential for off target AEs #t2d #obesity merit discussion, with comprehensive data reported today for Aleniglipron @StructureTx ir.structuretx.com/static-files/dea97d72-793b-4e3b-95c3-eā¦
-
Daniel J Drucker
@DanielJDrucker
Substance use disorders including AUD and GLP-1 medicines. A look ahead at 2026. Will the aspirational needle move closer to substantial efficacy?
www.nature.com/articles/d41591-025-00069-x -
Daniel J Drucker
@DanielJDrucker
The microbial metabolite TMA for the metabolic win #insulin resistance #obesity via inhibition of IRAK4 in mice #microbiome www.nature.com/articles/s42255-025-01413-8
-
Daniel J Drucker
@DanielJDrucker
Studies in mice highlight the importance of PKD in preserving β-cell function under aging and metabolic stress conditions #islets #diabetes www.sciencedirect.com/science/article/pii/S2212877825002042 @MolMetab #senescence
-
Daniel J Drucker
@DanielJDrucker
A global snapshot of metabolic syndrome #diabetes #hypertension #obesity www.nature.com/articles/s41467-025-67268-5
-
Daniel J Drucker
@DanielJDrucker
Sarcopenia is real, and important in many elderly. The exaggerationās and misinformation surrounding i)the magnitude of the problem and ii)benefits of unproven solutions in the context of GLP-1 medicines are also real. Keep calm, carry on, and remain data driven #weightlloss
Ash Paul
@pash22
The Importance and Uncertainties About Preserving Muscle via @ConscienHealth conscienhealth.org/2025/12/the-importance-and-uncertaintiā¦
-
Daniel J Drucker
@DanielJDrucker
Aā¬ļørate of eGFR decline in people with #t2d and a history of cardiovascular disease treated with oral semaglutide in the SOUL trial diabetesjournals.org/care/article/doi/10.2337/dc25-1080/1ā¦
-
Daniel J Drucker
@DanielJDrucker
Unambiguous (disappointing) results for oral semaglutide in the evoke trials. No impact on progressive deterioration of cognitive function #alzheimersdisease sciencehub.novonordisk.com/congresses/ctad2025/johannsen1ā¦
Daniel J Drucker
@DanielJDrucker
Some preliminary data on CSF and plasma biomarkers of disease activity and neuroinflammation from the evoke trials with oral semaglutide #alzheimersdisease #ctad2025 sciencehub.novonordisk.com/congresses/ctad2025/johannsen1ā¦
-
Daniel J Drucker
@DanielJDrucker
PIEZO2 identified as an essential regulator of juxtaglomerular granular cell calcium activity and renin in vivo www.cell.com/cell/fulltext/S0092-8674(25)01309-1
-
Daniel J Drucker
@DanielJDrucker
Adjunctive semaglutide over 26 wks significantly improved glycemic control and weight outcomes in individuals with schizophrenia spectrum disorders treated with clozapine or olanzapine #weightloss jamanetwork.com/journals/jamapsychiatry/article-abstract/ā¦
-
Daniel J Drucker
@DanielJDrucker
GLP-2R action is required for cold stress-induced jejunal villi lengthening, this adaptation is dispensable for body weight gain in the presence of GLP-1R signaling @uOttawa @HeartInstitute @CommsBio www.nature.com/articles/s42003-025-09281-4 www.nature.com/articles/s42003-025-09281-4
-
Daniel J Drucker
@DanielJDrucker
Targeting enteroendocrine cell GPCRs to treat metabolic disorders @kallyope www.cell.com/cell-metabolism/abstract/S1550-4131(25)00485-1 @Cell_Metabolism
-
Daniel J Drucker
@DanielJDrucker
An update on Duodenal Mucosal Resurfacing for maintenance of #weightloss New clinical data @FractylHealth ir.fractyl.com/news-releases/news-release-details/fractylā¦
-
Daniel J Drucker
@DanielJDrucker
After disappointments in neurodegenerative disorders #parkinsons #alzheimersdisease will GLP-1 medicines prove useful with an effective safety and efficacy profile in substance use disorders? www.nature.com/articles/d41586-025-03911-x
-
Daniel J Drucker
@DanielJDrucker
Overview of teduglutide safety and efficacy in adults and children with short bowel syndrome in Japan link.springer.com/article/10.1007/s12325-025-03398-y
-
Daniel J Drucker
@DanielJDrucker
An integrated analysis that combines electrophysiological and transcriptomic profiling, along with machine learning, of #islet cells from #t1d donors highlights the importance of α cell dysfunction @AlbertaDiabetes @jclinicalinvest www.jci.org/articles/view/195267
-
Daniel J Drucker
@DanielJDrucker
Data from the Evoke trials with semaglutide will be presented Dec 3. Here are the changes in cognitive function in the much smaller P2 ELAD trial #alzheimers #liraglutide www.nature.com/articles/s41591-025-04106-7
Daniel J Drucker
@DanielJDrucker
And finally, the long-awaited primary and secondary outcomes for the ELAD trial with liraglutide #alzheimers disease www.nature.com/articles/s41591-025-04106-7
-
Daniel J Drucker
@DanielJDrucker
And finally, the long-awaited primary and secondary outcomes for the ELAD trial with liraglutide #alzheimers disease www.nature.com/articles/s41591-025-04106-7
-
Daniel J Drucker
@DanielJDrucker
Isomeranzin, acting through Gnas and AMPK activation identified as a lead compound for enhancing energy expenditure and combating #obesity www.embopress.org/doi/full/10.1038/s44321-025-00335-y @EmboMolMed
-
Daniel J Drucker
@DanielJDrucker
Studies from Nikolaj Rittig & colleagues Pre-meal ketone supplementation reduced postprandial glucose, lipid and ghrelin concentrations #t2d link.springer.com/article/10.1007/s00125-025-06614-0 @DiabetologiaJnl
-
Daniel J Drucker
@DanielJDrucker
Important reminder šš§The transcription factor CUX1 regulates adipocyte differentiation in opposite directions in humans and mice, emphasizing the need for species-specific models in metabolic disease research š§Ŗ
www.sciencedirect.com/science/article/pii/S2212877825001978 @MolMetab @PennIDOM -
Daniel J Drucker
@DanielJDrucker
Some new preclinical and clinical data for CT-388, a once weekly cAMP signal-biased dual GLP-1R/GIPR agonist with minimal GLP-1R/GIPR internalization #obesity #weightloss www.sciencedirect.com/science/article/pii/S221287782500198X @MolMetab
-
Daniel J Drucker
@DanielJDrucker
A clinical study (1 yr) in PPL with #obesity raises the possibility that #exercise might preserve LEAP2 levels after #weightloss in females, supporting weight loss maintenance. www.cell.com/iscience/fulltext/S2589-0042(25)02549-0
-
Daniel J Drucker
@DanielJDrucker
Targeting FFAR4 for metabolic disorders. Still promising? www.cell.com/cell-reports/fulltext/S2211-1247(25)01358-0
-
Daniel J Drucker
@DanielJDrucker
Studies in mice reveal that during fasting and refeeding, glucagon regulates renal glucose reabsorption by utilizing the local cellular circadian machinery. #kidney www.nature.com/articles/s41467-025-65402-x
-
Daniel J Drucker
@DanielJDrucker
A valuable repository to the research community for a clearer understanding of circulating EV biology. www.nature.com/articles/s41556-025-01795-7
-
Daniel J Drucker
@DanielJDrucker
A significantly higher risk of second-generation DES stent failure in individuals with #t1d followed by those with type 2 diabetes, compared with PPL without diabetes. This elevated risk was attributed to both in-stent restenosis and stent thrombosisš§Ŗ. diabetesjournals.org/care/article-abstract/doi/10.2337/dcā¦
-
Daniel J Drucker
@DanielJDrucker
The daily torrent of real world data continues. Here (lower) rates of suicidal ideation, depression and anxiety in children treated with GLP-1 medicines in Florida š§Ŗwww.medrxiv.org/content/10.1101/2025.11.11.25339931v1
-
Daniel J Drucker
@DanielJDrucker
Rare but real. Hypophysitis www.nature.com/articles/s41574-025-01200-1 š§Ŗ
-
Daniel J Drucker
@DanielJDrucker
Here the authors highlight the therapeutic potential of targeting adipocyte TGR5 for MASLD intervention diabetesjournals.org/diabetes/article/doi/10.2337/db25-03ā¦
-
Daniel J Drucker
@DanielJDrucker
Here deletion of Xbp1 in β-cells (Xbp1β-/-) of non-obese diabetic mice before insulitis is protective against #diabetes
www.nature.com/articles/s41467-025-65635-w -
Daniel J Drucker
@DanielJDrucker
Towards a better understanding of GLP-1 medicine efficacy beyond PK-incorporation of receptor occupancy and residency time assessed in vivo www.thelancet.com/journals/ebiom/article/PIIS2352-3964(25ā¦
-
Daniel J Drucker
@DanielJDrucker
The proliferation of clocks continues to reveal multiple proteomic organ aging clocks that provide a biologically interpretable framework for tracking #aging and disease risk across diverse populations. www.nature.com/articles/s43587-025-01016-8
-
Daniel J Drucker
@DanielJDrucker
More detailed functional interrogation of enteric neuron subpopulations www.cell.com/cell/abstract/S0092-8674(25)01246-2?
-
Daniel J Drucker
@DanielJDrucker
Multiomic characterization of the aging mouse reveals fundamental insights into the aging process and identifies new therapeutic targets to maintain organ health www.cell.com/cell-metabolism/abstract/S1550-4131(25)00476-0
-
Daniel J Drucker reposted
JAMA
@JAMA_current
#glp-1 receptor agonist exposure with discontinuation before or during early #pregnancy was associated with greater gestational weight gain and increased risk of preterm delivery, gestational #diabetes, and hypertensive disorders.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20⦠-
Daniel J Drucker
@DanielJDrucker
A reminder that MODY (and type 1 diabetes) can present in older individuals and must remain in the differential diagnosis for new onset #diabetes across the lifespan diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #t2d #weightloss
www.novonordisk.com/content/nncorp/global/en/news-and-med⦠-
Daniel J Drucker
@DanielJDrucker
Beyond the bacterial #microbiome a new focus on harnessing the gut non-bacterial microbial entities in the therapeutics and prevention of metabolic diseases www.sciencedirect.com/science/article/pii/S2212877825001966 @MolMetab #microbiota
-
Daniel J Drucker
@DanielJDrucker
New from Lihi Eder and colleagues-The #obesity inflammation immune axis with a focus on #psoriasis related disorders www.nature.com/articles/s41584-025-01326-6
-
Daniel J Drucker
@DanielJDrucker
Oral semaglutide disappoints in the two evoke trials, failing to reduce the rate of cognitive decline #alzheimers disease #dementia www.novonordisk.com/content/nncorp/global/en/news-and-medā¦
-
Daniel J Drucker
@DanielJDrucker
On the cusp of closing the genetic association and mechanism gap while laying the foundation for future precision medicine approaches in type 2 #diabetes #genetics @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06600-6
-
Daniel J Drucker
@DanielJDrucker
P3 data for Efsubaglutide the once weekly immunoglobulin-based GLP-1 medicine approved in China for #t2d @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06593-2
-
Daniel J Drucker
@DanielJDrucker
As disclosure of evoke and evoke+ trial results for oral semaglutide in people with imaging or biomarker+ #alzheimers disease approaches, a reminder of the primary and secondary endpoints alzres.biomedcentral.com/articles/10.1186/s13195-024-01666-7
Daniel J Drucker
@DanielJDrucker
A reminder of the primary endpoint in the evoke trials, the change in the CDR ā Sum of Boxes (CDR-SB) score from baseline to week 104 #alzheimers www.understandingalzheimersdisease.com/-/media/Files/uAD/ā¦
-
Daniel J Drucker
@DanielJDrucker
Human #genetic evidence in humans is consistent with direct TAS2R38 actions in postprandial glycemia, supporting TAS2R38 as a novel therapeutic target for glucose regulation.
diabetesjournals.org/diabetes/article-abstract/74/12/2444⦠-
Daniel J Drucker
@DanielJDrucker
Towards reducing the already low risk of peri-procedural GLP-1 medicines linked aspiration. Fasting duration, rather than time since last GLP-1 dose, is a key determinant of retained gastric solid content link.springer.com/article/10.1007/s10620-025-09570-2
-
Daniel J Drucker
@DanielJDrucker
Studies in aging male mice with extensive multi-OMICs analyses show that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment broadly counteracts age-related changes n part via the hypothalamic GLP-1R #aging www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00474-7
-
Daniel J Drucker
@DanielJDrucker
In mice, specifically eliminating p16Ink4a+senescent endothelial cells is a potential therapeutic strategy for metabolic disease www.cell.com/cell-metabolism/abstract/S1550-4131(25)00443-7
-
Daniel J Drucker
@DanielJDrucker
In mice, specifically eliminating p16Ink4a+senescent endothelial cells is a potential therapeutic strategy for metabolic disease www.cell.com/cell-metabolism/abstract/S1550-4131(25)00443-7
-
Daniel J Drucker
@DanielJDrucker
Preclinical studies reveal that CCKBR-Gs and -Gq signaling, rather than CCKBR-Gi signaling, are beneficial for #alzheimers disease (AD) treatment. www.cell.com/cell/abstract/S0092-8674(25)01238-3
-
Daniel J Drucker
@DanielJDrucker
A small P2 trial of 24 patients with #t1d randomized to placebo vs. Tirzepatide. Meaningful #weightloss without SAEs
diabetesjournals.org/care/article/doi/10.2337/dc25-2379/1⦠-
Daniel J Drucker
@DanielJDrucker
A spotlight on key concepts defining postprandial glucagon metabolism in people with and without type 1 #diabetes diabetesjournals.org/diabetes/article/doi/10.2337/db25-05ā¦
-
Daniel J Drucker
@DanielJDrucker
Preclinical data suggest that GLY-200, an orally administered polymer that targets mucus and enhances barrier function, in combination with GLP-1RAs, holds promise as a
novel therapeutic strategy for #obesity www.sciencedirect.com/science/article/pii/S2212877825001942 -
Daniel J Drucker
@DanielJDrucker
Can one target SLC25A51 the major determinant of the mitochondrial NAD+ pool to improve hepatocyte health and regeneration? www.nature.com/articles/s42255-025-01408-5
-
Daniel J Drucker
@DanielJDrucker
Here using #genetics proxies and association with measurable GLP-1R dependent variables, the authors dismiss the non-metabolic roles of GLP1R in relevant cardiovascular tissues for GLP-1R dependent cardioprotection diabetesjournals.org/care/article/doi/10.2337/dc25-1822/1ā¦
-
Daniel J Drucker
@DanielJDrucker
Does the future of managing benign thyroid dysfunction encompass incorporation of #genetics in personalized management of thyroid diseases? academic.oup.com/jcem/advance-article/doi/10.1210/clinem/ā¦
-
Daniel J Drucker
@DanielJDrucker
The ongoing allure of intestinally-restricted TGR5 ligands for increasing GLP-1 and the treatment of metabolic disorders #diabetes #obesity here with a non-absorbable carrier drug conjugate www.science.org/doi/10.1126/scitranslmed.ado5177
-
Daniel J Drucker
@DanielJDrucker
The 100 yr pursuit for non-injectable #insulin ..Here based on mouse and mini pig data, āa skin-permeable polymer may enable non-invasive transdermal delivery of insulin, relieving patients with #diabetes from subcutaneous injectionsā www.nature.com/articles/s41586-025-09729-x
-
Daniel J Drucker
@DanielJDrucker
In Finland #prediabetes was prevalent in pediatric patients with #obesity and was associated particularly with steatotic liver disease and prevalence increased steeply over time, independent of the degree of obesity www.nature.com/articles/s41366-025-01950-y
-
Daniel J Drucker
@DanielJDrucker
The consequences of misinformation are real and often tragic #vaccines #measles www.nature.com/articles/d41586-025-03769-z
-
Daniel J Drucker
@DanielJDrucker
New insights into islet ER stress responses, proinsulin biosynthesis, ERAD and ERD1 using β-cell-specific Hrd1-KO mice & rodent (and human islet) β-cells treated acutely with HRD1 inhibitor. www.jci.org/articles/view/187341 @jclinicalinvest
-
Daniel J Drucker
@DanielJDrucker
In adults with a history of seizure disorder in TriNetX, GLP-1 RA initiation was associated with reduced risks of seizure recurrence, hospitalization, and mortality compared with other glucose-lowering therapies onlinelibrary.wiley.com/doi/10.1111/epi.70022
-
Daniel J Drucker
@DanielJDrucker
Does genetic variation in GLP-2R signaling influence the development of binge eating disorders and/or the therapeutic response to GLP-1 medicines? #bulimia www.sciencedirect.com/science/article/abs/pii/S0166432825ā¦
-
Daniel J Drucker
@DanielJDrucker
Here the authors reveal precise preventive and therapeutic strategies to ameliorate Insulin Resistance-related cardiometabolic health and longevity www.nature.com/articles/s41467-025-64985-9
-
Daniel J Drucker
@DanielJDrucker
How does tirzepatide talk to your brain and quiet food noise? A case report with electrophysiological insights www.nature.com/articles/s41591-025-04035-5
-
Daniel J Drucker
@DanielJDrucker
Revisiting the traditional paradigms and goals for initial management of #t2d A focus on achievement of #weightloss with cost effective GLP-1 medicines diabetesjournals.org/care/article-abstract/doi/10.2337/dcā¦
-
Daniel J Drucker
@DanielJDrucker
An optogenetics enabled enteric nervous system epithelium gut organ platform for systematic discovery and mechanistic exploration of functional neuroimmune connections www.nature.com/articles/s41467-025-64995-7
-
Daniel J Drucker
@DanielJDrucker
Preclinical studies highlight the biological rationale for targeting NLRP3 w/wo GLP-1R agonism in inflammatory conditions such as #obesity www.sciencedirect.com/science/article/pii/S2212877825001899 @MolMetab
-
Daniel J Drucker
@DanielJDrucker
Giants in #diabetes science recognized with awards at the Levine-Riggs symposium. Congratulations to Dr. Kevan Herold @Yale and Dr. Alvin Powers @VanderbiltU Thank you for your innovation and dedication to rigorous translational diabetes science #t1d #t2d www.cityofhope.org/research/riggs-institute/dmri-events-eā¦
-
Daniel J Drucker
@DanielJDrucker
Extension of the adipose tissue brain axis controlling energy homeostasis. Will the next generation of #obesity therapeutics include targeted delivery of leptin-sensitizing miRNAs to the CNS to reverse central leptin resistance and produce #weightloss www.cell.com/cell-metabolism/abstract/S1550-4131(25)00439-5
-
Daniel J Drucker
@DanielJDrucker
Towards the next chapter of #microbiome research and metabolism-moving from dysbiosis and associations to translational reproducibilty and personalized medicine www.cell.com/cell-metabolism/abstract/S1550-4131(25)00445-0 @Cell_Metabolism
-
Daniel J Drucker
@DanielJDrucker
Living longer, healthier and prospering. The promise of GLP-1 medicines #aging #longevity #healthspan www.nature.com/articles/s41587-025-02932-1
-
Daniel J Drucker
@DanielJDrucker
Based on extensive mouse studies
demonstrating miR-432 exacerbates #obesity induced dysregulation of glucose and lipid metabolism, the authors propose miR-342 antagomirs to treat cardiometabolic disorders diabetesjournals.org/diabetes/article/doi/10.2337/db25-02⦠-
Daniel J Drucker
@DanielJDrucker
Extraislet β cells are virtually absent in the human #t1d pancreas www.science.org/doi/10.1126/sciadv.adz2251
-
Daniel J Drucker
@DanielJDrucker
A new retrospective cohort study found a lower risk of NAION in patients with type 2 #diabetes taking semaglutide compared with those taking non-GLP-1 RA medications in a large, diverse population academic.oup.com/milmed/advance-article-abstract/doi/10.1ā¦
-
Daniel J Drucker
@DanielJDrucker
Shooting your age in golf is a challenge and holy grail for some-might it get a bit easier in the future? #aging #longevity www.nature.com/articles/d41586-025-03524-4
-
Daniel J Drucker
@DanielJDrucker
An Evoke (ish) trial Amuse Bouche? Oral semaglutide (n=35, placebo 36) did not improve executive function over 16 weeks in people with major depressive disorder; results from secondary analyses suggested effects on specific domains of cognition www.cell.com/med/abstract/S2666-6340(25)00343-5
-
Daniel J Drucker
@DanielJDrucker
Lysine restriction reveals P. goldsteinii and its metabolite MIAA mediating LRD-mediated obesity reduction, potentially via the FTO-SLC2A4 axis to restrict adipose tissue expansion #obesity www.nature.com/articles/s41467-025-64892-z
-
Daniel J Drucker
@DanielJDrucker
New from the @HansClevers
Drug screening and human organoids @NatRevDrugDisc www.nature.com/articles/s41573-025-01317-y -
Daniel J Drucker
@DanielJDrucker
New from the Locksley lab A nutrient sensitive enteroendocrine GLP-2 Telocyte TSLP ILC2 circuit to control mucosal immunity www.nature.com/articles/s41590-025-02328-y @NatImmunol @UCSF
-
Daniel J Drucker
@DanielJDrucker
P2B 24 week data for the GCGR-GLP-1R co-agonist Pemvidutide #mash resolution without worsening of fibrosis at 24 weeks but not fibrosis improvement without worsening of MASH www.thelancet.com/journals/lancet/article/PIIS0140-6736(2ā¦
-
Daniel J Drucker reposted
Katalin Susztak
@KSusztak
I am deeply honored to receive the 2025 Homer W. Smith Award from @ASNKidney.
This recognition is not just mine ā it belongs to the many people who shaped my path in science and medicine. š #kidneyweek -
Daniel J Drucker
@DanielJDrucker
The latest review on #mash and an overview of resmetirom and semaglutide for moderate to advanced fibrosis jamanetwork.com/journals/jama/article-abstract/2841071
-
Daniel J Drucker
@DanielJDrucker
Distinguishing features of autoantibody-negative and autoantibody-positive type 1 #diabetes link.springer.com/article/10.1007/s00125-025-06580-7
-
Daniel J Drucker
@DanielJDrucker
Diet associations with sarcopenic #obesity from NHANES www.nature.com/articles/s41366-025-01940-0
-
Daniel J Drucker
@DanielJDrucker
New insights into the oxidative proinsulin folding and suppression of the proinsulin aggregation inside quality control granules, essential for secretion of #insulin www.nature.com/articles/s41556-025-01794-8
-
Daniel J Drucker
@DanielJDrucker
Thank you to our veterans and active service members, we appreciate your sacrifice
-
Daniel J Drucker
@DanielJDrucker
Deadlines are approaching (some next week!) for @KeystoneSymp #isletbiology and #diabetes : #betacell Compensation, Failure and Recovery, this March in Breckenridge! See scholarship, abstract and discount reg dates: keysym.us/KSDiabetes26 #ksdiabetes26
-
Daniel J Drucker
@DanielJDrucker
Some but not all of the remarkable actions of GLP-1 medicines are not strictly dependent on #weightloss findings with real clinical implications #mash www.novonordisk.com/content/nncorp/global/en/news-and-med⦠@AASLDtweets
-
Daniel J Drucker
@DanielJDrucker
A CNS mode of action for liraglutide in experimental #pcos in rats dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/doā¦
-
Daniel J Drucker
@DanielJDrucker
More insights in the enduring pursuit of the molecular mechanisms of metformin action www.nature.com/articles/s41594-025-01710-6
-
Daniel J Drucker
@DanielJDrucker
New concepts linking ketohexokinase to fructose metabolism, GLP-1, alcohol intake and liver injury in mice www.nature.com/articles/s42255-025-01402-x
-
Daniel J Drucker
@DanielJDrucker
More dissenting opinions on projecting relative cardiovascular risk of Semaglutide vs. Tirzepatide. āIn the head-to-head comparison of tirzepatide versus semaglutide, the hazard ratio was 1.06 (0.95 to 1.18).ā www.nature.com/articles/s41591-025-04102-x Keep calm and carry on š½ #aha2025
Daniel J Drucker
@DanielJDrucker
That famous GLP-1 expert Yogi Berra knew that the cardioprotective actions of GLP-1 medicines are not simply quantifiable with surrogate measurements and biomarkers, hence he would have been cautious about using risk engines for comparative cardiovascular risk and outcomes #cvd
-
Daniel J Drucker
@DanielJDrucker
Gut barrier function, systemic inflammation and the pathophysiology of metabolic disorders #t2d #obesity journals.physiology.org/doi/abs/10.1152/ajpcell.00704.2025
-
Daniel J Drucker
@DanielJDrucker
Metformin Does Not Improve Walking Performance over 6 Months in Lower Extremity Peripheral Artery Disease Without #t2d The PERMET Randomized Clinical Trial jamanetwork.com/journals/jama/fullarticle/2841244
-
Daniel J Drucker
@DanielJDrucker
Impressive risk reduction on top of statins #cvd #heartdisease #pcsk9 www.nejm.org/doi/full/10.1056/NEJMoa2514428
-
Daniel J Drucker
@DanielJDrucker
That famous GLP-1 expert Yogi Berra knew that the cardioprotective actions of GLP-1 medicines are not simply quantifiable with surrogate measurements and biomarkers, hence he would have been cautious about using risk engines for comparative cardiovascular risk and outcomes #cvd
-
Daniel J Drucker
@DanielJDrucker
Can the authors use the same data parameters from SURPASS CVOT to determine the predicted vs. actual CV outcomes for Dulaglutide vs. Tirzepatide? This would help validate the predictive model, where #weightloss independent non quantifiable CV actions of GLP-1 are not measured
European Society of Cardiology Journals
@ESC_Journals
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial academic.oup.com/ehjopen/article/5/5/oeaf117/8246115
@ehjopen @SaDeRosa78 @ProfMagnusBack @SABOURETcardio #ehjopen -
Daniel J Drucker
@DanielJDrucker
Cardiorenal outcomes and safety for use of SGLT2i vs. DPP4i in PPL in Ontario with #t2d and #dementia Real world administrative data @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06595-0
-
Daniel J Drucker
@DanielJDrucker
Based on preclinical studies with a glucokinase activator the authors propose that targeting immunometabolic pathways may offer a therapeutic strategy to alleviate cardiac dysfunction and reduce infarct vulnerability in #t2d www.biorxiv.org/content/10.1101/2025.04.10.648128v2
-
Daniel J Drucker
@DanielJDrucker
Here studies in mice demonstrate that #probiotic mediated GLP-1 modulation can bypass dietary fiber requirements to maintain gut homeostasis www.science.org/doi/10.1126/sciadv.adx6869
-
Daniel J Drucker
@DanielJDrucker
Results from the evoke trials with oral semaglutide #alzheimersdisease are imminent. The real world data continues to arrive for GLP-1 medicines and #t2d cardiab.biomedcentral.com/articles/10.1186/s12933-025-029ā¦
-
Daniel J Drucker
@DanielJDrucker
More synthetic gene switches in mice. Here melatonin regulated GLP-1 expression as a therapeutic output exclusively secreted during nighttime, highlighting potential as an experimental cell therapy for #obesity dependent type-2 #diabetes #circadian www.nature.com/articles/s41467-025-64761-9
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that AQP7 is a key regulator of adipose homeostasis and a potential therapeutic target for reducing fat accumulation and metabolic imbalances associated with high glucose exposure. www.nature.com/articles/s44324-025-00085-y
-
Daniel J Drucker
@DanielJDrucker
An update on Teplizumab, a new era for #t1d prevention and management diabetesjournals.org/care/article-abstract/doi/10.2337/dcā¦
-
Daniel J Drucker
@DanielJDrucker
Studies in mice lead to the proposal that combined treatment with GKA and incretin mimetics may be useful in GCK-MODY and in more common forms of type 2 #diabetes diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
New from the Scherer lab @UTSWMedCenter The microprotein adipogenin (Adig) identified as a key cofactor that modulates seipin function, lipid droplet biology and fat storage in adipose tissue www.science.org/doi/10.1126/science.adr9755
-
Daniel J Drucker
@DanielJDrucker
Studies in mice identify a lipid metabolic circuit between bacteria and host that is disrupted by diet and can be targeted therapeutically #microbiota #weightloss #ceramides www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00441-3
-
Daniel J Drucker
@DanielJDrucker
Insights on downstream immunity from blood methylome signatures in children exposed to maternal type 1 diabetes #t1d #genetics #epigenetics www.nature.com/articles/s42255-025-01403-w
-
Daniel J Drucker
@DanielJDrucker
Eloralintide moves the needle for Amylin agonism #weightloss #obesity in P2 trials investor.lilly.com/news-releases/news-release-details/lil⦠@OW2025 #ow2025
Daniel J Drucker
@DanielJDrucker
Details for the Eloralintide #weightloss trial #obesity www.thelancet.com/journals/lancet/article/PIIS0140-6736(2ā¦
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose T cell-derived sCD52 as a therapeutic target to mitigate #obesity-associated #masld and glucose intolerance www.sciencedirect.com/science/article/pii/S2212877825001863
-
Daniel J Drucker
@DanielJDrucker
The ongoing enthusiasm for studying and addressing #sarcopenia associated with metabolic disorders #weightloss www.nature.com/articles/s41574-025-01197-7
-
Daniel J Drucker
@DanielJDrucker
The exploration of optimal Amylin agonism continues with interrogation of higher doses of Cagrilintide in the RENEW program #weightloss #obesity www.novonordisk.com/content/dam/nncorp/global/en/investorā¦
-
Daniel J Drucker
@DanielJDrucker
The interaction of GLP-1 medicines with the immune system is complex, enabled by direct and indirect actions, including neural inter organ communication. These studies have been led @SinaiHealth by CK Wong. His latest perspective here @jclinicalinvest www.jci.org/articles/view/194751
-
Daniel J Drucker
@DanielJDrucker
How to define clinical sarcopenia and goals for improving muscle and overall health www.nature.com/articles/s43587-025-01004-y
-
Daniel J Drucker
@DanielJDrucker
Here the use of #genetics for #pcos revealed multiple drug targets and repurposing opportunities, enabling personalized treatment strategies, paving the way for precision medicine www.nature.com/articles/s41588-025-02393-x
-
Daniel J Drucker
@DanielJDrucker
How do GLP-1 medicines interact with immune cells to reduce #inflammation? From T cells, to the brain, #weightloss and much more, there is no simple unifying one size fits all pathway. "Sometimes we find as many as six impossible things before breakfast" www.jci.org/articles/view/194751
-
Daniel J Drucker
@DanielJDrucker
Will GLP-1 medicines modify the rates and/or outcomes of one or more #cancers A review on the biology, limitations of the data and the road ahead from @LWellberg and colleagues in @jclinicalinvest www.jci.org/articles/view/194743/
-
Daniel J Drucker reposted
Eric Topol
@EricTopol
GLP-1 drugs have intrinsic potent anti-inflammatory action beyond their metabolic beneficial impact on glucose regulation and weight loss @DanielJDrucker @jclinicalinvest
www.jci.org/articles/view/194751 -
Daniel J Drucker
@DanielJDrucker
A new review series on key aspects of GLP-1 biology from @jclinicalinvest First up, Cooper, van Raalte and the kidney www.jci.org/articles/view/194749
-
Daniel J Drucker
@DanielJDrucker
Emerging evidence supports #weightloss independent mechanisms of action for GLP-1 medicines, with reduction of #inflammation a likely contributing factor. Yet GLP-1R expression in the immune system is rare and ascertainment can be challenging www.cell.com/cell-metabolism/abstract/S1550-4131(25)00325-0
-
Daniel J Drucker
@DanielJDrucker
New from Prof Tomas @TomasLab_ICL Both basal and agonist-induced GLP-1R phosphorylation are critical for receptor signalling in β-cells www.biorxiv.org/content/10.1101/2025.11.01.686001v1 @imperialcollege
-
Daniel J Drucker
@DanielJDrucker
Another Cochrane review #obesity āThe effects of semaglutide on quality of life, MACE, and mortality are likely limited or uncertainā www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD01509ā¦
-
Daniel J Drucker reposted
Retraction Watch
@RetractionWatch
āWhy I no longer engage with Nature publishing groupā: Researcher responds after being asked to review a manuscript.
hxstem.substack.com/p/why-i-no-longer-engage-with-nature -
Daniel J Drucker
@DanielJDrucker
A valuable reference for comparative studies of mitochondrial adaptations across space and time, and in pathophysiological contexts. www.sciencedirect.com/science/article/pii/S2212877825001851 @MolMetab
-
Daniel J Drucker
@DanielJDrucker
Reduced risk of serious infections with GLP-1 medicines. Mechanistically, how does that unfold? www.journalofinfection.com/article/S0163-4453(25)00245-2/ā¦
-
Daniel J Drucker
@DanielJDrucker
The latest review on the future of GLP-1 medicines from Prof Bailey @diabetologiajnl link.springer.com/article/10.1007/s00125-025-06581-6
-
Daniel J Drucker
@DanielJDrucker
It doesnāt get much better than this. Dream big, have fun, good luck! @BlueJays
-
Daniel J Drucker
@DanielJDrucker
Based on adipose tissue transcriptome analysis w/wo #exercise the authors propose novel molecular pathways regulated by #exercise training can lead to therapeutic targets for #obesity and metabolic disease. www.biorxiv.org/content/10.1101/2025.10.11.681273v1
-
Daniel J Drucker reposted
Elisabeth Bik
@MicrobiomDigest
40 Percent of Stroke Animal Studies May Have Problematic Images
Red flags during a literature review led to the discovery of over 200 papers on animal models of stroke with duplicated images, which is likely an underestimate.
www.the-scientist.com/40-percent-of-stroke-animal-studies⦠-
Daniel J Drucker
@DanielJDrucker
The enteric nervous system in health and disease. A detailed transcriptomic atlas of the ENS during distinct environmental challenges revealing a set of coordinated responses to perturbations www.science.org/doi/10.1126/science.adr3545
-
Daniel J Drucker
@DanielJDrucker
The latest beneficial attribute of C-peptide positivity in #t1d @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06578-1
-
Daniel J Drucker
@DanielJDrucker
The hostās circadian system entrains SCβ-cell function to optimize the circadian control of insulin secretion #stemcells #islets www.cell.com/stem-cell-reports/fulltext/S2213-6711(25)002ā¦
-
Daniel J Drucker
@DanielJDrucker
This insightful Cochrane review written prior to SURPASS CVOT concludes that Tirzepatide produces meaningful #weightloss #obesity www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD01601ā¦
-
Daniel J Drucker
@DanielJDrucker
The oral small molecule GLP-1RA orforglipron continues to post solid results #weightloss in both the ATTAIN and ACHIEVE programs #t2d #obesity investor.lilly.com/static-files/81645112-510f-4ce8-a860-cā¦
-
Daniel J Drucker
@DanielJDrucker
The ongoing PSA screening debate-new data-screening understandably leads to higher rates of #prostatecancer diagnosis yet 13% reduction in prostate cancer-related mortality www.nejm.org/doi/full/10.1056/NEJMoa2503223
-
Daniel J Drucker
@DanielJDrucker
Isocaloric Time Restricted Eating shifts circadian clocks in women with overweight or obesity but does not improve markers of cardiometabolic health www.science.org/doi/10.1126/scitranslmed.adv6787
-
Daniel J Drucker
@DanielJDrucker
H9C2 cardiomyocyte cells have not been shown to express the GLP-1R.
Here the authors define multiple actions of Liraglutide on these cells ex vivo www.mdpi.com/1648-9144/61/10/1754 -
Daniel J Drucker
@DanielJDrucker
Gut brain communication. A review of the distinct spinal and vagal afferent types alongside viscerofugal pathways revealed by advances in neurogenetic techniques and high-resolution anterograde tracing www.nature.com/articles/s41575-025-01132-1
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that inhibition of the serine threonine kinase FAM20C in adipocytes may serve as a potential therapy for #t2d by restoring adipocyte health www.jci.org/articles/view/191075
-
Daniel J Drucker
@DanielJDrucker
Once again.....Real world data #t2d reveals GLP-1RAs and DPP-4is were associated with a small increase in risk of biliary disease, but not of acute pancreatitis compared with SGLT2is diabetesjournals.org/care/article-abstract/doi/10.2337/dcā¦
-
Daniel J Drucker
@DanielJDrucker
Do GLP-1 medicine improve #psoriasis in people with #obesity independent of #weightloss The debate continues academic.oup.com/ced/advance-article-abstract/doi/10.1093ā¦
-
Daniel J Drucker
@DanielJDrucker
Here intestinal fructose metabolism drives GLP-1 secretion required to potentiate insulin secretion, thereby establishing a gut-pancreas axis that counter-regulates fructose-induced hyperglycaemia. physoc.onlinelibrary.wiley.com/doi/10.1113/JP289067 physoc.onlinelibrary.wiley.com/cms/asset/d106a78a-90cf-4bā¦
-
Daniel J Drucker
@DanielJDrucker
SURMOUNT-OSA Weight loss drives a substantial proportion of benefit www.sciencedirect.com/science/article/abs/pii/S1389945725ā¦
-
Daniel J Drucker
@DanielJDrucker
Turns out that if you lose weight you feel better dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70202
-
Daniel J Drucker
@DanielJDrucker
RACK1 functions as a dual-compartment scaffold, assembling GCGRāPKA at the plasma membrane and PKAcαāCREB in the nucleus, enabling precise glucagon signaling and gluconeogenesis www.cmghjournal.org/article/S2352-345X(25)00207-3/fulltext
-
Daniel J Drucker
@DanielJDrucker
In patients with Monoclonal Gammopathy of Unknown Significance (MGUS) and metabolic comorbidities, GLP-1 RA therapy was associated with significantly improved Progression Free and Overall Survival and reduced risk of progression to multiple myeloma onlinelibrary.wiley.com/doi/10.1111/eci.70140
-
Daniel J Drucker
@DanielJDrucker
Surprise, or clinical validation of previous findings? 2009. Liraglutide reduces infarct size and death independent of weight loss or glycemic control in mice diabetesjournals.org/diabetes/article/58/4/975/118/GLP-1R⦠HARMONY Outcomes Trial 2018 Lancet Albiglutide produces 22% reduction in MACE, <1% weight loss
GoggleDocs
@GoggleDocs
šØSELECT trial surprisešØ
š Semaglutide ⤵ļøcardiovascular events 20% regardless of wt loss.
šøš«losing <5% had same CV benefit as those losing >5%.
š¹Only 33% of benefit explained by waist circ. changes.
šReframes GLP-1s from weight loss drugs to CV disease modifiers.
š www.thelancet.com/journals/lancet/article/PIIS0140-6736(2⦠-
Daniel J Drucker
@DanielJDrucker
Here the authors further support the link between #leptin signaling and tissue #fibrosis demonstrating that a leptin-neutralizing antibody may be a promising therapeutic approach for reducing fibrosis in the kidney, liver, lung, heart, and blood vessels www.science.org/doi/10.1126/sciadv.ady7904
-
Daniel J Drucker
@DanielJDrucker
#vitamind deficiency associates with increased risk for a broad range of medical conditions. Yet RCTs of Vitamin D replacement often fail to show therapeutic benefit. Here critical illness and risk of acute kidney injury insight.jci.org/articles/view/193523 @JCI_insight
-
Daniel J Drucker
@DanielJDrucker
Preclinical studies identify hypothalamic FSTL1 as a key mediator counteracting diet induced #obesity and provide a potential pharmacological strategy for obesity-related metabolic disorders #insulin sensitivity www.cell.com/neuron/fulltext/S0896-6273(25)00749-4
-
Daniel J Drucker
@DanielJDrucker
In todayās #ai enabled academic world Fake it till you make it has a whole new vexatious meaning www.nature.com/articles/d41586-025-03341-9
-
Daniel J Drucker reposted
KristenRHoward, PhD, ARNP
@KRHoward72
news.vt.edu/content/news_vt_edu/en/articles/2025/10/hnfe-ā¦
Excited to share our latest research @davykevinp @JohnSpeakman4 @Olalla_Prado @GuillermoZorri4 @BrendaDavy @VT_TBMH
Link to full article
doi.org/10.1073/pnas.2519626122 -
Daniel J Drucker
@DanielJDrucker
Combined use of SGLT-2i and GLP-1RA for prevention of cardiorenal complications-A dynamic duo in #t2d care @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06565-6
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines reduce rates of stroke in PPL with #t2d Here, real world registry data on initiation of GLP-1 medicines after ischemic stroke. TGTBT? link.springer.com/article/10.1007/s00415-025-13470-w
-
Daniel J Drucker
@DanielJDrucker
Not your bartenders IPA, here reduction of gut inflammation by metabolic reprogramming of CD4+āT cells toward the enhancement of mitochondrial respiration. #microbiota www.nature.com/articles/s42255-025-01396-6
-
Daniel J Drucker
@DanielJDrucker
Studies of T cell acute lymphoblastic leukemia reveal that canagliflozin possesses potent anti-leukaemic effects underpinned by proliferative defects, cell cycle disruption and apoptosis, actions synergized by restriction of serine and glycine @MolMetab www.sciencedirect.com/science/article/pii/S2212877825001826
-
Daniel J Drucker
@DanielJDrucker
Pemvidutide over 24 weeks in #masld A P2 dose ranging study showing significant reductions in hepatic steatosis www.sciencedirect.com/science/article/pii/S2589555925001612
-
Daniel J Drucker
@DanielJDrucker
Multiple gene therapy approaches are being studied to take on the challenges of extending the duration of GLP-1 medicines. Should they be tunable and/or have a kill/off switch? www.biorxiv.org/content/10.1101/2025.05.30.656889v3
-
Daniel J Drucker
@DanielJDrucker
Insights from optogenetics in conjunction with hormone secretion measurements, electrophysiology, and cytoplasmic free Ca2+ concentration ([Ca2+]i) imaging to interrogate the relative roles of paracrine and electrical control of β-cells by Ī“-cells. diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
In this review the authors advocate for body weight independent mechanisms underlying the control of BP by GLP-1 medicines www.nature.com/articles/s41440-025-02418-2 #hypertension
-
Daniel J Drucker
@DanielJDrucker
In this review the authors assert that human #genetics has shed light on MASLD predisposition and its causal association with type 2 #diabetes and insulin resistance, enabling the field to progress towards precision-medicine therapeutics. www.nature.com/articles/s42255-025-01394-8
-
Daniel J Drucker
@DanielJDrucker
In people with HIV, Semaglutide for 32 weeks may have a beneficial impact on visuospatial cognitive function in PWH, associated with its effect on inflammation academic.oup.com/cid/advance-article-abstract/doi/10.1093ā¦
-
Daniel J Drucker reposted
Nature Reviews Drug Discovery
@NatRevDrugDisc
For readers interested in next-generation GLP-1-based drugs such as Lilly's oral candidate orforglipron, here's a comprehensive review from @DanielJDrucker
rdcu.be/eLlPq
www.nature.com/articles/s41573-025-01183-8 -
Daniel J Drucker
@DanielJDrucker
Does the phenotype of MC4R deficiency overlap with metabolically healthy #obesity www.nature.com/articles/s41591-025-03976-1
-
Daniel J Drucker
@DanielJDrucker
Handgrip strength inversely correlates with mortality in people with preclinical obesity. Will improving handgrip strength improve health? What sayeth association nation? academic.oup.com/jcem/advance-article/doi/10.1210/clinem/ā¦
-
Daniel J Drucker
@DanielJDrucker
The P3 Retatrutide TRIUMPH trials #obesity dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70209
-
Daniel J Drucker reposted
Nature Metabolism
@NatMetabolism
#throwback
REVIEW | S Deota, @SatchinPanda et al.
The time is now: accounting for time-of-day effects to improve reproducibility and translation of metabolism research
www.nature.com/articles/s42255-025-01237-6 -
Daniel J Drucker
@DanielJDrucker
An update on beta cell GABA biology using mouse genetics to inactivate GAD65 and GAD67. GABA is dispensable for beta cell mass, but essential for dynamic function #islets @MolMetab www.sciencedirect.com/science/article/pii/S2212877825001759
-
Daniel J Drucker
@DanielJDrucker
A VMHGalnt2-originated brain-liver neurocircuit that perceives and counterregulates #hypoglycemia and may pave the way to innovative therapeutic strategies against metabolic disorders characterized by glucose dysregulation. www.cell.com/cell-metabolism/abstract/S1550-4131(25)00391-2
-
Daniel J Drucker
@DanielJDrucker
New roles for Sec31A, a gene involved in transporting proteins from the endoplasmic reticulum (ER), as a key regulator of alpha cell survival under stress #islets www.nature.com/articles/s41467-025-64169-5
-
Daniel J Drucker reposted
JAMA
@JAMA_current
#glp1 medicines now address weight loss and other health conditions through innovative formulations and expanded indications, highlighting key questions about their efficacy and safety.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20⦠-
Daniel J Drucker
@DanielJDrucker
The Orforglipron ACHIEVE program #t2d continues to report solid A1c outcomes #weightloss details not yet reported investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
The GLP-1 medicines P3 space will continue to expand-differentiation on safety, tolerability, efficacy and indication is possible but challenging www.kailera.com/press-release/kailera-therapeutics-announā¦
-
Daniel J Drucker reposted
EASO
@EASOobesity
@EASOobesity and @novonordiskfond are delighted to announce that the Obesity Prize for Excellence and New Investigator Awards will continue annually through 2030!
easo.org/easo-novo-nordisk-foundation-obesity-prize-for-e⦠-
Daniel J Drucker
@DanielJDrucker
Due to the widespread use of non-validated reagents, accurate localization of GLP-1R expression in the immune system is challenging. Most of the immune/hematopoietic cells depicted here donāt express the GLP-1R cellandbioscience.biomedcentral.com/articles/10.1186/s135ā¦
-
Daniel J Drucker
@DanielJDrucker
When will GLP-1 gene therapy succeed in the clinic? Many have their eye on the prize yet obstacles remain www.cell.com/molecular-therapy-family/nucleic-acids/fulltā¦
-
Daniel J Drucker
@DanielJDrucker
Crying wolf. The ongoing saga of periprocedural discontinuation of GLP-1 medicines. Searching for an imbalance of complications dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/doā¦
-
Daniel J Drucker
@DanielJDrucker
Actually, we donāt yet have a single well powered RCT showing clear success with a meaningful effect size for any GLP-1 medicine in any substance use disorder
Eric Topol
@EricTopol
What explains the success of GLP-1 drugs for treating alcohol and substance abuse disorders?
A new review. We don't know yet.
academic.oup.com/jes/article/9/11/bvaf141/8277723?searchr⦠-
Daniel J Drucker
@DanielJDrucker
An islet cell autoantibody against GAD65 can directly impact and impair secretory function in islets inĀ vitro and inĀ vivo through a mechanism that involves inhibition of mitochondrial energetics. diabetesjournals.org/diabetes/article-abstract/doi/10.233ā¦
-
Daniel J Drucker
@DanielJDrucker
β-cell mass does not differ between individuals with and without PBH #hypoglycemia after RYGB argue against expansion of β-cell mass to explain PBH. diabetesjournals.org/diabetes/article/doi/10.2337/db25-05⦠ada.silverchair-cdn.com/ada/content_public/journal/diabetā¦
-
Daniel J Drucker
@DanielJDrucker
Dysregulation and accumulation of T cell PM cholesterol has the potential to lead to aberrant gut TH17 effector function, altered immune-epithelial communication, and modulation of intestinal and systemic nutrient metabolism. www.science.org/doi/10.1126/science.adt4169
-
Daniel J Drucker
@DanielJDrucker
Here enthusiasm for targeting preweaning ketosis to drive beige adipogenesis to offer a therapeutic approach to combat #obesity and metabolic diseases in adulthood. www.nature.com/articles/s42255-025-01378-8
-
Daniel J Drucker
@DanielJDrucker
Towards reversing #fibrosis #cirrhosis #mash www.globenewswire.com/news-release/2025/10/09/3163960/0/eā¦
-
Daniel J Drucker
@DanielJDrucker
Genetic proxies for body weight reduction via GIP receptor targeting reduces the risk of MACE and heart failure, mediated partly through lower BMI and partly through lower HbA1c academic.oup.com/eurheartj/advance-article/doi/10.1093/euā¦
-
Daniel J Drucker
@DanielJDrucker
Sweetening the diet with artificial sweeteners reveals in a clinical trial that prolonged consumption of S&SEs in a healthy diet is a safe strategy for #obesity management #weightloss #microbiota www.nature.com/articles/s42255-025-01381-z
-
Daniel J Drucker
@DanielJDrucker
The ongoing pursuit of islet cell identity, here SMOC1 as a β-cell dedifferentiation gene www.nature.com/articles/s41467-025-62670-5
-
Daniel J Drucker
@DanielJDrucker
More #weightloss data combining Cannabinoid receptor 1 blockade with semaglutide ir.skyebioscience.com/news-releases/detail/244/skye-bioscā¦
-
Daniel J Drucker
@DanielJDrucker
Reduced numbers of GLP-1+ L cells and #ibd Causality or association? www.cmghjournal.org/article/S2352-345X(25)00197-3/fulltext
-
Daniel J Drucker
@DanielJDrucker
Among reasons for discontinuation of GLP-1 medicines initiated for #weightlossdue cost or insurance-related issues was the most common reason cited onlinelibrary.wiley.com/doi/10.1002/oby.70058
-
Daniel J Drucker
@DanielJDrucker
Inflammation is a key driver of the pathophysiology of cardiometabolic disorders #obesity #t2d and new metabolic medicines based on GLP-1 action exert their magic in part by reducing inflammation. A new review from Professor Donath summarizes the field www.sciencedirect.com/science/article/pii/S1074761325004224
-
Daniel J Drucker
@DanielJDrucker
Efferocytosis-associated reprogramming of the islet macrophages and the subsequent influence on the adaptive immune response could be beneficial in modulating diabetic autoimmunity #diabetes #t1d www.nature.com/articles/s41586-025-09560-4
-
Daniel J Drucker
@DanielJDrucker
Academic highlight for me this am ā¦@SickKidsNewsā© catching up with rhe great Dennis Daneman luminary in pediatric endocrinology and #diabetes and leader in pediatrics ā¦@uoftmedicineā© Razor sharp and congenial over 5 decades
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines and #arthritis www.nature.com/articles/s41584-025-01302-0
-
Daniel J Drucker
@DanielJDrucker
Incoming nutritional epidemiology. Low Carbohydrate Diets may not be beneficial for primary prevention of #t2d unless they prioritize plant-based protein, healthy fats, and high-quality carbohydrates. diabetesjournals.org/care/article-abstract/doi/10.2337/dcā¦
-
Daniel J Drucker
@DanielJDrucker
Novel insights into the molecular underpinnings of islet cell dysfunction in #t1d highlighting pathways that may be leveraged to preserve residual β-cell function and modulate α-cell activity @bcellorg www.jci.org/articles/view/195267
-
Daniel J Drucker
@DanielJDrucker
Rare but real. Genital infections in males #t2d on SGLT2i jamanetwork.com/journals/jamanetworkopen/fullarticle/2839404
-
Daniel J Drucker
@DanielJDrucker
Prolonged glucagon exposure and the kidney-helpful or harmful? www.nature.com/articles/s41467-025-63529-5
-
Daniel J Drucker
@DanielJDrucker
Human #genetics implies that therapeutic inhibition of SLC30A8, mediating zinc transport up to and including complete knockout, may treat type 2 diabetes safely and effectively @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06530-3
-
Daniel J Drucker
@DanielJDrucker
āNutrition isnāt rocket science; itās harderā A highly readable book that blows up common misconceptions, canards and profiteering charlatans, while wrestling with calories, #diets #precision nutrition #vitamins and more. Foundational for the public and the nutrition glitterati
Kevin Hall
@KevinH_PhD
Iām excited to announce my new book FOOD INTELLIGENCE coauthored with brilliant journalist @juliaoftoronto! Cutting through the confusion about diet & health, #foodintelligence describes the fascinating science of how food both nourishes and harms us.
www.penguinrandomhouse.com/books/671334/food-intelligenceā¦
#foodintelligence combines my scientific expertise with Juliaās incisive journalism to help you better understand nutrition science, how our food environment drives metabolic disease, & what to do about it. This book has been years in the making & itās finally a reality! @Avery_Books -
Daniel J Drucker
@DanielJDrucker
Here it is proposed that furin plays an important role in liberation of GLP-1 from alpha cells www.sciencedirect.com/science/article/pii/S2212877825001668
-
Daniel J Drucker
@DanielJDrucker
Clinical trial results reporting for industry-still room for improvement. Meanwhile in academia, home to many industry critics, the timely reporting rates remain abysmal publichealth.realclearjournals.org/research-articles/2025ā¦
-
Daniel J Drucker
@DanielJDrucker
Some promising data for #weightloss maintenance after discontinulation of GLP-1 medicines using duodenal mucosal resurfacing ir.fractyl.com/news-releases/news-release-details/fractylā¦
-
Daniel J Drucker
@DanielJDrucker
A therapeutically targetable pathway promoting MASH fibrosis involving a non-apoptotic function of caspase-8 and a newly discovered HSC activator, meteorin.
www.nature.com/articles/s42255-025-01355-1 -
Daniel J Drucker reposted
Prof. Nikolai Slavov
@slavov_n
bioRxiv has a dedicated section for negative results.
Use it.
Share negative results.
Your colleagues will appreciate it. -
Daniel J Drucker
@DanielJDrucker
Based on studies of autophagy in non-obese, insulin secretory-deficient KATP-GOF mice the authors propose that #intermittentfasting prevents the gradual loss of beta cell identity by enhancing autophagy link.springer.com/article/10.1007/s00125-025-06545-w
-
Daniel J Drucker
@DanielJDrucker
Bimagrumab exits stage left as the healthy #weightloss saga continues to unfold #obesity www.reuters.com/business/healthcare-pharmaceuticals/eli-lā¦
-
Daniel J Drucker
@DanielJDrucker
From the lizard venom and John Eng, in licensing to clinical development and approval April 28 2005. The remarkable story of Amylin Pharma and exenatide www.nature.com/articles/s42255-025-01383-x
-
Daniel J Drucker
@DanielJDrucker
Use of GLP-1 medicines in patients with HFrEF and implanted cardiac devices. Caution please www.jacc.org/doi/10.1016/j.jchf.2025.102573
-
Daniel J Drucker
@DanielJDrucker
New from Jennifer Stern. A role for the glucagon receptor in the lifespan extending effects of caloric restriction link.springer.com/article/10.1007/s11357-025-01899-w
-
Daniel J Drucker
@DanielJDrucker
New from Mark Ruszniak @VUBasicSciences @VanderbiltU An essential role for the GLP-1R in hematopoietic stem cell engraftment academic.oup.com/jimmunol/advance-article/doi/10.1093/jimā¦
-
Daniel J Drucker
@DanielJDrucker
From strength to greater strength, terrific recruitment of Professor Klatt to @uoftmedicine @nutrisci_uoft @UofT
Kevin C. Klatt, PhD, RD
@KCKlatt
Really excited to announce that I've accepted an Assistant Professor position in the Department of Nutritional Sciences in the Faculty of Medicine at the University of Toronto! Very excited to venture north (š„¶) & build out my own research group in human nutrition &metabolism š„³
-
Daniel J Drucker
@DanielJDrucker
The 100 year pursuit of oral #insulin delivery #diabetes continues-here is the latest technology and chapter www.science.org/doi/10.1126/sciadv.ady6386
-
Daniel J Drucker
@DanielJDrucker
Towards establishing consensus standards to unify indirect calorimetry experiments and their analysis for more consistent, meaningful and reproducible results-the latest proposals www.nature.com/articles/s42255-025-01360-4
-
Daniel J Drucker
@DanielJDrucker
More genetic evidence supporting an association between GLP1R agonists and higher risk of chronic tubulo-interstitial nephritis journals.lww.com/md-journal/fulltext/2025/09190/geneticalā¦
-
Daniel J Drucker
@DanielJDrucker
PDAC associated #diabetes vs #t2d greater insulin sensitivity, ~81% lower insulin secretion and ~40% lower beta cell function #pancreaticcancer link.springer.com/article/10.1007/s00125-025-06543-y
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose bone marrow adipose tissue as a biomarker and/or therapeutic target for diverse human diseases www.nature.com/articles/s41467-025-63395-1
-
Daniel J Drucker
@DanielJDrucker
New from the J Beaudry lab @beaudrj @uoftmedicine Roles for brown fat in lipid assimilation and oxidation in response to GIP in mice @nutrisci_uoft @BBDC_UofT www.embopress.org/doi/full/10.1038/s44319-025-00582-7
-
Daniel J Drucker reposted
EASD
@EASDnews
ā ļøThe EU Medicines Agency & Heads of Medicines Agencies warn of a surge in illegal GLP-1 products (e.g. semaglutide, liraglutide, tirzepatide) sold online for weight-loss/ #diabetes. These pose serious health risks. GLP-1s are prescription-only!
More š www.ema.europa.eu/en/news/warning-about-sharp-rise-illega⦠-
Daniel J Drucker
@DanielJDrucker
The potential for a once monthly Amylin-GLP-1 medicine combination-early PK data
Daniel J Drucker
@DanielJDrucker
PK data support monthly dosing for MET-097i
Daniel J Drucker
@DanielJDrucker
One of several key assets #weightloss
Daniel J Drucker
@DanielJDrucker
After encountering unpredictable off target AEs with small molecule GLP-1RAs Pfizer buys a peptide based GLP-1 medicine platform from Metsara #obesity #weightloss www.pfizer.com/news/press-release/press-release-detail/pfā¦
-
Daniel J Drucker
@DanielJDrucker
PK data support monthly dosing for MET-097i
Daniel J Drucker
@DanielJDrucker
One of several key assets #weightloss
Daniel J Drucker
@DanielJDrucker
After encountering unpredictable off target AEs with small molecule GLP-1RAs Pfizer buys a peptide based GLP-1 medicine platform from Metsara #obesity #weightloss www.pfizer.com/news/press-release/press-release-detail/pfā¦
-
Daniel J Drucker
@DanielJDrucker
One of several key assets #weightloss
Daniel J Drucker
@DanielJDrucker
After encountering unpredictable off target AEs with small molecule GLP-1RAs Pfizer buys a peptide based GLP-1 medicine platform from Metsara #obesity #weightloss www.pfizer.com/news/press-release/press-release-detail/pfā¦
-
Daniel J Drucker
@DanielJDrucker
After encountering unpredictable off target AEs with small molecule GLP-1RAs Pfizer buys a peptide based GLP-1 medicine platform from Metsara #obesity #weightloss www.pfizer.com/news/press-release/press-release-detail/pfā¦
-
Daniel J Drucker
@DanielJDrucker
Thirst in mice-a septal pathway that integrates multiple layers of presystemic signals to fine-tune drinking behavior www.nature.com/articles/s41593-025-02056-4
-
Daniel J Drucker
@DanielJDrucker
Here small molecule binding can rescue destabilizing GPCR variants throughout a proteinās structure. www.nature.com/articles/s41594-025-01659-6
-
Daniel J Drucker
@DanielJDrucker
Happy birthday Professor Buse!
-
Daniel J Drucker
@DanielJDrucker
Studies in rats reveals that insulinādependent release of endozepines from NTS-astrocytes is fundamental to control blood glucose levels www.sciencedirect.com/science/article/pii/S2212877825001620
-
Daniel J Drucker
@DanielJDrucker
Retrospective data from the VA health system suggests that compared to new users of DPP-4 inhibitors GLP-1 RA use was associated with a reduced risk of developing Pulmonary Hypertension www.medrxiv.org/content/10.1101/2025.09.18.25336100v1
-
Daniel J Drucker
@DanielJDrucker
The first GLP-1 medicine, twice daily exenatide was approved April 28 2005. Several decades later, the pace of innovation is expanding rapidly, encompassing new medicines and receptors, unique delivery options, and expanding therapeutic indications jamanetwork.com/journals/jama/article-abstract/2838996
-
Daniel J Drucker
@DanielJDrucker
Studies of prohormone convertase knockouts in mouse islets reveal plasticity in proglucagon processing to support intra-islet α cell-to-β cell communication, normally dominated by glucagon secretion www.science.org/doi/10.1126/sciadv.ady8048
-
Daniel J Drucker
@DanielJDrucker
Friday September 26 @uoftmedicine @SinaiHealth The 2025 Gerard N Burrow Lecture. Professor Alvin Powers #islets #diabetes #t1d #t2d @VanderbiltU @VUMChealth 8 am Mt. Sinai Join us! @AlPowers7
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines #weightloss #obesity and frailty. Insights from the STEP HFpEF trials with reduction of frailty endpoints after semaglutide www.sciencedirect.com/science/article/pii/S2213177925005384
-
Daniel J Drucker
@DanielJDrucker
Incident #t1d Sweden, with its non-restrictive pandemic response, saw a transient increase in type 1 #diabetes incidence that was only partially associated with SARS-CoV-2 infections link.springer.com/article/10.1007/s00125-025-06540-1 @DiabetologiaJnl
-
Daniel J Drucker
@DanielJDrucker
Inhibition of the glucagon receptor using LY2409021 during OGTT in totally pancreatectomised individuals does not produce detectable effects on glucose, lipid or amino acid metabolism @DiabetologiaJnl link.springer.com/article/10.1007/s00125-025-06534-z
-
Daniel J Drucker
@DanielJDrucker
A comprehensive metabolomeāphenome database guiding the development of biomarkers for enhanced diagnostic, predictive and treatment strategies www.nature.com/articles/s42255-025-01371-1
-
Daniel J Drucker
@DanielJDrucker
#easd25 highlights. Modern GLP-1 medicines such as tirzepatide are cardioprotective, can/should be tested using ethical trial designs and the dose response for metabolic endpoints does not perfectly mirror that for reduction of MACE #cvd #t2d
-
Daniel J Drucker
@DanielJDrucker
Are some GLP-1 medicines more cardioprotective than others? #easd25 A new real world study using US Medicare data www.novonordisk.com/content/nncorp/global/en/news-and-medā¦
-
Daniel J Drucker
@DanielJDrucker
Worth a read for context on the "lean mass muscle loss" #obesity GLP-1 medicine debate. Keep an eye on muscle function and health, diet quality and resistance #exercise and not just the DXA scan @SA_Diabetes @MolMetab #weightloss www.sciencedirect.com/science/article/pii/S2212877825001607
-
Daniel J Drucker
@DanielJDrucker
Among many highlights today #easd25 @EASDnews The @novonordiskfond Prize lecture novonordiskfonden.dk/en/news/scientist-who-uncovered-how-ā¦
-
Daniel J Drucker
@DanielJDrucker
Hard to make a figure that misrepresents to a greater extent the cause of type 2 #diabetes but when you have a favourite academic theory and hammer, the nails abound
The Lancet Diabetes & Endocrinology
@TheLancetEndo
Understanding the cause of type 2 #diabetes www.thelancet.com/journals/landia/article/PIIS2213-8587(2ā¦
#t2d #remission
#easd2025 -
Daniel J Drucker
@DanielJDrucker
Based on preclinical studies of thermogenesis, dietary interventions implementing use of specific branched fatty acids or modulation of proteins involved in their metabolism might be a promising strategy to treat #obesity and related metabolic diseases www.nature.com/articles/s41586-025-09517-7
-
Daniel J Drucker
@DanielJDrucker
Preclinical studies suggest that GLP-1R agonism can reduce ethanol-mediated hepatotoxicity despite continued ethanol consumption and elevate blood alcohol levels www.nature.com/articles/s44324-025-00077-y
-
Daniel J Drucker
@DanielJDrucker
SURPASS PEDS Tirzepatide 5 or 10mg qw in Youth onset type 2 #diabetes ages 10-18 www.thelancet.com/journals/lancet/article/PIIS0140-6736(2ā¦
-
Daniel J Drucker
@DanielJDrucker
25mg oral semaglutide for #weightloss #obesity www.nejm.org/doi/full/10.1056/NEJMoa2500969?query=featureā¦
-
Daniel J Drucker
@DanielJDrucker
As @novonordisk awaits @US_FDA decision on 25mg oral semaglutide expected in Q4, orforglipron bests 14mg oral semaglutide in people with #t2d investor.lilly.com/news-releases/news-release-details/lilā¦
-
Daniel J Drucker
@DanielJDrucker
If you think Europe is not pulling its weight in paying for drug development, run the numbers for šØš¦ The DireStraits scenario from @TheEconomist economist.com/by-invitation/2025/09/16/europe-is-not-pullā¦
-
Daniel J Drucker
@DanielJDrucker
Optimizing healthy #weightloss with GLP-1 medicines-don't overlook the role of muscle www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25ā¦
-
Daniel J Drucker
@DanielJDrucker
Oral orforglipron over 72 weeks for #weightloss #obesity #easd2025 www.nejm.org/doi/full/10.1056/NEJMoa2511774?query=featureā¦
-
Daniel J Drucker
@DanielJDrucker
Some new clinical data from Kallyope on investigational GLP-1 secretagogues dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/doā¦
-
Daniel J Drucker
@DanielJDrucker
By identifying murine Agrp neurons as a target of LacPhe, the authors suggest this exercise-induced metabolite might have therapeutic benefits in various human diseases. www.nature.com/articles/s42255-025-01377-9
-
Daniel J Drucker
@DanielJDrucker
Here the authors compare cohorts of PPL with #obesity #t2d and conclude metabolic surgery remains superior to medical treatment (GLP-1 medicines) for multiple outcomes www.nature.com/articles/s41591-025-03893-3
-
Daniel J Drucker
@DanielJDrucker
The 2025 Claude Bernard Prize Awardee the brilliant Andrew Hattersley @UniofExeter @Exeter_Diabetes @EASDnews #genetics Scholar and gentleman #diabetes
-
Daniel J Drucker
@DanielJDrucker
The hold/discontinue GLP-1 before a procedureā has no clothes. Here findings suggest that minimally sedated gastroscopy prior to colonoscopy, routine GLP-1 agonist withholding, and overly restrictive fasting are not required. onlinelibrary.wiley.com/doi/10.1111/jgh.70071
-
Daniel J Drucker
@DanielJDrucker
Studies from Gary Lewis @uoftmedicine show that GLP-2-enhanced mesenteric lymph flow and TG output and inhibition of VEGFR3 abolished serotonin-induced lymph flow and TG output in rats @UHN_Research journals.physiology.org/doi/epdf/10.1152/ajpgi.00205.2025
-
Daniel J Drucker
@DanielJDrucker
GLP-1 medicines continue to challenge conventional wisdom, with multiple new indications, molecules and mechanisms. Maria Gonzalez Rellan @ChusaGzlzRellan @uoftmedicine provides an update @jama jamanetwork.com/journals/jama/article-abstract/2838996?
-
Daniel J Drucker
@DanielJDrucker
There are several clinical trials of prebiotics in people with metabolic disorders. Here prebiotic treatment with inulin type fructans for 12 weeks without weight reduction is insufficient to improve NAFLD. www.mdpi.com/2072-6643/16/11/1571
Daniel J Drucker
@DanielJDrucker
The latest therapeutic triumph for inulin in mice with hepatic steatosis #microbiota www.nature.com/articles/s42255-025-01356-0 www.nature.com/articles/s42255-025-01356-0
-
Daniel J Drucker
@DanielJDrucker
The latest therapeutic triumph for inulin in mice with hepatic steatosis #microbiota www.nature.com/articles/s42255-025-01356-0 www.nature.com/articles/s42255-025-01356-0
-
Daniel J Drucker
@DanielJDrucker
Happy birthday to the energetic President of @EASDnews The #diabetes community has greatly benefitted from your leadership
-
Daniel J Drucker
@DanielJDrucker
Based on studies in mice the authors propose the core clock system as a potential therapeutic target to improve cardiometabolic health. www.sciencedirect.com/science/article/pii/S2212877825001565 @MolMetab
-
Daniel J Drucker
@DanielJDrucker
Here colleagues identify 3 myokines whose expression is increased during insulin resistance that can stimulate beta-cell differentiation in vitro, representing promising candidates to regenerate functional beta-cell mass www.cell.com/cell-reports/fulltext/S2211-1247(25)01054-X
-
Daniel J Drucker
@DanielJDrucker
Based on studies of mice with increased energy expenditure the authors propose myeloid CAMKK2 as a key regulator of macrophage function and a potential therapeutic target for treating #obesity and related metabolic disorders www.sciencedirect.com/science/article/pii/S2212877825001577
-
Daniel J Drucker
@DanielJDrucker
By showing changes in 2 #microbiota species after 12 weeks of Rx with GLP-1 medicines, the authors establish a novel mechanistic link between incretin-based therapies and host immune homeostasis, www.biorxiv.org/content/10.1101/2025.09.07.674712v1
-
Daniel J Drucker
@DanielJDrucker
In a retrospective study of 953 GLP-1 med users undergoing endoscopy there were no aspiration events. GLP-1 users had lower rates of post-procedural oxygen requirement (OR 0.43) hospitalization (OR 0.73) shorter hospital stay and mortality (0.1 vs. 0.9%) www.mdpi.com/2077-0383/14/17/6147
-
Daniel J Drucker
@DanielJDrucker
"Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients" The real world data skirmishes are coming fast and furious-Is the data reliable? pubmed.ncbi.nlm.nih.gov/40938549/
-
Daniel J Drucker
@DanielJDrucker
All about the #kidney #diabetes www.nature.com/articles/s41574-025-01171-3
-
Daniel J Drucker
@DanielJDrucker
A new #obesity paradox informed by #genetics 266 variants across 205 genomic loci where adiposity-increasing alleles were simultaneously associated with lower cardiometabolic risk www.nature.com/articles/s41591-025-03931-0
-
Daniel J Drucker
@DanielJDrucker
Studies of the BNST uncovered PKCĪ“-BNST neurons as a site of semaglutide action and suggest the BNST may be an important component and a target of the #weightloss effects of GLP1R agonists www.cell.com/cell/fulltext/S0092-8674(25)00976-6
-
Daniel J Drucker
@DanielJDrucker
A multi-omics overview of perturbations in the #t1d pancreas at the single cell level #islets www.science.org/doi/10.1126/sciadv.ady0080
-
Daniel J Drucker
@DanielJDrucker
Congratulations to all the awardees including Emerita Professor Patricia Brubaker @BBDC_UofT @physiologyuoft recognized with the Outstanding Mentorship Award @uoftmedicine @DiabetesCanada @TheEndoSociety
EndoMedia
@EndoMedia
Congratulations to @TheEndoSociety's 2026 Laureate Award winners! www.endocrine.org/news-and-advocacy/news-room/2025/endocr⦠#endo2026 #endocrinology
-
Daniel J Drucker
@DanielJDrucker
The complexity and therapeutic potential of NAD science @NatureAging www.nature.com/articles/s43587-025-00947-6
-
Daniel J Drucker
@DanielJDrucker
More evidence that #genetic variation influences presentation of monogenic #diabetes with diabetes risk ranging from 11% to 81% www.nature.com/articles/s42255-025-01372-0 @NatMetabolism
-
Daniel J Drucker
@DanielJDrucker
More data showing importance of common genetic variation in shaping the clinical presentation of early-onset monogenic disorders #diabetes @NatMetabolism www.nature.com/articles/s42255-025-01372-0
-
Daniel J Drucker
@DanielJDrucker
In this review of GLP-1 and bone health in people with #obesity the authors find that the database of useful studies is limited and the impact of glucagon-like peptide-1 receptor agonists (GLP-1Ra) on bone health remains unclear #osteoporosis #fractures link.springer.com/article/10.1007/s00198-025-07664-1
-
Daniel J Drucker
@DanielJDrucker
Our latest survey of widely used reagents for GLP-1 receptor detection @Cell_Metabolism continues to find room for improvement. Trust yet verify, together we can all do our part for reagent validation www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00325-0
Daniel J Drucker
@DanielJDrucker
Why are we so laser-focused on accurate detection and localization of the authentic GLP-1 receptor? Science should not be an endeavor where sloppiness is tolerated and excused. Suboptimal science causes confusion, needless controversy and erodes the public trust in scientists
-
Daniel J Drucker
@DanielJDrucker
Why are we so laser-focused on accurate detection and localization of the authentic GLP-1 receptor? Science should not be an endeavor where sloppiness is tolerated and excused. Suboptimal science causes confusion, needless controversy and erodes the public trust in scientists
-
Daniel J Drucker
@DanielJDrucker
Here the authors make inferences about macrophage GLP-1R signaling linked to senescence and efferocytosis using a GLP-1R antibody that is not validated for detection of the GLP-1R. www.sciencedirect.com/science/article/pii/S22132317250037ā¦
-
Daniel J Drucker
@DanielJDrucker
Role model fighter @usopen champion šØš¦šØš¦ www.cbc.ca/sports/tennis/us-open-tennis-dabrowski-routlifā¦
-
Daniel J Drucker
@DanielJDrucker
Gap junctionāmediated electrical communication between adipocytes and sensory neurons may regulate feeding
www.sciencedirect.com/science/article/pii/S2212877825001541 -
Daniel J Drucker
@DanielJDrucker
An update on exciting advances #t1d #stemcells #islets #diabetes www.nature.com/articles/d41586-025-02802-5
-
Daniel J Drucker
@DanielJDrucker
Here effector-memory ILC2s identified as mediators of persistent intestinal adaptation to type 2 inflammation and revealing a cytokine-driven strategy for increasing long-term resilience at mucosal barriers. www.cell.com/cell/fulltext/S0092-8674(25)00972-9?
-
Daniel J Drucker
@DanielJDrucker
20 years after their first approval @WHO adds GLP-1 medicines to their list of essential medicines #t2d #obesity www.who.int/news/item/05-09-2025-who-updates-list-of-esseā¦
-
Daniel J Drucker
@DanielJDrucker
Here microbial ImP, produced via UrdA, as a direct pathological mediator of the gut-brain axis in #parkinsonsdisease www.nature.com/articles/s41467-025-63473-4 #microbiota
-
Daniel J Drucker
@DanielJDrucker
Leading Canadian lipidologist and #genetics expert Professor Robert Hegele elected to @RSCTheAcademies
-
Daniel J Drucker
@DanielJDrucker
Todayās enthusiasm for targeting BAT is exemplified Neuritin-1 which emerges as a potential target for the treatment of metabolic disorders. www.nature.com/articles/s41467-025-62255-2
-
Daniel J Drucker
@DanielJDrucker
Compelling metabolic benefits of semaglutide over 30 weeks in patients with schizophrenia Rxed with second-generation antipsychotic agents jamanetwork.com/journals/jamapsychiatry/article-abstract/ā¦
-
Daniel J Drucker
@DanielJDrucker
The authors believe that characterization of hormone secretion, & postprandial multi-omics dynamics under mixed meals and four distinct macronutrient loads, provides a molecular basis for advancing precision nutrition therapies in metabolic diseases. www.cell.com/cell-reports-medicine/fulltext/S2666-3791(25ā¦
-
Daniel J Drucker
@DanielJDrucker
An amygdalaāliver axis that regulates rapid glycaemic adaptations to stress and links recurrent stress to metabolic dysfunction www.nature.com/articles/s41586-025-09420-1
-
Daniel J Drucker
@DanielJDrucker
A partial list of papers using the AGR-021 antisera from @Alomone_Labs to detect "the GLP-1 Receptor"; this antibody does not detect the GLP-1R and completely lacks sensitivity and specificity. Free to read @Cell_Metabolism www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00325-0
Daniel J Drucker
@DanielJDrucker
What proportion of antibodies used for detecting the GLP-1R exhibit high sensitivity and specificity? Sadly, very few, resulting in mis localization and misinterpretation of considerable data in the field www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00325-0 @Cell_Metabolism
-
Daniel J Drucker
@DanielJDrucker
The sustained enthusiasm for augmentation of energy expenditure remains evident, here with PDE5A identified as a novel regulator of energy homeostasis, suggesting its inhibition as a valuable adjuvant therapy for metabolic disorders #obesity @MolMetab www.sciencedirect.com/science/article/pii/S2212877825001504
-
Daniel J Drucker
@DanielJDrucker
What proportion of antibodies used for detecting the GLP-1R exhibit high sensitivity and specificity? Sadly, very few, resulting in mis localization and misinterpretation of considerable data in the field www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00325-0 @Cell_Metabolism
-
Daniel J Drucker
@DanielJDrucker
More than 10 years ago, we highlighted the problem with widespread use of non-validated GLP-1R antisera. Have things improved? Hard to tell. Yet every few weeks, a new paper using spurious GLP-1R antisera appears, enabling incorrect conclusions academic.oup.com/endo/article-abstract/154/1/127/2423344
Daniel J Drucker
@DanielJDrucker
Our latest assessment of 3 widely used GLP-1R antisera independently with @daveyboyhod Some are useful, others not fit for purpose. Use of non-validated antisera sows confusion in the field and creates problems that are difficult to later rectify www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00325-0
-
Daniel J Drucker
@DanielJDrucker
The latest suggestion to improve insulin action. Targeting insulin induced DLK-dependent signaling might offer a novel therapeutic strategy to improve insulin sensitivity in metabolic disease. @MolMetab pdf.sciencedirectassets.com/282671/AIP/1-s2.0-S2212877825ā¦
-
Daniel J Drucker
@DanielJDrucker
An infant with residual small bowel length of 9ācm and #shortbowelsyndrome received teduglutide for 6 years, resulting in complete discontinuation of parenteral nutrition. Regenerative medicine via GLP-2 therapy aspenjournals.onlinelibrary.wiley.com/doi/10.1002/ncp.70023
-
Daniel J Drucker
@DanielJDrucker
Leader in molecular biology of Class B GPCR signaling. Congrats Professor!
Alejandra TomƔs CatalƔ
@TomasLab_ICL
Iām delighted to share that I have been promoted to Professor of Cell Biology at Imperial College London. I am deeply grateful to those who have supported me along the way, through the many ups and downs that led to this point.
-
Daniel J Drucker
@DanielJDrucker
In the STEER study, there were 15 (0.1%) cardiovascular events recorded with WegovyĀ®, and 39 events (0.4%) were recorded with tirzepatide. The average follow-up duration was 3.8 months for the WegovyĀ® group and 4.3 months for the tirzepatide group. #esc2025 #cvd #heartdisease
Novo Nordisk
@novonordisk
#press: Novo Nordisk shares findings from a real-world study for people with obesity and cardiovascular disease at #esc2025. Read the full press release.
-
Daniel J Drucker
@DanielJDrucker
Happy special birthday to my friend and colleague the incomparable Jens Juul Holst @UCPH_Research @Metabolcenter @EASDnews @uni_copenhagen @novonordiskfond
-
Daniel J Drucker
@DanielJDrucker
DENND1B, a regulator of clathrin-mediated endocytosis identified as a regulator of MC4R activity and body weight in dogs & humans informing our understanding of melanocortin signaling, a critical pathway in hypothalamic regulation of energy homeostasis
www.science.org/doi/10.1126/science.ads2145 -
Daniel J Drucker
@DanielJDrucker
Some thoughts on establishing causality and the way forward for #microbiome research @NatRevGastroHep www.nature.com/articles/s41575-025-01041-3
-
Daniel J Drucker
@DanielJDrucker
HYPOMAP provides a detailed atlas of the human hypothalamus in a spatial context enabling drug development @GilesYeo www.nature.com/articles/s41586-024-08504-8
-
Daniel J Drucker
@DanielJDrucker
New studies in mice revealing distinct roles for prolactin-related peptide and its receptors in control of food intake @MolMetab @seeleyrj @UMich www.sciencedirect.com/science/article/pii/S2212877824002242
-
Daniel J Drucker
@DanielJDrucker
In 2024, it became increasingly clear that some of the clinical benefits of GLP-1 may be secondary to weight loss independent reduction of inflammation www.science.org/doi/10.1126/science.adn4128
-
Post not available here, view on X
Daniel J Drucker
@DanielJDrucker
And published today, the P3 data for the long-acting GLP-2 analogue Glepaglutide in short bowel syndrome @AGA_Gastro www.gastrojournal.org/article/S0016-5085(24)05787-1/fulltext
-
Daniel J Drucker
@DanielJDrucker
A summary of the @AmDiabetesAssn statement on compounded GLP-1 Medicines "Non-FDA-approved compounded incretin products are not recommended for use due to uncertainty about their content and resulting concerns about safety, quality, and effectiveness" diabetesjournals.org/care/article/doi/10.2337/dci24-0091/ā¦
-
Daniel J Drucker
@DanielJDrucker
GDF15 positioned as a dynamic biomarker of psychosocial stress accessible in human blood and saliva, pointing towards a shared psychobiological pathway linking mental and mitochondrial energetic stress. www.biorxiv.org/content/10.1101/2024.04.19.590241v4
-
Daniel J Drucker
@DanielJDrucker
Does loss of GIPR signaling sensitize GLP-1R+ neurons, enhancing the actions of GLP-1R agonists? New data from @seeleyrj @UMich @MolMetab @UMDiabetes www.sciencedirect.com/science/article/pii/S2212877824002059
-
Daniel J Drucker
@DanielJDrucker
Using multiple techniques the authors affirm that Gfral expression is overwhelmingly restricted to the brainstem in healthy mice @MolMetab @cusm_muhc @seeleyrj www.sciencedirect.com/science/article/pii/S2212877824002011
-
Daniel J Drucker
@DanielJDrucker
A new reagent for interrogation of glucagon action-the long acting GCGR agonist LY3324954 #weightloss #diabetes
@MolMetab @KirkMHabegger @UABNews www.sciencedirect.com/science/article/pii/S2212877824002047 -
Daniel J Drucker
@DanielJDrucker
The evolving science of gut bitter taste receptors @NatRevGastroHep www.nature.com/articles/s41575-024-01005-z
-
Daniel J Drucker
@DanielJDrucker
Fuelled by resmetirom, the expanding interest in thyroid hormones and thyromimetics on the liver @NatRevGastroHep
www.nature.com/articles/s41575-024-00991-4 -
Daniel J Drucker
@DanielJDrucker
In depth measurement of metabolism in intact human liver tissue ex vivo using global 13C tracing, non-targeted mass spectrometry and model-based metabolic flux analysis @NatMetabolism www.nature.com/articles/s42255-024-01119-3
-
Daniel J Drucker
@DanielJDrucker
Causal models of #obesity pathogenesis @NatMetabolism @KevinH_PhD @davidludwigmd @JohnSpeakman4 @garytaubes From CIM to EBM and more www.nature.com/articles/s42255-024-01106-8 @ClemmensenC
-
Daniel J Drucker
@DanielJDrucker
Studies in mice, #islet cells, and zebrafish identify that hyperaminoacidemia-induced α cell hyperplasia requires ErbB3 signaling @jbiolchem www.jbc.org/article/S0021-9258(24)02000-3/fulltext
-
Daniel J Drucker
@DanielJDrucker
Here the authors put forward the case for tirzepatide and GIP act directly in adipocytes to influence adipose tissue metabolism @Cell_Metabolism www.cell.com/cell-metabolism/fulltext/S1550-4131(24)00186-4
-
Daniel J Drucker
@DanielJDrucker
In a few years from now, what will be the most important therapeutic indication(s) for GLP-1 medicines and how might that work? @yeahyeahyasmin @TheAtlantic surveys the landscape beyond #obesity #t2d #heartdisease www.theatlantic.com/health/archive/2024/06/ozempic-obesitā¦
-
Daniel J Drucker
@DanielJDrucker
The scientists who spurred the development of the new #obesity drugs, Drs. Lotte Knudsen and Richard DiMarchi www.science.org/doi/10.1126/science.adq6452
-
Daniel J Drucker
@DanielJDrucker
Here the authors propose that timing of #exercise in mice informs intricacies of human exercise physiology, offering valuable implications for interventions @NatMetabolism www.nature.com/articles/s42255-024-01057-0
-
Daniel J Drucker
@DanielJDrucker
In a retrospective cohort study from 2008-2021, metabolic surgery was associated with a stronger reduction in primary incidence of CHF compared to treatment with GLP1-RA #heartfailure @NatureMedicine www.nature.com/articles/s41591-024-03052-0
-
Daniel J Drucker
@DanielJDrucker
A deeper dive into #weightloss with semaglutide in the SELECT trial #heartdisease @NatureMedicine www.nature.com/articles/s41591-024-02996-7 #obesity
-
Daniel J Drucker
@DanielJDrucker
Real world data from TriNetX for 1,890,020 pts from 2013-19 reveals GLP-1RAs were associated with a reduced risk of incident HCC and hepatic decompensation compared to other anti- #diabetes medications in patients with #t2d @AGA_Gastro #cancer www.gastrojournal.org/article/S0016-5085(24)00494-3/fulltext
-
Daniel J Drucker
@DanielJDrucker
Congratulations to Professor Ron Evans @salkinstitute The 2024 Japan Prize Laureate in Medical Science www.japanprize.jp/en/prize_past_2024_prize02.html
-
Daniel J Drucker
@DanielJDrucker
Does reduction of #inflammation contribute to the glucose-and #weightloss independent actions of GLP-1RA to reduce complications? How might that happen given limited immune cell GLP-1R expression? www.cell.com/cell-metabolism/fulltext/S1550-4131(18)30179-7
-
Post not available here, view on XPost not available here, view on X
Daniel J Drucker
@DanielJDrucker
Congratulations to Dr. Aaron Schimmer @pmcancercentre @UHN @UHN_Research @cancersociety @TerryFoxCanada on his election to the Royal Society of Canada for innovation and sustained excellence in the translation biology of cancer therapeutics @CIHR_IRSC @uoftmedicine
-
Daniel J Drucker
@DanielJDrucker
Do REG proteins provide therapeutic opportunities for metabolic disorders? Perspective on Reg3γ from @seeleyrj #microbiota www.nature.com/articles/s12276-023-01054-5
-
Daniel J Drucker
@DanielJDrucker
GDF15, here an #exercise myokine, functions as a contraction-induced protein that enhances GSIS #insulin through activating the canonical signaling pathway in a GFRAL-independent manner in mice #islets @Diabetes_ADA @DrJohnKirwan @seeleyrj
diabetesjournals.org/diabetes/article/doi/10.2337/db22-00⦠-
Daniel J Drucker
@DanielJDrucker
Unlocking the secrets of GPR35 A new review @TrendsinPharma www.cell.com/trends/pharmacological-sciences/fulltext/S01ā¦
-
Daniel J Drucker
@DanielJDrucker
Congratulations to @MatthiasTschop 2023 Banting Awardee @AmDiabetesAssn and @cevansmo 2023 Outstanding scientific achievement awardee, two outstanding clinician scientists #diabetes diabetes.org/newsroom/press-releases/2023/extraordinary-lā¦
-
Daniel J Drucker
@DanielJDrucker
Here it is proposed that advances in SSTR2 structure and function will help with designing therapeutic drugs with specific pharmacological profiles against neuroendocrine tumors #acromegaly @NatureComms www.nature.com/articles/s41467-023-36673-z
-
Daniel J Drucker
@DanielJDrucker
How does GLP-1 engage the liver to reduce metabolic liver disease? #nafld #mafld #nash #t2d #obesity Some direct vs. indirect pathways #endocrinereviews academic.oup.com/edrv/advance-article-abstract/doi/10.121ā¦
-
Daniel J Drucker
@DanielJDrucker
Interested in joining a reasonably competent, always curious group of scientists working on translating basic science to the clinic? The Drucker lab @SinaiHealth @BBDC_UofT is looking for full time technical assistance. Cool projects, friendly people, tolerable supervisor š
-
Daniel J Drucker
@DanielJDrucker
Scientists are under pressure to repeatedly produce highly novel data that fundamentally shifts understanding of current concepts. Is this realistic? Does it prompt us to stretch the truth in our relentless search for innovation/novelty? How often are stories too good to be true?
-
Daniel J Drucker
@DanielJDrucker
Glucose lowering agents #diabetes and risk of sudden death. Can clear conclusions be made? A review from Professor Scheen @UniversiteLiege www.sciencedirect.com/science/article/abs/pii/S1262363622ā¦
-
Daniel J Drucker
@DanielJDrucker
@FractylHealth initiates new scientific programs with Professors Cherrington and @seeleyrj to understand duodenal mucosal resurfacing and enlists stellar academic KOLs to form the "ERASE Taskforce" to understand #diabetes #obesity and the gut www.fractyl.com/fractyl-health-initiates-landmark-scientiā¦
-
Daniel J Drucker
@DanielJDrucker
Beyond #weightloss The potential mechanisms responsible for both the resolution of #t2d and the induction of #hypoglycaemia #bariatricsurgery @NatureRevEndo www.nature.com/articles/s41574-022-00757-5
-
Daniel J Drucker
@DanielJDrucker
New discussions on metformin and GDF-15 and #weightloss Is the rise in GDF-15 simply a measure of metformin target engagement of cell stress pathways or contributory for a component of weightloss? @StephenORahilly @ClemmensenC @NatureRevEndo www.nature.com/articles/s41574-022-00764-6
-
Daniel J Drucker
@DanielJDrucker
Two years of once weekly 2.4 mg semaglutide for PPL with #obesity 12.6% placebo subtracted #weightloss @NatureMedicine www.nature.com/articles/s41591-022-02026-4
-
Daniel J Drucker
@DanielJDrucker
How does GLP-1 control inflammation? The answer depends on the type of #inflammation, where it arises, and how it is transduced. Some new insights here including data linking intestinal IEL T cell GLP-1Rs to control of gut #microbiota @Cell_Metabolism www.sciencedirect.com/science/article/pii/S15504131220034ā¦
-
Daniel J Drucker
@DanielJDrucker
Some new insights into how GLP-1 regulates gut and systemic T cell-dependent #inflammation #microbiota from @ckwong_sci @uoftmedicine @SinaiHealth with a focus on the role of intestinal intraepithelial lymphocytes @Cell_Metabolism www.cell.com/cell-metabolism/fulltext/S1550-4131(22)00346-1
-
Daniel J Drucker
@DanielJDrucker
The latest from @TimoMueller_IDO and colleagues @PioneerCampus @helmholtz_diabc New approaches to selective targeting of the PPARÉ/É£ dual-agonist class using GLP-1R to mediate cell entry #diabetes #obesity #inflammation #weightloss @NatMetabolism www.nature.com/articles/s42255-022-00617-6
-
Daniel J Drucker
@DanielJDrucker
Are there really competing paradigms for #obesity pathogenesis? And why is it useful for some to rewrite the nearly identical review every few months? @ejcneditor www.nature.com/articles/s41430-022-01179-2
-
Daniel J Drucker
@DanielJDrucker
After decades in the limelight, the hypothalamus shares the stage with the hindbrain and circuits controlling food intake @NatMetabolism www.nature.com/articles/s42255-022-00606-9
-
Daniel J Drucker
@DanielJDrucker
Congratulations to Professor @aledmedwards @thesgconline @uoftmedicine @UofTNews on his appointment as an Officer of the Order of Canada for advancing Canadaās global reputation as a leader in open science research by founding the groundbreaking Structural Genomics Consortium.
-
Daniel J Drucker
@DanielJDrucker
Lessons from the GLP-1 receptor knockout rat and the (identical) response to bariatric surgery #nafld link.springer.com/article/10.1007/s11605-022-05361-6
-
Daniel J Drucker
@DanielJDrucker
Here, elevated Glp1 signaling, elucidated using the antagonist Ex-9, rather than weight loss, is linked to the increased prevalence of SGA births following bariatric surgery in mice @DannyBenz325 @JCI_insight insight.jci.org/articles/view/156424
-
Daniel J Drucker
@DanielJDrucker
Thoughts from Sam Klein Inter organ communication and links between #obesity and #diabetes @Cell_Metabolism www.cell.com/cell-metabolism/fulltext/S1550-4131(21)00631-8
-
Daniel J Drucker
@DanielJDrucker
A complex set of preclinical studies āsuggest that targeting adipose factors in colorectal cancer patients with #obesity may represent a therapeutic strategy for preventing metastatic disease.ā @NatureComms www.nature.com/articles/s41467-021-25333-9
-
Daniel J Drucker
@DanielJDrucker
Nausea occurs in about 25% of subjects treated with GLP1RAs and dissipates in the majority of subjects. Can science guide equally effective GLP1RAs with less nausea? @BrJPharmacol bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15647
-
Daniel J Drucker
@DanielJDrucker
It took almost 4 decades and thousands of dedicated scientists, but GLP-1R agonists are slowly changing the options and improving outcomes for PPL with #t2d #cvd and now #obesity @juliaoftoronto @seeleyrj @ObesitySociety @ObesityCan www.vox.com/22553793/gila-monster-lizard-venom-inspired-o⦠via @voxdotcom
-
Daniel J Drucker
@DanielJDrucker
Gain and loss of function studies reveal āthe BAFF/APRIL axis is a multifaceted immune regulator of weight gain and adipose tissueā in mice @UCHealthNews @MatthiasTschop @seeleyrj @NatureComms www.nature.com/articles/s41467-021-23084-1
-
Daniel J Drucker
@DanielJDrucker
A @CellCellPress Snapshot on the Gut #microbiota Brain Axis. If one looks carefully, you can even see one of our favorite L cell peptides #diabetes #obesity #inflammation @pipethero @ucla www.cell.com/cell/fulltext/S0092-8674(21)00350-0
-
Daniel J Drucker
@DanielJDrucker
More evidence linking bile acid receptors to control of enteroendocrine cell fate in mice @DarleenSandoval @seeleyrj www.biorxiv.org/content/10.1101/2021.04.22.440705v1
-
Daniel J Drucker
@DanielJDrucker
The GLP-1 literature is challenging since ++ studies use non-validated reagents to infer erroneous conclusions. The GLP-1R is not detected in hepatocytes by rigorous RNA and Antibody analyses. Yet dozens of papers present data to the contrary Caveat Emptor www.frontiersin.org/articles/10.3389/fphar.2020.600175/full
-
Daniel J Drucker
@DanielJDrucker
A new historical perspective on the discovery of #insulin and key milestones in insulin science from @jflier @diabetesmaster @MolMetab www.sciencedirect.com/science/article/pii/S221287782100034X
-
Daniel J Drucker
@DanielJDrucker
It turns out that the secrets of bariatric surgery are not encoded within Intestinal extracellular vesicles @seeleyrj journals.physiology.org/doi/abs/10.1152/ajpgi.00224.2020
-
Daniel J Drucker
@DanielJDrucker
Meandering not running to the clinic. The utility, predictive value and effect size for pharmacogenomics #t2d @DiabetologiaJnl link.springer.com/article/10.1007/s00125-021-05402-w
-
Daniel J Drucker
@DanielJDrucker
āRestoring ER homeostasis, enhancing ER-associated degradation of misfolded protein, and boosting chaperoning activity, are emerging therapeutic approaches for #diabetes treatmentā @TrendsinPharma www.cell.com/trends/pharmacological-sciences/fulltext/S01ā¦
-
Daniel J Drucker
@DanielJDrucker
SaxendaĀ® (liraglutide) @novonordisk injection 3 mg daily becomes the first @US_FDA -approved therapy to treat #obesity in adolescents in more than a decade Updated prescribing label issued in USA www.nejm.org/doi/full/10.1056/NEJMoa1916038
-
Post not available here, view on X
Daniel J Drucker
@DanielJDrucker
This #islet amino acid glucagon work was driven by @nadia_ivb working with Professor Bernal-Mizrachi and colleagues. Nadia is now a postdoctoral fellow @umichmedicine working with @seeleyrj Check out Nadia's science here. Another future star #diabetes orcid.org/0000-0001-9796-2916
-
Daniel J Drucker
@DanielJDrucker
āNew data challenges the textbook physiology of both GLP-1 and glucagon and presents a critical paradigm shift for the fieldā via @DarleenSandoval diabetes.diabetesjournals.org/content/69/11/2238
-
Daniel J Drucker
@DanielJDrucker
Many Journals take a high minded view of novelty and replication science from the Editorial page. Just try submitting a carefuuly done paper that totally refutes the major conclusions of a NSC paper and watch the priorities evaporate @NatureComms www.nature.com/articles/s41467-020-17817-x
-
Daniel J Drucker
@DanielJDrucker
Do you really know what you are measuring with your āspecificā glucagon ELISA? @Mercodia onlinelibrary.wiley.com/doi/abs/10.1111/jdi.13325?af=R
-
Daniel J Drucker
@DanielJDrucker
āMany reported effects of #exercise training in mice are likely secondary to metabolic stress of ambient housing temperature, making it challenging to translate to humansā @NatureComms www.nature.com/articles/s41467-020-15311-y
-
Daniel J Drucker
@DanielJDrucker
I know what you are thinking-but no mention here of hedonistic behaviors or mind altering substances www.nature.com/articles/d41586-020-00455-0
-
Daniel J Drucker
@DanielJDrucker
24 years ago, Turton, Bloom and colleagues described an inhibitory role for GLP-1 in control of food intake in rats. This Friday 8 am CWER 3d floor 60 Murray at CWER, I will describe how the GLP-1 #obesity story has evolved, and where the field is going www.nature.com/articles/379069a0
-
Daniel J Drucker
@DanielJDrucker
Will Amylin Analogues Make a come Back #obesity ? Calcitonin Receptor Neurons in the Mouse Nucleus Tractus Solitarius Control Energy Balance via the Non-aversive Suppression of Feeding www.cell.com/cell-metabolism/fulltext/S1550-4131(19)30677-1
-
Post not available here, view on X
Daniel J Drucker
@DanielJDrucker
Great to see the two papers @nature @NatMetabolism reasonably aligned with comparable insights from mouse models linking #metformin to #weightloss #gdf15 @DrGregSteinberg www.nature.com/articles/s42255-019-0146-4
-
Daniel J Drucker
@DanielJDrucker
Contrasting roles of intestinal vs. pancreatic proglucagon-derived peptides after nutrient stimulation and VSG for circulating GLP-1 vs. glucose homeostasis #bariatricsurgery @DarleenSandoval @seeleyrj @JCI_insight insight.jci.org/articles/view/129452
-
Daniel J Drucker
@DanielJDrucker
A new study in mice @DarleenSandoval DPP4 inhibition, and glucoregulatory roles of GIP and pancreatic GLP-1. Whither the DPP4 gut GLP-1 axis? @DiabetologiaJnl link.springer.com/article/10.1007/s00125-019-4963-5
-
Daniel J Drucker
@DanielJDrucker
Some New Insights into Neural Sites of GLP-1R Action @CellReports www.cell.com/cell-reports/fulltext/S2211-1247(19)30684-9
-
Daniel J Drucker
@DanielJDrucker
Mice with RYGB #bariatricsurgery Combined loss of GLP-1R and Y2R does not attenuate metabolic benefit @MolMetab www.sciencedirect.com/science/article/pii/S2212877819302339
-
Daniel J Drucker
@DanielJDrucker
Enteral hyperosmolar-induced thirst? We have gut nodose brain vasopressin axis for that www.nature.com/articles/s41586-019-1066-x
-
Daniel J Drucker
@DanielJDrucker
Bile Diversion to the Ileum. Bile Acids, GLP-1 #microbiota Akkermansia and Intestinal FXR Mediate the Metabolic Improvements of Bariatric Surgery in Mice www.gastrojournal.org/article/S0016-5085(18)35259-4/fulltext
-
Daniel J Drucker
@DanielJDrucker
Don't miss my buddy @seeleyrj today 1:30 PM The @asmbs Integrated Health Keynote Speaker #ow2018 @ObesityWeek A single digit handicap golfer, entertaining informative speaker, focused on mechanistic interrogation of the metabolic benefits of #bariatricsurgery #obesity
-
Daniel J Drucker
@DanielJDrucker
Why has no publisher launched a new Journal entitled āMetforminā? It could publish biweekly on a broad range of topics. Here is a new cool PD-L1 phosphorylation story #cancer www.cell.com/molecular-cell/fulltext/S1097-2765(18)30599-9
-
Daniel J Drucker
@DanielJDrucker
Good morning to colleagues and friends in China studying GLP-1 synthesis and secretion-a note of caution-the GLUTag cells you purchase from BioVector www.biovector.net/product/420149.html are being sold illegally, and may in fact not be GLUTag cells. Reviewers might question their authenticity
-
Daniel J Drucker
@DanielJDrucker
Mapping the distribution of liraglutide, Glp1r, and fos-activation in the mouse brain www.nature.com/articles/s41598-018-28496-6
-
Daniel J Drucker
@DanielJDrucker
A Comparison of Rodent Models of VSG @seeleyrj #obesity #diabetes #bariatricsurgery www.soard.org/article/S1550-7289(18)30368-X/fulltext
-
Daniel J Drucker
@DanielJDrucker
The question from ā¦@LoraHeislerā© #2018ada Where and how can one target 5-HT circuits in the CNS to safely, effectively and selectively reduce food intake #weightloss #obesity Is the dorsal raphe the key?
-
Daniel J Drucker
@DanielJDrucker
Loss of the glucagon receptor triggers a metabolic maelstrom. Here @KirkMHabegger reveals roles of FXR and FGF-21 #diabetes #weightloss diabetes.diabetesjournals.org/content/early/2018/06/20/dbā¦
-
Daniel J Drucker
@DanielJDrucker
Kallyope and @novonordisk team uo A gutsy move
-
Daniel J Drucker
@DanielJDrucker
Interested in postdoctoral training in gut peptides #glp1 #gip #islets #diabetes #obesity #metabolism New opportunity @DukeU Molecular Physiology
-
Daniel J Drucker
@DanielJDrucker
The Bile Acid GLP-2 biological axis continues to enlarge. Not only does GLP-2 inhibit gallbladder emptying, loss of GLP-2R reduces circulating levels of BA and markedly alters profile of plasma BAs in mice @MolMetab www.molmetab.com/article/S2212-8778(18)30505-2/fulltext?rā¦
-
Post not available here, view on X
Daniel J Drucker
@DanielJDrucker
CNS GLP-2 controls food intake, #insulinsensitivity #gucose yet like GLP-1R, is dispensabe for metabolic improvements arising following vertical sleeve gastrectomy #bariatricsurgery in mice @seeleyrj www.molmetab.com/article/S2212-8778(18)30505-2/fulltext?rā¦
-
Daniel J Drucker
@DanielJDrucker
Early developmental deletion of LepRb from vGat or Nos1 neurons produced dramatic #obesity, but deletion of LepRb from Pomc, Agrp, Ghrh, or Htr2c neurons minimally altered energy balance @seeleyrj Martin Myers @umichmedicine www.molmetab.com/article/S2212-8778(18)30432-0/fulltext?rā¦
-
Daniel J Drucker
@DanielJDrucker
Dispersed but discrete-here a dominant role for liraglutide acting through glutamergic neurons #weightloss in mice @ADA_Journals diabetes.diabetesjournals.org/content/early/2018/05/04/dbā¦
-
Daniel J Drucker
@DanielJDrucker
Oscars are coming-even some documentary movies are worth viewing repeatedly they never get old-not sure I will ever tire of watching "The GLP-1 CVOT Story-The Cardioprotective Empire Strikes Back" #diabetes @Trends_Endo_Met @TheLancetEndo #heartdisease #cvd
-
Daniel J Drucker
@DanielJDrucker
By invitation only @seeleyrj @DarleenSandoval welcome the hindbrain to the hypothalamic "all you can eat" buffet of neurocircuitry controlling #bodyweight #obesity & energy homeostasis www.nature.com/articles/nrn.2018.8
-
Daniel J Drucker
@DanielJDrucker
Caspase pioneer, co-discovered and developed sitagliptin, ex senior Vice-President @Merck CEO #kallyope Mother, Wife, Champion of honesty; some told her without a PhD or M.D. she was unlikely to succeed Meet Nancy Thornberry #womeninscience
-
Daniel J Drucker
@DanielJDrucker
It is rare to encounter a scientist in industry whose passion for discovery, pursuit of scientific truth & personal integrity trumps all corporate policy & marketing dictats. Meet Lotte Bjerre Knudsen @lotte_bjerre
Novo Nordisk
@novonordisk
We're celebrating all the amazing #womeninscience! šŖ Hear how Lotte Bjerre Knudsen took an underdog molecule to a treatment for millions of people with diabetes and obesityĀ #choosescience cards.twitter.com/cards/18ce53unguf/5bspq
-
Daniel J Drucker
@DanielJDrucker
The GLP-1 story #t2d @jclinicalinvest No flashy science, just physiology pharmacology dose responses time courses No amazing papers in glam journals Highly reproducible Old School www.jci.org/articles/view/97233
-
Daniel J Drucker
@DanielJDrucker
www.nature.com/articles/s41598-017-14010-x More Yoghurt Please Recombinant Incretin (GLP-1)-Secreting Microbe Improves Metabolic Dysfunction in HFD-Fed Rodents
-
Daniel J Drucker
@DanielJDrucker
GDF-15 Real Slim Shady Metabolic Magical Molecule of the Month #obesity #weightloss w primate data @Amgen @ScienceTM stm.sciencemag.org/content/9/412/eaan8732
-
Daniel J Drucker
@DanielJDrucker
Donāt underestimate the power of the lizard. Trust me on this one
www.wsj.com/articles/miners-tiptoe-around-lizard-in-lates⦠-
Daniel J Drucker
@DanielJDrucker
Role of GLP-1 in the metabolic success of bariatric surgery @EndoMedia @DarleenSandoval #diabetes #obesity academic.oup.com/endo/article/doi/10.1210/en.2017-00564/4ā¦
-
Daniel J Drucker
@DanielJDrucker
Wed pm trip via @EWRairport ? Make time to catch the latest from the maestro of metabolic surgery mechanisms @seeleyrj @RWJMS #obesity #t2d
-
Daniel J Drucker
@DanielJDrucker
Phil Scherer @UTSWNews the #easd2017 @EASDnews EFSD Novo Nordisk Prize winner. Outstanding innovative science from a scholar & gentleman
-
Daniel J Drucker
@DanielJDrucker
Laurie Baggio & @JussherLab dissect direct & indirect control of heart rate in mice. Roles for SNS & atrial GLP1R www.molmetab.com/article/S2212-8778(17)30605-1/fulltex
-
Daniel J Drucker
@DanielJDrucker
Congratulations to @lotte_bjerre & @novonordisk scientists for bench to bedside development of #liraglutide #t2d Special day @US_FDA #cvd
-
Daniel J Drucker
@DanielJDrucker
The 2017 Banting lecturer, & updates on GLP-1, bariatric surgery, gut vs islet hormones, CV outcome trials & more goo.gl/I91z1H
-
Daniel J Drucker
@DanielJDrucker
Shifting the paradigm? A GLP-1 pioneer discusses paracrine vs. endocrine GLP-1 incretin concepts @Cell_Metabolism www.cell.com/cell-metabolism/fulltext/S1550-4131(17)30174-2
-
Daniel J Drucker
@DanielJDrucker
Bile acids stimulate L cell secretion & GLP-2 pays it forward by ensuring gallbladder refilling for the next meal goo.gl/0g8u3H
-
Daniel J Drucker
@DanielJDrucker
The 2017 Laureate Awards #endo2017 @TheEndoSociety Recognizing outstanding contributions to endocrine science. Congrats to Matthias Tschop
-
Daniel J Drucker
@DanielJDrucker
TGR5 & FGF15/19 move over-GLP-2 joins the enteroendocrine bile acid party to control gallbladder filling goo.gl/gHHx0S @MolMetab
-
Daniel J Drucker
@DanielJDrucker
Are you kiddin me? Seriously? This is not even gonna be close #endo2017 @TheEndoSociety Four weeks to go. Orlando EMS on stand by #diabetes
-
Daniel J Drucker
@DanielJDrucker
3 months to April 27; 30 yrs of incretin biology @MountSinai Brubaker, Holst, Accili, Nauck, Sandoval, Tschoep research.lunenfeld.ca/tdmr2017/
-
Daniel J Drucker
@DanielJDrucker
Ok, ok, so we didn't actually score the cover-but you can still read our latest DPP4 mousterpiece @Cell_Metabolism authors.elsevier.com/a/1UMhZ5WXUl3M-b
-
Daniel J Drucker
@DanielJDrucker
Intestinal glycolysis by FDG PET/CT & glucose decrement post gastrectomy-why does the gut up its glycolysis game? diabetes.diabetesjournals.org/content/early/2016/11/30/dbā¦
-
Daniel J Drucker
@DanielJDrucker
Stressed out before #electionday ? The hypothalamic Sim1 PVN GLP-1R circuit might be involved www.ncbi.nlm.nih.gov/pubmed/27810935 @SfNtweets @seeleyrj
-
Daniel J Drucker
@DanielJDrucker
A well-deserved salute to excellence in Editorial leadership #diabetescare: āLagniappeā and āSeeing Is Believingā! care.diabetesjournals.org/content/39/7/1069
-
Daniel J Drucker
@DanielJDrucker
Outstanding #diabetes scientist Myers @UMich to become EIC #diabetes @AmDiabetesAssn in 2017 www.umms.med.umich.edu/faculty-search
-
Kevin Hall
@KevinH_PhD
How strongly does appetite counter weight loss? New preprint #asapbio biorxiv.org/content/early/2016/04/29/051045
Daniel J Drucker
@DanielJDrucker
@KevinH_PhD @seeleyrj Timely reminder #ifadrc #diabetes #obesity The brain is critical for maintaining #weightloss
-
Daniel J Drucker
@DanielJDrucker
PYY improves #islet function #bariatric surgery, rats vs. mice @CellReports You decide www.ncbi.nlm.nih.gov/pubmed/27117413 and www.ncbi.nlm.nih.gov/pmc/articles/PMC3773824/
-
Daniel J Drucker
@DanielJDrucker
Food-regulated E. coli proteins talk to #brain & L cell via MC4R to control #glp-1 #pyy #obesity @Cell_Metabolism
-
Daniel J Drucker
@DanielJDrucker
Timely review of chemosensing properties and therapeutic potential of gut endocrine cells www.ncbi.nlm.nih.gov/pubmed/26442437



















































































































































































































































































































































































































